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Abstract
The Retinoblastoma protein (pRB) is a key regulator of the cell cycle and is
functionally inactivated in most cancers. pRB has been proposed to utilize simultaneous
interactions with E2F transcription factors and chromatin regulatory proteins to repress
transcription and block cell cycle progression. The goal of this study is to characterize the
physiological role of pRB interactions with chromatin regulatory proteins. I used gene
targeted mice carrying point mutations in the murine Rb1 gene (Rb1∆L) that specifically
disrupt pRB’s LXCXE binding cleft, and thereby its ability to interact with chromatin
regulatory proteins while leaving its ability to bind E2Fs intact. Embryonic fibroblasts from
Rb1∆L/∆L mice fail to properly arrest DNA synthesis in response to senescence inducing
signals such as oncogene expression and γ Irradiation. Failure to incorporate repressive
heterochromatin marks like H3K9me3 results in de-repression of key cell cycle genes during
senescence. However, this function of pRB is dispensable during normal differentiation and
development, suggesting a specific role during stress responsive cell cycle arrest.
Furthermore, during cellular senescence, pRB uses LXCXE binding cleft dependent
interactions to recruit Promyelocytic leukemia protein (PML) to E2F target gene promoters.
This function of pRB is important for establishment of heterochromatin marks and stable
silencing of these genes thereby creating a permanent cell cycle arrest. Disruption of this
function of pRB by the ∆L mutation confers susceptibility to escape from senescence and
allows transformation in vitro. However, the same mutation does not enhance tumorigenesis
in tumor models with activated ras mutations. Rb1∆L/∆L mice expressing oncogenic
KrasG12D show delayed lung tumor formation compared to controls, which correlate with
increased apoptosis in the early lesions following ras activation. Furthermore, DMBA
treatment to induce ras mutations also fail to reveal greater susceptibility to cancer in
Rb1∆L/∆L mice suggesting that loss of chromatin regulation by pRB has context dependent
outcomes and does not universally enhance tumorigenesis in vivo.
Overall, this thesis enhances our current understanding of the unique role of pRB
among the pocket proteins in cell cycle regulation by showing how pRB utilizes LXCXE
binding cleft mediated interactions to stably block cell cycle in response to oncogenic stress
signals.
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Chapter 1

1

Introduction

1.1 Cancer, and the discovery of the first tumor suppressor
gene RB1
Cancer is uncontrolled cell division. Appropriate control of the cell division cycle
is of utmost importance for tissue homoeostasis in multi-cellular organisms. Deregulation
of this proliferative control is one of the major hallmarks of cancer (Hanahan and
Weinberg, 2011). Ironically, much of our understanding of how a normal cell cycle is
regulated has come from studying cancer. It led us to the discovery and understanding of
the function of proto-oncogenes and tumor suppressor genes, the normal regulators of
cell proliferation. This discovery of the genetic basis of cancer has transformed our
understanding of the disease and greatly aided in the development of targeted therapies.
Retinoblastoma is a rare childhood cancer of the retina (Moll et al., 1997;
Seregard et al., 2004). Retinoblastoma can occur as a unilateral disease, where only one
eye is affected or can be presented as bilateral retinoblastoma where both the eyes are
affected. Interestingly, the bilateral disease is very common in children with a family
history of retinoblastoma. Alfred Knudson, in 1971, proposed a landmark theory of the
genetic basis for retinoblastoma by using statistical analysis of the clinical data. He
famously called it the “two hit hypothesis” (Knudson, 1971). According to this
hypothesis, the generation of retinoblastoma requires two independent mutational events.
Patients with familial retinoblastoma inherit one mutational event in their genome
making them susceptible to retinoblastoma. A random second ‘hit’ can cause
retinoblastoma in these individuals. Where as in individuals who do not inherit the first
mutational event two independent mutations are required to cause retinoblastoma.
Knudsen’s hypothesis predicted the existence of a gene whose protein product suppresses
retinoblastoma occurrence. Eventually, in 1986 two labs independently cloned the
retinoblastoma gene 1(RB1); the first tumor suppressor gene (Friend et al., 1986; Lee et
al., 1987). Analysis of the RB1 gene from retinoblastoma patients further confirmed
Knudsen’s hypothesis. Patients with familial retinoblastoma were in fact found to carry
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one mutant allele of RB1 in all their cells and they loose the remaining wild type allele as
a result of loss of heterozygosity (LOH) (Cavenee et al., 1983) (Dryja et al., 1984).

1.1.1

The retinoblastoma 1 gene product (pRB) is a cell cycle
regulator
Shortly after the cloning of the RB1 gene, several viral oncoproteins (adenoviral

protein E1A, Human papilloma virus protein E7, and Simian virus 40 T antigen) were
shown to interact with the retinoblastoma 1 gene product, pRB (DeCaprio et al., 1988;
Dyson et al., 1990; Dyson et al., 1989; Ludlow et al., 1989; Whyte et al., 1988; Whyte et
al., 1989). All these oncoproteins were found to use a similar region to interact with pRB
and this interaction is necessary for their ability to transform cells (Figge et al., 1988;
Moran, 1988). At the same time, pRB was shown to contain properties of a cell cycle
regulatory protein. pRB was shown to be phosphorylated in a cell cycle dependent
manner in late G1 just before cells enter S-phase. This suggested that pRB might regulate
the G1 to S phase transition in the cell cycle (DeCaprio et al., 1989). Finally, the last
piece of the puzzle, the E2F transcription factor, was identified as a cellular target for
pRB. pRB is shown to inhibit the transcriptional activity of E2Fs in the G1 phase of the
cell cycle (Chellappan et al., 1991; Helin et al., 1992; Hiebert et al., 1992). E2F
transcriptional activity peaks at the G1/S transition, which also corresponds with the
hyper-phosphorylation of pRB by the cyclin/CDK complexes. Taken together, these
studies led to the identification of a G1 checkpoint controlled by pRB through its
interaction and inhibition of E2F transcription factors (Dyson, 1998).

1.2 The pocket protein family
Two pRB related proteins p107 and p130 were discovered based on their shared
ability to interact with viral oncoproteins (Cobrinik et al., 1993; Ewen et al., 1991;
Hannon et al., 1993; Li et al., 1993; Mayol et al., 1993; Zhu et al., 1993). They are
encoded by RBl1 (retinoblastoma like 1) and RBl2 (retinoblastoma like 2) genes
respectively. The p107 and p130 proteins share high structural homology with pRB and
together they are often referred to as ‘pocket proteins’ (Classon and Dyson, 2001;
Mulligan and Jacks, 1998).
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The name ‘pocket protein’ is derived from the ‘pocket domain’ that is common to all
three proteins in the family (Fig.1.1). The pocket region can be further divided into the
small and large pocket. The small pocket consists of A and B domains separated by a
spacer region. The A and B domains each form cyclin like folds that interact to form a
globular pocket (Gibson et al., 1994; Lee et al., 1998). The small pocket is the minimal
domain capable of interacting with viral oncoproteins (Kaelin et al., 1990). The large
pocket region on the other hand, includes the ‘small pocket’ along with the C-terminal
domain (Qin et al., 1992; Yang et al., 2002). The large pocket is required for E2F binding
in vivo and is the minimal growth suppression domain in the pocket proteins.
One of the highly conserved features among the pocket proteins is the LXCXE
binding cleft (Lee et al., 1998). The LXCXE binding cleft is the name used to describe
the region of the pRB pocket that binds to the LXCXE peptide motif. The LXCXE motif
was originally identified in viral oncoproteins such as adenovirus E1A, SV40 TAg and
HPV-E7 that bind to the pocket domain of pRB. This peptide motif is necessary for the
viral oncoproteins to bind pRB and transform cells (Kim et al., 2001). The crystal
structure of the pRB A/B domain bound to the HPV E7 LXCXE peptide motif has
identified a surface exposed cleft within the B region that binds to the LXCXE peptide
(Lee et al., 1998). Interestingly, binding of the LXCXE peptide does not prevent the
binding of an E2F peptide to the small pocket suggesting the possibility of a ternary
complex (Lee et al., 1998).
The high sequence conservation of the LXCXE binding site residues, and the fact
that this site is targeted for disruption by viral oncoproteins suggests that cellular
interactions mediated by this cleft are key to pRB function. Over the years a number of
cellular proteins have been identified that are found to interact with pRB through its
LXCXE binding cleft (Dick, 2007). Interestingly, most of the proteins that bind to pRB
through the LXCXE binding cleft are found to have enzymatic activities that can alter
chromatin structure and act as co-repressors of transcription. These include proteins such
as, histone deacetylases (HDAC1, HDAC2) (Brehm et al., 1998; Luo et al., 1998;
Magnaghi-Jaulin et al., 1998), histone demethylases (RBP2) (Benevolenskaya et al.,
2005), DNA methyl transferases (DNMT1) (Robertson et al., 2000a), helicases (Brg1,
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Brm) (Dunaief et al., 1994; Singh et al., 1995b), histone methyl transferases (Suv39h1,
RIZ, and Suv4-20h1/h2) (Gonzalo et al., 2005; Nielsen et al., 2001; Steele-Perkins et al.,
2001) and histone binding proteins like HP1 (Nielsen et al., 2001; Vandel et al., 2001).
Even though there is extensive sequence conservation among the three
mammalian pocket proteins, there are a few subtle differences that separate them. In
general, there are more similarities between p107 and p130 than between either of them
and pRB. Both p107 and p130 contain B domain insertions. Furthermore, p107 and p130
also have a longer spacer region connecting the A and B domains (Lacy and Whyte,
1997; Woo et al., 1997; Zhu et al., 1995a). These long spacers allow them to stably
interact with the cyclin/CDK complexes. Also, p107 and p130 contain a unique Nterminal domain that can inhibit cyclin dependent kinases (Woo et al., 1997).
pRB, also has some unique structural features mainly in the C-terminal domain
that distinguishes it from p107 and p130. The pRB-C terminal fragment is uniquely
capable of binding specifically to E2F1 (Dick and Dyson, 2003; Julian et al., 2008) and is
implicated in regulating functions outside of normal cell cycle control. The C-terminal of
pRB also contains binding sites for cyclin-CDK complexes and protein phosphatase 1
(PP1) (Adams et al., 1999; Durfee et al., 1993; Tamrakar and Ludlow, 2000; Vietri et al.,
2006). Recently, a competitive interaction between cyclin/CDKs and protein phosphatase
1 (PP1) with pRB-C terminal was described suggesting a potential regulatory mechanism
(Hirschi et al., 2010).

1.3 The E2F family of transcription factors
E2F transcription factors are a family of proteins that have important roles in cell
proliferation in eukaryotes (Chen et al., 2009; DeGregori and Johnson, 2006). So far,
eight mammalian E2Fs (1-8) have been identified (Fig. 1.2). E2F1, E2F2 and E2F3 are
generally described as activator E2Fs due to their ability to strongly activate E2F
transcriptional targets. E2Fs 4-8 are grouped under repressor E2Fs due to their ability to
block E2F dependent transcription.
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Figure 1.2 Domain structures of the E2Fs
The nuclear localization signal (NLS), the nuclear export signal (NES), the DNA binding domain (DBD),
the dimerization domain (DD), and the transactivation domain (TA) are shown. (A) The activator E2Fs (B)
The repressor E2Fs (C) The atypical E2Fs.
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The pocket protein interaction motif in E2Fs is their transactivation domain. E2Fs
were shown to have preferential binding to specific pocket protein partners. E2Fs 1-3
interact exclusively with pRB (Chen et al., 2009). E2F4 can interact with pRB but in
general both E2F4 and E2F5 show preferential binding to p107 and p130 (Chen et al.,
2009). E2F6, E2F7, and E2F8 lack a transactivation domain and do not interact with any
of the pocket proteins.
E2Fs 1-6, all contain a DNA binding domain and a dimerization domain that is
required for interaction with the DP proteins (Girling et al., 1993; Wu et al., 1995; Zheng
et al., 1999). Three mammalian DP proteins (DP1, DP2/3, and DP4) have been identified
so far. Hetero-dimerization with DP is critical for the function of E2F1-6 as they are not
capable of interacting with DNA on their own. However, E2F7 and E2F8 have two DNA
binding domains and can interact with DNA as homo or hetero-dimers independently of
DP (Di Stefano et al., 2003; Maiti et al., 2005; Moon and Dyson, 2008).

1.4 Cell cycle regulation by the pocket proteins
The ability of the pocket proteins to regulate cell cycle is generally attributed to
their ability to directly bind to and repress E2F transcription factors (Dyson, 1998;
Hanahan and Weinberg, 2000; Trimarchi and Lees, 2002). Growth factor stimulation
inactivates the pocket proteins through phosphorylation by cyclin dependent kinases
(CDKs) releasing the E2F proteins to activate transcription of the cell cycle genes
(Classon and Harlow, 2002a). Viral oncoproteins, like E1A, bind to the pocket proteins
preventing them from interacting with E2Fs thereby inducing cell proliferation (Whyte et
al., 1988; Whyte et al., 1989). Similarly, in cancer cells, the pRB pathway is inactivated
either by direct mutation of the RB1 gene, deregulation of CDKs, or inactivation of cyclin
dependent kinase inhibitors such as p16INK4A. These mutational events serve to stably
deregulate E2F transcription (Sherr and McCormick, 2002) leading to uncontrolled cell
proliferation.
However, apart from the negative regulation of E2Fs, pRB-E2F complexes were
found to be capable of actively repress gene transcription from E2F promoters
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Figure 1.3 Current model of pRB function in G1/S phase transition
In G1, pRB interacts with the transactivation domain of E2F/DP heterodimer and blocks their activation of
E2F target genes. pRB is capable of recruiting chromatin regulatory proteins to further repress the
activation of these genes by generating a repressive chromatin environment. During G1 into S phase
transition cyclin/Cdk complexes phosphorylate pRB and mediate the release of E2F/DP complexes. The
free E2Fs activate the transcription of E2F target genes to drive the progression into S-phase and rest of the
cell cycle.
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(Hamel et al., 1992; Weintraub et al., 1992). These observations suggested that pRB-E2F
might be part of a bigger transcriptional repressor complex. In fact, pRB has been found
to associate with a number of proteins that can regulate chromatin structure and repress
transcription at E2F responsive promoters (Dick, 2007). These findings have expanded
the model such that pRB is recruited to promoters by sequence specific transcription
factors such as E2Fs. In turn, pRB recruits co-repressors such as HDACs through its
LXCXE binding cleft to E2F responsive promoters. These chromatin regulatory factors
modify chromatin in the neighboring regions and actively silence transcription (Fig. 1.3).

1.4.1

Overlapping and unique roles of individual pocket proteins
All the pocket proteins (pRB, p107 and p130) are in principle, capable of forming

inhibitory complexes with E2Fs and recruiting co-repressors through the LXCXE binding
cleft. However, several studies have found that specific pocket protein-E2F complexes
predominate in different phases of the cell cycle and regulate the activity of E2Fs.
The differential activity of the pocket proteins seems partly due to their
differential expression pattern during the cell cycle (Classon and Dyson, 2001). pRB
expression is relatively unchanged throughout the cell cycle and it is expressed in both
proliferating and non-cycling cells (Buchkovich et al., 1989). In contrast, p107 is an E2F
target gene and its expression reflects free-E2F activity (Xiao et al., 1996; Zhu et al.,
1995b). So, the expression of p107 is low in quiescent cells but increases sharply as cells
enter S-phase. p130 expression is found to be very high in quiescent and terminally
differentiated cells and low in proliferating cells (Cobrinik et al., 1993).
Our understanding of the distinct roles of the pocket proteins in development and
cell cycle regulation has been greatly aided by the use of gene-targeted mouse models
with specific disruption of individual pocket proteins. Disruption of the mouse Rb1 gene
results in embryonic lethality between E13.5 and E15 (Clarke et al., 1992; Jacks et al.,
1992; Lee et al., 1992). The Rb1-/- embryos have increased proliferation and apoptosis in
the nervous system and altered development and proliferation of the lens (Clarke et al.,
1992; Jacks et al., 1992; Lee et al., 1992). However, many of the defects in Rb1-/- mice
can be attributed to the proliferative defects in the placenta (de Bruin et al., 2003a). When
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Rb1-/- mice were produced with normal placenta using tetraploid aggregation, many of
the defects were rescued and these mice could survive until birth (Wu et al., 2003).
However, they die shortly after birth with defects in skeletal muscle formation. This was
found to be due to the failure of Rb1-/- myoblasts to terminally differentiate into
multinucleated myotubes (Huh et al., 2004b). In addition, fibroblasts generated form Rb1/-

embryos (MEFs) also display proliferative defects in culture characterized by a

shortened G1 cell cycle phase and reduced cell size (Herrera et al., 1996b). They also fail
to arrest properly in response to a variety of growth inhibitory signals such as TGFβ treatment , p16INK4a expression and DNA damage (Harrington et al., 1998; Herrera et
al., 1996a; Medema et al., 1995).
On the other hand, p107-/- and p130-/- mice are viable, and normal (Lee et al.,
1996). Combined disruption of both p107 and p130 however, results in lethality at birth,
with severe defects in bone development (Cobrinik et al., 1996). This suggested that p107
and p130 have highly overlapping functions and can compensate for the loss of one
another.
The relatively normal development of the Rb1-/- mice suggested that in some
contexts p107 and p130 might compensate for the loss of pRB to maintain proliferative
control. In fact, combined disruption of pRB and p107 or pRB and p130 resulted in early
embryonic lethality between E11 and E13 (Dannenberg et al., 2004; Lee et al., 1996).
Also, these embryos display more severe apoptotic and proliferative defects compared to
the Rb1 deletion alone. This suggested that the pocket proteins have partially overlapping
functions and can compensate for the loss of other pocket proteins in certain contexts.
Triple knockout (TKO) fibroblasts lacking all the three pocket proteins were
generated by differentiating targeted ES cells to further study the compensation among
pocket proteins. These TKO fibroblasts were spontaneously immortal and showed
defective arrest in the G1 under a variety of conditions (Dannenberg et al., 2000b; Sage et
al., 2000b). Recently, TKO embryos lacking pocket proteins were successfully generated
and these embryos survive until E9-E11. Some TKO cells were also found to be capable
of exiting the cell cycle in G1 and differentiating into epithelial and neural cell lineages
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(Wirt et al., 2010). These surprising results suggested that G1 arrest and cell cycle exit
could still occur in the absence of pocket protein activity in certain contexts.
Taken together, mouse models of pocket proteins have defined an essential role
for pRB in mammalian development. pRB is required for placental development and
muscle differentiation and proper proliferative control of certain tissues. On the other
hand p107 and p130 have highly overlapping functions and play an essential role in bone
development.

1.5 pRB’s unique role in tumor suppression
In humans, loss of pRB results in the development of retinoblastoma early in life.
Furthermore, RB1 gene and/or components of the pRB regulatory pathway are mutated or
silenced in most human cancers (Sherr, 1996; Sherr and McCormick, 2002). Surprisingly,
a vast majority of the tumor-derived mutations identified in the pocket protein family are
found in the RB1 gene, suggesting a unique role for pRB among its siblings (Dick, 2007;
Mulligan and Jacks, 1998).
Mouse models of pocket protein disruption also revealed pRB to be the major
tumor suppressor among its family members. Rb1+/- mice develop tumors in the
intermediate and the anterior lobes of the pituitary as well as medullary thyroid
carcinomas (Harrison et al., 1995). In contrast, mice lacking p107 (Rbl1-/-) or p130 (Rbl2/-

) do not develop tumors in their lifetime (Classon and Harlow, 2002a). However, Rb1+/-

mice do not develop retinoblastoma on their own and induction of retinoblastoma in mice
requires disruption of both pRB and p107 (Chen et al., 2004b; Robanus-Maandag et al.,
1998).
Taken together, these studies highlighted the unique role for pRB in
tumorigenesis. However, the mechanistic basis for this unique tumor suppressive ability
of pRB is still not known. Hence, an in depth analysis of the pRB tumor suppressor
protein function is of great interest to cancer researchers.
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1.6 A structure function approach to studying pRB function
One of the most intriguing features of pRB inactivation in human cancers is the
rarity of missense mutant alleles. The vast majority of tumor derived alleles of RB1 gene
are deletions or non-sense mutations with only a very few missense changes (Valverde et
al., 2005). In comparison, most cancer-derived mutations in the TP53 gene target the
DNA binding domain, suggesting its crucial role in p53 tumor suppressor function (Sherr
and McCormick, 2002). Hence, relating pRB’s proliferative control in culture to its tumor
suppressive ability in vivo has not been possible from mutation data.
The discovery that viral oncoproteins (like E1A, TAg, and E7) and E2F
transcription factors interact with the same region of pRB called the “pocket domain” has
prompted investigators to map the functional domains of pRB. Cell culture assays, for
pRB’s role in proliferation and transcriptional repression identified the “large pocket”
(aa379-928) as the minimal domain of pRB required for mediating these functions (Qin
et al., 1992; Yang et al., 2002). However, several non-E2F cellular proteins have been
discovered that interact with the large pocket in a manner similar to viral oncoproteins
making it difficult to interpret how these numerous interactions control cell cycle
progression (Dick, 2007). Structural analysis of the few available tumor derived missense
mutations has shown that they non-specifically disrupt the over all protein structure, and
as such, disrupt most of the interactions mediated by the large pocket (Dick, 2007).
The description of the crystal structure of pRB bound to a peptide derived from
HPV E7 and similar structures of pRB bound to E2Fs in the recent years has allowed
researchers to take a rational, structure guided approach to dissect the function of pRB
(Burke et al., 2010; Lee et al., 2002; Lee et al., 1998; Rubin et al., 2005; Xiao et al.,
2003). A number of discreet point mutations have been generated that specifically disrupt
individual interactions within the large pocket without adversely affecting other pRB
interactions (Dick and Dyson, 2003; Dick et al., 2000). These point mutants confirmed
some of the previously proposed mechanisms of pRB function such as pRB-E2Fs in
transcriptional control while revealing some novel functions of pRB outside of
transcriptional regulation.
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1.7 Gene targeted mice to study the contribution of the
LXCXE binding cleft to pRB function
As stated previously, most of the proteins that bind to pRB through the LXCXE
binding cleft have enzymatic activities that can alter chromatin structure and can act as
co-repressors of transcription. The ability to bring these chromatin regulating activities to
E2F responsive promoters allows pRB to influence broader genomic regions than just the
DNA footprint of the E2F transcription factor.
In order to study the role that the chromatin regulator-pRB-E2F complexes play in
cell cycle control, our lab and others have generated point mutants of pRB that
specifically disrupt the LXCXE binding cleft (Dick, Sailhamer et al. 2000) (Fig. 1.4).
Cell culture assays showed that this mutant of pRB is partially defective in transcriptional
repression and cell cycle arrest (Chan et al., 2001). Furthermore, studies done in other
labs have shown this mutant to be defective in its ability to mediate myogenic
differentiation in vitro (Chen and Wang, 2000). These observations prompted our lab to
investigate the physiological role of these interactions in an in vivo setting by introducing
this mutant allele into the mouse germ line (Isaac et al., 2006a). We call this mutation
RB-∆LXCXE and the mice Rb1∆LXCXE/∆LXCXE or in short Rb1∆L/∆L mice. The Rb1∆L/∆L mice
are viable, follow Mendelian inheritance, and develop relatively normally (Isaac et al.,
2006a). This is in contrast to the Rb1-/- mice that die by embryonic day 15.5 due to
proliferative defects in the placenta (Wu et al., 2003). This suggested that the LXCXE
binding cleft interactions are dispensable for early embryonic development.
Characterization of the pRB∆L protein in cells isolated from these mice revealed that it is
expressed at similar levels to the wild type. As expected, pRB∆L is defective for
interactions mediated by the LXCXE binding cleft, while retaining E2F binding.
Importantly, unlike the Rb1-/- cells, the levels of the other pocket proteins (p107 and
p130) are not elevated in the Rb1∆L/∆L MEFs, suggesting compensatory effects are
unlikely (Isaac et al., 2006a).
Further characterization of the Rb1∆L/∆L mice, and cells derived from them,
provided interesting insights into the physiological role of the pRB-LXCXE interactions.
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Figure 1.4 The RB-∆LXCXE mutation
Disruption of the LXCXE binding cleft of pRB through three discreet amino-acid substitutions. The RB∆LXCXE mutation only disrupts the interactions mediated by the LXCXE binding cleft of pRB while
leaving the other interactions such as E2F binding intact.
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Rb1∆L/∆L females fail to nurse their pups and histological analysis showed epithelial
hyperplasia in the mammary ducts (Francis et al., 2009b). A very interesting
observationthat came from studying the Rb1∆L/∆L cells is that pRB has a novel role out
side of G1 that is important for proper mitotic chromosome segregation and genome
stability (Coschi et al., 2010). Strikingly, this non-G1 function of pRB is found to be
tumor suppressive.
Studies done using the embryonic fibroblasts (MEFs) from Rb1∆L/∆L mice in terms
of proliferative control provided surprising insights into the physiological role of the
LXCXE type interactions. Rb1∆L/∆L MEFs show similar growth rate compared to wild
type MEFs and exit from the cell cycle in response to confluence arrest and serum
starvation. The transcriptional repression of E2F target genes also remains largely
unaltered in these cells (Isaac et al., 2006a). This suggested that the recruitment of
chromatin regulators by the pRB-LXCXE binding cleft is not essential for cell cycle gene
repression and cell cycle exit in this paradigm of reversible growth arrest. However, it
also raised a very interesting question of what physiological circumstances require the
pRB-LXCXE interactions and whether this transcriptional repression function contributes
to tumor suppression by pRB.
Strikingly, MEFs derived from the Rb1∆L/∆L mice show defective cell cycle arrest
in response to a variety of stress stimuli such as the growth inhibitory cytokine TGF-β,
CDK inhibitors such as p16Ink4a and p21Cip1. This suggested that chromatin regulation by
pRB is required only under specific growth inhibitory contexts for the induction of cell
cycle arrest. My work will expand on this concept in chapter 2 where I studied chromatin
regulation by pRB in the context of cellular senescence (Talluri et al., 2010) & (Chapter
2). Cellular senescence is widely considered a key tumor suppressive mechanism that
prevents the proliferation of precancerous cells from becoming tumorigenic. The next
section will introduce cellular senescence and highlight the studies that show the key
anti-proliferative and tumor suppressive properties of senescence. I will also highlight the
current literature about pRB’s role in senescence.
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1.8 Cellular senescence
Cellular senescence can be defined as a stable cell cycle arrest in which cells exit
the cell cycle and remain post-mitotic for an extended period of time (Campisi, 2005).
Although, by definition, senescence seems very similar to terminal differentiation, these
two stable cell cycle exit paradigms differ fundamentally in many ways. Whereas
terminal differentiation is a developmentally regulated process that helps in functional
specialization of cells, senescence is more of an aging and disease-associated phenotype.
Senescence is proposed to be a stress responsive phenotype that curtails the growth and
expansion of potentially deleterious cells and aids in tissue homeostasis.

1.8.1

Biomarkers of senescence
Senescent cells show a number of distinct morphological features as well as

characteristic changes in gene expression and chromatin structure (Campisi and d'Adda di
Fagagna, 2007a). However, there is no single reliable marker to identify senescent cells
and a combination of different markers is commonly used to determine whether a cell
population is senescent or not.
The most commonly used biomarker marker for senescence is the expression of a
lysosomal enzyme called senescence associated β-galactosidase (SA-β-gal) (Dimri et al.,
1995). In senescent cells the enzymatic activity of SA-β-gal increases at pH 6.0 and can
be easily determined using a biochemical assay. The increased activity of SA-β-gal was
later found to be a result of increased lysosomal content and activity in senescent cells
(Kurz et al., 2000; Lee et al., 2006).
Another important biomarker for senescence is the cell cycle arrest. Senescent
cells predominantly arrest in the G1 phase of the cell cycle (Sherwood et al., 1988).
Senescent cells are also refractory to growth factor stimuli and can remain arrested for an
indefinite period of time. The cell cycle arrest is normally determined by pulse labeling
the cells with BrdU followed by flow-cytometric analysis. One other simple marker is the
cell morphology. Cells undergoing senescence often display a large and flat morphology
in cell culture. Apart from this, senescent cells also show increased number of vacuoles
and increase in size of the nucleus and nucleolus.
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Senescent cells show a distinctive gene expression pattern reflective of their
phenotype. In general, they down regulate proliferative genes such as Cyclin E1, Cyclin
A2, PCNA etc., and up regulate anti proliferative genes such as p16Ink4a, p19Arf, and
p21Cip1 (Campisi and d'Adda di Fagagna, 2007a) (Chicas et al., 2010). For this reason,
increased expression of p16Ink4a and p19Arf proteins is also routinely used as a marker for
senescence in cells and tissue sections.

1.8.2

Types of senescence

1.8.2.1

Replicative senescence

Senescence was originally identified as a phenomenon that limits the replicative
life span of primary human diploid fibroblasts (HDFs) grown in culture (Hayflick and
Moorhead, 1961). The authors of this study noticed that all the cell strains that they
derived from a number of different fetal tissues undergo senescence after a finite number
of divisions in culture. It has been shown later that this phenomenon is a result of gradual
shortening of telomeres with each round of DNA replication (Wright and Shay, 2001).
This is now commonly known as the Hayflick limit, or replicative senescence.
Replicative senescence has since been observed in a number of different of cell types
isolated from various tissues of all ages and also from cells derived from different species
(Campisi and d'Adda di Fagagna, 2007a). All primary cultures irrespective of their origin
undergo a finite number of divisions before they eventually senesce. Cell cultures are
very heterogeneous and senescent cells can also be detected in young cultures even
though at low numbers. The number of senescent cells in a culture progressively
increases to a point where there is no further increase in the number of cells over time
(Cristofalo and Sharf, 1973; Smith and Whitney, 1980).

1.8.2.2

Premature senescence

Surprisingly, a number of factors were later found to induce senescence in
cultured cells independent of telomere length (Campisi, 2005; Dimri, 2005). Factors such
as oxidative stress, γ irradiation and chemotherapeutic drugs induce senescence even in
young cultures. This type of senescence is often called premature senescence. The
number of factors that can trigger premature senescence is rapidly expanding. The
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landmark finding that expression of activated oncogenes induces premature senescence in
primary cultures has generated significant interest in studying the molecular mechanisms
of senescence and its relevance to human disease (Serrano et al., 1997a). This along with
a number of in vitro and in vivo studies over the last decade have placed senescence as a
key tumor suppressive mechanism along with apoptosis that acts to prevent cancerous
growth of damaged cells in response to a variety of stress signals (Campisi, 2001). Two
such stress signals that are relevant to this thesis will be discussed in more detail in the
following sections.

1.8.2.2.1

Senescence induced by oxidative stress in culture

Standard cell culture techniques involve culturing cells at 20% Oxygen (O2).
Human diploid fibroblasts (HDFs) grown under these conditions undergo approximately
50 population doublings before senescing. But, when HDFs were cultured at a more
physiological oxygen levels of 3% O2 they were able to undergo an additional 20
population doublings before senescing (Chen et al., 1995). The converse is also true
where increasing the oxygen levels in culture to >20% resulted in early senescence (von
Zglinicki et al., 1995). These studies showed that oxidative stress is one of the major
inducers of premature senescence in culture. However, the sensitivity to oxygen levels
varies considerably between cell types and between fibroblasts from different species.
For example, mouse embryonic fibroblasts (MEFs) are more sensitive to oxygen levels in
the culture medium and senesce approximately after 10-15 population doublings when
grown at 20% O2 (Parrinello et al., 2003). But, when cultured at 3% O2 they grow for
over 100 population divisions suggesting that oxygen sensitivity is a major driver of
senescence in these cells (Parrinello et al., 2003).

1.8.2.2.2

Oncogene induced senescence (OIS)

Oncogene induced senescence (OIS) is the commonly used term to describe
premature senescence induced by the expression of activated oncogenes in primary cells.
Since the surprising discovery that expression of oncogenic HrasV12 induces senescence
and a permanent exit from the cell cycle in primary cells (Serrano et al., 1997a), a
number of different oncogenes have been reported to induce premature senescence,
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suggesting that this is a common mechanism to counter oncogene induced transformation
(Courtois-Cox et al., 2008).
How do oncogenes induce senescence? At first glance, it seems paradoxical that
cancer causing oncogenes, as their name implies, activate senescence. Numerous studies
in the past decade have tried to solve this apparent paradox and have advanced our
understanding of how oncogenes elicit a senescence response (Di Micco et al., 2006;
Mallette et al., 2007). When over expressed, activated oncogenes induce hyper
proliferation, which puts an enormous stress on the cell’s replication machinery. This
slows the rate of replication fork progression and results in increased firing of replication
origins and shortening of the inter-origin distance. This eventually leads to stalling of
replication forks. Fork stalling leads to DNA double strand breaks and activation of the
DNA damage response (DDR) characterized by phosphorylation and activation of
ATM/ATR kinases and further down stream signaling through the p53 and pRB tumor
suppressor pathways, the major effectors of the senescence response. Fibroblasts
genetically lacking or depleted for key DDR proteins such as ATM and CHK2 fail to
senesce in response to oncogene expression suggesting a crucial role for DDR in
activating senescence. Furthermore, persistent DDR signaling seems to be essential for
the maintenance of a senescent state in fibroblasts, because depletion of ATM in already
senescent cells induces DNA replication and cell cycle re-entry.
DNA damage and activation of DDR seems to be the common denominator in
senescence induced by most stimuli. In fact, replicative senescence, which is induced by
shortening of telomeres, has also been shown recently to activate DDR (Abdallah et al.,
2009). Critically shortened telomeres are identified as DNA breaks by cellular DNA
damage sensing machinery resulting in the activation of senescence response.

1.8.3

Chromatin changes during senescence
Senescence is often associated with widespread changes in epigenetic

modifications and heterochromatin organization. Human diploid fibroblasts such as
IMR90, that are undergoing either replicative or premature senescence often display
DAPI rich nuclear foci. These foci are now called senescence associated heterochromatic
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foci (SAHF) (Narita et al., 2003a). A lot of our understanding of chromatin changes
during senescence and their relevance to the senescence state has come from the study
and characterization of these structures. SAHFs are devoid of active transcription and are
highly enriched with repressive histone modifications such as H3K9me3 and H3K27me3
and heterochromatin protein1 (HP1) (Chandra et al., 2012; Narita et al., 2003a). In
addition, activating histone modifications such as H3K9ac and H3K4me3 are often
excluded from SAHFs. As the cells senescence, proliferative genes such as cyclin A
become enclosed in these foci, a mechanism proposed to be important for stable silencing
of these genes (Narita et al., 2003a).
Chromosome painting experiments showed that SAHFs are in fact individual
chromosomes compacted into these DAPI dense bodies, highlighting global changes in
the chromatin architecture during senescence (Funayama et al., 2006a; Zhang et al.,
2005). A number of proteins have been reported that are either associated with SAHFs or
are actively involved their formation. The histone variant macroH2A that is normally
enriched in the inactive X chromosome gets incorporated into SAHFs (Zhang et al.,
2005). The histone chaperone proteins Asf1a and HIRA are also necessary for SAHF
formation and cell cycle exit during senescence (Zhang et al., 2007b; Zhang et al., 2005).
Both these proteins are involved in the incorporation of the histone variant H3.3 into the
nucleosomes suggesting that formation of SAHF might involve deposition of H3.3
(Galvani et al., 2008; Tagami et al., 2004).
Histone H1, the linker histone is lost in cells undergoing senescence and its loss
also correlates with the ability of cells to form SAHFs (Funayama et al., 2006a).
Surprisingly, the levels of high mobility group A (HMGA) proteins HMGA1 and
HMGA2 increase during senescence (Funayama et al., 2006a; Narita et al., 2006).
HMGA proteins are overexpressed in a number of cancers and are originally linked to
transcriptional activation of a number of genes (Fusco and Fedele, 2007). It is interesting
to note that HMGA proteins bind to the minor groove of AT rich DNA, which is also the
binding site for linker histoneH1, prompting the suggestion that HMGA proteins replace
Histone H1 on the DNA during senescence. Expression of HMGA1 or HMGA2 in
primary human fibroblasts is sufficient to induce SAHF formation and senescence (Narita
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et al., 2006). Conversely, knockdown of HMGA proteins impairs HrasV12 induced
SAHF formation (Narita et al., 2006). However, the precise role of HMGA proteins in
chromatin compaction and SAHF formation is still not clear.
The enrichment of H3K9me3 and HP1 protein in SAHFs suggested that these
epigenetic changes might play a direct role in the formation of SAHFs (Narita et al.,
2003a). It has been previously shown that recognition of H3K9me3 by the bromodomain of HP1 protein and further recruitment of Suv39h1, the enzyme that trimethylate’s histone H3, aids in spreading of this repressive mark and formation of
constitutive heterochromatin at the pericentromeric DNA (Bannister et al., 2001; Lachner
et al., 2001). However, over expression of a dominant negative form of HP1β that
drastically reduces the chromatin bound fraction of HP1 proteins failed to impair ras
induced SAHF formation, suggesting that epigenetic changes and SAHF formation might
be regulated independently during senescence (Zhang et al., 2007b; Zhang et al., 2007c).
In fact, a recent study suggested that chromatin compaction into SAHFs and epigenetic
modifications might occur independently of one another (Chandra et al., 2012). The
authors over expressed JMJD2D demethylase that preferentially demethylates H3K9me3
or knocked down SUZ12, a component of PRC2 complex responsible for H3K27me3 to
reduce the global levels of these repressive marks. Upon ras expression the H3K9me3 or
H3K27me3 depleted cells still formed SAHFs to a similar extent as control cells
(Chandra et al., 2012). This suggested that these epigenetic modifications are not a
prerequisite for the formation of SAHFs.
A causal role for SAHFs during senescence has not been shown. However,
senescence arrest in HDFs that form SAHFs is relatively more stable compared to the
cells that do not form SAHFs during senescence suggesting that SAHFs might contribute
to the long-term stability of senescent arrest by stably repressing the expression of
proliferative genes (Beausejour et al., 2003; Narita et al., 2003a).

1.8.4

The PML gene and PML nuclear bodies in senescence
The Promyelocytic leukemia gene (PML) was originally identified in patients

with acute Promyelocytic leukemia (APL). Leukemia cells from these patients harbor a
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reciprocal chromosomal translocation t (15; 17) resulting in the fusion of the PML gene
with retinoic acid receptor α gene (RAR α) (Piazza et al., 2001). The resulting PMLRAR α fusion protein is oncogenic and is sufficient to cause leukemia in transgenic mice
(Piazza et al., 2001). The evidence for PML in tumor suppression comes from the
analysis of tumorigenesis in PML-/- mice. PML-/- mice do not develop spontaneous
tumors but are highly susceptible to carcinogenesis in response to chemical and physical
stimuli such as DMBA treatment and ionizing (γ) radiation (Salomoni and Pandolfi,
2002). Crossing of PML-RAR α transgenic mice with PML-/- results in dramatic
acceleration and increase of leukemia incidence, suggesting that inactivation of the tumor
suppressive function of PML by the fusion protein might be a key step in AML
pathogenesis (Rego et al., 2001).
PML is implicated in several biological processes such as growth suppression,
differentiation, apoptosis, senescence and innate immunity (Jensen et al., 2001). The
PML gene consists of 9 exons and alternative splicing generates multiple isoforms. The
major PML isoforms are designated PML I-VII, which mainly differ in their C-terminal
sequences (Fig. 1.5)(Jensen et al., 2001). The nuclear PML isoforms I-VI are essential
components of the highly dynamic nuclear structures known as PML nuclear bodies
(NBs). Over 30 cellular proteins co-localize with PML in these nuclear bodies and some
of the proteins such as p53 and pRB physically interact with PML (Jensen et al., 2001).
PML is also extensively modified by post-translational modifications and Sumoylation
has been suggested to be important for NB formation (Seeler and Dejean, 2001). Most of
the biological functions of PML have been linked to these nuclear bodies. The oncogenic
PML-RAR α fusion protein disrupts these nuclear bodies and several viruses encode
proteins that specifically disrupt the nuclear body formation further highlighting their
importance (Dyck et al., 1994; Everett, 2001).
There are on average 5-15 NBs in most cells but their number and size
dramatically increases in response to cellular stress such as viral infection, DNA damage,
and aberrant oncogene expression (Salomoni and Pandolfi, 2002). Interferon is one of the
best known inducers of PML expression (Chelbi-Alix et al., 1995; Regad and ChelbiAlix, 2001). Recently, p53 has been shown to directly bind to the PML gene promoter
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Figure 1.5 Domain structure of the PML isoforms
Alternative splicing of the C terminal region results in the translation of different PML isoforms. All
isoforms contain the first three exons, which encode the RBCC motif, a tripartite motif that contains a zincfinger RING domain (R), two zinc finger motifs (B- boxes) and a coiled-coil domain (CC). The RBCC
domain promotes dimerization and the formation of the NB structures. The cellular localization of the
isoforms is governed by the presence or absence of the nuclear localization signal (NLS) and nuclear export
signal (NES) encoded by exon 6 and 9, respectively. Adapted from Nicola J.M. Brown et.al, Frontiers in
Bioscience 14, 1684-1707, January 1, 2009.
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and activate its transcription in response to oncogene expression and DNA damaging
agents (de Stanchina et al., 2004).
The link between PML and senescence was discovered when it came up in
genomic screens for genes up regulated in response to oncogenic HrasV12 expression in
primary human fibroblasts (Ferbeyre et al., 2000). PML levels increase both during ras
induced, and replicative senescence, and senescent cells show a dramatic increase in the
number and size of the PML NBs. Over expression of PML itself can induce senescence
in a p53 and pRB dependent manner depending on the cell type (Ferbeyre et al., 2000;
Mallette et al., 2004). However, this feature is specific to PML-IV isoform suggesting its
key role in promoting senescence among the isoforms (Bischof et al., 2002).
Interestingly, over-expression of PML-IV fails to induce senescence in PML-/- MEFs
suggesting that PML-IV alone is not sufficient for the induction of senescence and one or
more of the other isoforms might play a role (Bischof et al., 2002). The key evidence for
the essential role for PML in senescence comes from PML-/- MEFs which fail to senesce
in response to oncogenic HrasV12 expression (Pearson et al., 2000).

1.8.5

Differences between human and mouse fibroblasts
undergoing senescence
Mouse models and cells derived from mice are traditionally used as a tool to

model human biology and to study the mechanism of human disease. Similarly, MEFs
from knockout mouse models have been used to study senescence and its role as a tumor
suppressor mechanism. As pointed out in the earlier sections, senescence mechanisms
differ between cell types, cell strains and between species. The mechanism of senescence
also depends on how a particular cell type responds to different stress signals.
Primary human cells undergo replicative senescence in culture after a certain
number of population doublings (Hayflick and Moorhead, 1961). This is due to critical
shortening of telomeres that triggers a DNA damage response leading to cell cycle arrest.
But, mouse cells do not succumb to replicative senescence owing to their longer telomere
DNA (30–150 kb versus 10 kb in humans) (Kipling and Cooke, 1990). However, mouse
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cells are more sensitive to oxidative stress under standard cell culture conditions (20%
O2) and senesce after ~10-15 population doublings (Parrinello et al., 2003).
Expression of oncogenic ras induces premature senescence in both mouse and
human primary cells (Campisi, 2005). The p53 and pRB tumor suppressor pathways are
the key regulators of cellular senescence in both human and mouse cells (Campisi, 2005).
The p53 protein induces senescence partly by transcriptional activation of the cyclin
dependent inhibitors (CKIs) such as p21. The pRB protein primarily blocks the cell cycle
in G1 by inhibiting the transcriptional activity of E2F family proteins. The Arf-p53
pathway is considered to be the dominant pathway regulating senescence in mouse cells,
compared to the p16/pRB pathway. MEFs from p16Ink4a null or Rb1-/- embryos enter at
least a partial state of senescence in culture and in response to oncogenic stress
(Krimpenfort et al., 2001; Sharpless et al., 2001; Sherr and DePinho, 2000) whereas
MEFs from p19Arf null or Trp53-/- mice continue to proliferate under the same
circumstances (Harvey et al., 1993; Kamijo et al., 1997). So, it has been suggested that
the Arf–p53 pathway is the principal mediator of senescence in mouse cells. However,
pRB/p107 double-knockout and pRB/p107/p130 triple knockout MEFs escape
senescence in culture and are resistant to ras induced premature senescence (Dannenberg
et al., 2000b; Peeper et al., 2001b; Sage et al., 2000b). Furthermore, acute depletion of
pRB in MEFs is sufficient to reverse senescence suggesting its crucial role (Sage et al.,
2003). These studies suggest that the p16/pRB pathway is also important for senescence
in mouse cells.
Mouse embryonic fibroblasts (MEFs) unlike some human fibroblasts such as
IMR90 do not condense their whole chromosomes to form SAHFs (Kennedy et al.,
2010). Mouse cells under all growth conditions contain heterochromatin bodies in their
nuclei that stain with DAPI and are called chromocentres (Probst and Almouzni, 2008).
Chromocentres are pericentromeric heterochromatin regions that are rich in repetitive
sequences. Whether mouse fibroblasts undergo global heterochromatin reorganization
during senescence irrespective of the lack of visible chromosome condensation is still not
clear and needs further investigation.
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1.8.6

Oncogene induced senescence in vivo
Recent reports showed senescence in several mouse models of cancer both in

response to oncogene activation (HrasG12V, KrasG12V, NrasG12D BrafV600E, Akt1
etc.,) and loss of tumor suppressors (Pten, pRB, Vhl etc.,) (Chen et al., 2005; Collado et
al., 2005; Collado and Serrano, 2010; Dankort et al., 2007; Dhomen et al., 2009;
Majumder et al., 2008; Sarkisian et al., 2007; Shamma et al., 2009; Young et al., 2008).
In these mouse models the pre-malignant lesions such as lung adenomas and melanocytic
nevi are often enriched in senescent cells. In contrast, senescent cells are rarely found in
their corresponding malignant stages, such as lung adenocarcinomas and malignant
melanomas suggesting a tumor suppressive role for senescence in vivo. Senescence is
also observed in pre-malignant human lesions such as melanocytic nevi and Prostatic
intraepithelial neoplasia (PIN) lesions suggesting its relevance to the human disease
(Chen et al., 2005; Michaloglou et al., 2005).
Studies in several oncogene induced cancer models such as Nras induced B cell
lymphomas, BrafV600E induced lung tumors and melanomas, and HrasG12V induced
mammary tumors provided strong evidence for senescence as a tumor suppressive
mechanism (Dankort et al., 2007; Goel et al., 2009; Sarkisian et al., 2007). Activation of
oncogenes in these mouse models only resulted in a few small lesions associated with
increased SA-β-gal activity, and markers of senescence. Interestingly, disruption of the
regulatory pathways involved in oncogene induced senescence has been shown to result
in increased susceptibility to tumorigenesis in these models. Simultaneous activation of
oncogenes combined with loss of p53, p16 or Suv39h1, resulted in malignant
transformation (Braig et al., 2005a; Chen et al., 2005; Sarkisian et al., 2007). Importantly,
this is associated with the loss of senescent markers, strongly suggesting a tumor
suppressive role for senescence in these models.

1.8.7

pRB’s role in senescence
Early experiments in cancer cells lacking pRB suggested a critical role for it in

senescence. Reintroduction of pRB into cancer cells that lack pRB induces senescence
(Xu et al., 1997). Conversely, acute loss of pRB in senescent mouse embryonic
fibroblasts (MEFs) results in increased DNA synthesis, cell cycle re-entry and subsequent
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reversal of cellular senescence (Sage et al., 2003). Rb1-/- MEF’s arrest in culture with
features of senescence, but they escape from this arrest and immortalize sooner than
control cells expressing the wild type protein (Dannenberg et al., 2000b; Sage et al.,
2000b). These studies suggested a key role for pRB in establishing the stability of
senescent cell cycle arrest.
The retinoblastoma protein appears to be capable of influencing senescence arrest
at various levels. First, pRB represses the transcription of genes involved in DNA
replication by directly binding to and inhibiting E2F transcription factors and through
histone deacetylation of their respective promoters (Narita et al., 2003a). Indeed, pRB is
found to be enriched on E2F target gene promoters during senescence (Chicas et al.,
2010; Narita et al., 2003a) Acute knock down of pRB in primary human fibroblasts that
are induced to senesce with oncogenic ras (HrasV12) show deregulated DNA synthesis as
reflected in continued incorporation of BrdU and deregulated E2F transcription (Chicas
et al., 2010).
Second, pRB is required for the enrichment of repressive histone methylation
(H3K9me3) on E2F target gene promoters during senescence (Chicas et al., 2010). The
precise mechanism of how pRB regulates the deposition of this repressive histone
modification is still not known. However, this illustrates how pRB dependent chromatin
regulation can exert its influence on transcriptional repression across E2F responsive
promoters.
Lastly, pRB plays a role in the formation of SAHFs themselves, and thus also
influences higher order chromatin structure in senescence as well. Knock down of pRB
results in decreased formation of SAHFs (Chicas et al., 2010; Narita et al., 2003a). Since
SAHFs represent the compaction of entire individual chromosomes (Funayama et al.,
2006a; Zhang et al., 2005), these structures represent considerable reorganization of
higher order chromatin structure that is pRB dependent. The exact signals that trigger
this compaction, and the mechanisms of chromosome condensation that facilitates their
formation are only beginning to be elucidated. Promyelocytic leukemia (PML) bodies
appear to be a crucial component in the pathway to assembling SAHFs and they have
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recently been shown to co-localize to genes that are silenced in a pRB dependent manner
(Vernier et al., 2011). Again, it is unclear if pRB’s actual function in the induction of
chromosome condensation to form SAHFs mediates these events or if they are merely
downstream of earlier pRB dependent steps.
Senescence, unlike other cell cycle exit paradigms, has distinguished itself as
having a bona fide tumor suppressive role and pRB may need to use its full tumor
suppressive ability in order to maintain the fidelity of this arrest. Since loss of pRB
results in deregulated gene expression, DNA synthesis, and eventual escape from
senescence, it is imperative that we investigate further the steps in gene silencing and
higher order chromatin assembly that are controlled by pRB. In this way we will come to
a thorough understanding of pRB function as a tumor suppressor protein.

1.9 Objectives of the present study
The LXCXE binding cleft is one of the highly conserved regions of pRB. The
obvious suggestion from this observation would be that the function mediated by the
LXCXE binding cleft is critical for the normal function of pRB. Despite a fair number of
in vitro studies in cell lines using pRB mutants defective for the LXCXE interactions, the
specific physiological contexts where these interactions are essential for pRB function as
a tumor suppressor are not well known. The overall aim of this study is to characterize
the role of the LXCXE binding cleft of pRB in cell cycle exit and tumor suppression
using stress induced senescence as a physiological context.
First, I studied the ability of the Rb1∆L/∆L cells to permanently exit the cell cycle in
response to developmental signals and stress stimuli that are potentially oncogenic. I
hypothesized that the LXCXE binding cleft has a specific role in establishing permanent
exit from the cell cycle in response to oncogenic insults. So, I tested this hypothesis using
two modes of permanent cell cycle exit, terminal differentiation and cellular senescence.
The results are discussed in detail in chapter 2 of the thesis.
In chapter 3 I further explored the role of pRB-LXCXE binding cleft mediated
interactions during cellular senescence. I show how the Rb1∆L mutation disrupts the
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ability of pRB to stably repress the transcription of cell cycle genes during cellular
senescence. I further characterize the proteins that cooperate with pRB in a LXCXE
dependent manner to maintain the stability of senescence arrest in primary mouse
fibroblasts.
Finally in chapter 4, I tested the effect of Rb1∆L mutation on transformation
potential in Rb1∆L/∆L cells both in vitro and in vivo. I used in vitro immortalization and
transformation assays to test the ability of Rb1∆L/∆L cells to escape senescence. In vivo, I
used an oncogenic Kras driven tumor model to study the effect of the Rb1∆L mutation on
senescence induction and tumorigenesis in the lung.
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Chapter 2

2

A G1 checkpoint mediated by the retinoblastoma
protein that is dispensable in terminal differentiation but
essential for senescence
2.1

Abstract

Terminally differentiated cell types are needed to live and function in a post-mitotic
state for a lifetime. Cellular senescence is another type of permanent arrest that blocks
proliferation of cells in response to genotoxic stress. Here we show that the
retinoblastoma protein (pRB) uses a mechanism to block DNA replication in senescence
that is distinct from its role in permanent cell cycle exit associated with terminal
differentiation. Our work demonstrates that a subtle mutation in pRB, which cripples its
ability to interact with chromatin regulators, impairs heterochromatinization and
repression of E2F responsive promoters during senescence. In contrast, terminally
differentiated nerve and muscle cells bearing the same mutation fully exit the cell cycle
and block E2F responsive gene expression by a different mechanism. Remarkably, this
reveals that pRB recruits chromatin regulators primarily to engage a stress-responsive G1
arrest program.

2.2

Introduction

Terminal differentiation is fundamental to the development of a multicellular
organism (Buttitta and Edgar, 2007). Of particular importance is the commitment to
permanently exit the cell cycle. Many cells enter a post-mitotic state early in life and
must remain viable and non-proliferative throughout the lifespan of the organism.
Cellular senescence is another form of proliferative control that can be induced as a
natural consequence of aging, or prematurely in response to stimuli such as DNA damage
(Campisi and d'Adda di Fagagna, 2007b). The physiological differences between
terminal differentiation and senescence suggest that there may be differences in their
mechanisms of growth control, however, the robust control of cell cycle entry is an
obvious similarity. Comparisons between the two are rare in current literature.
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Coupling cell cycle exit with terminal differentiation requires the coordinated
activities of the retinoblastoma (RB) family of proteins and cyclin dependent kinase
(CDK) inhibitors (Buttitta and Edgar, 2007). Studies in organisms such as Drosophila
and C. elegans support a general model in which cell cycle exit requires simultaneous
regulation of E2F transcription by RB family proteins and cyclin/CDK activity by their
inhibitors (Boxem and van den Heuvel, 2001; Buttitta et al., 2007; Firth and Baker,
2005). While it is unclear how this regulation is coordinated, it has been speculated that
changes in chromatin structure could offer an explanation. Under this interpretation,
heterochromatinization of cell cycle promoters blocks cyclin/CDKs from activating
transcription through E2Fs, likewise promiscuous E2F activity is unable to induce
expression of cyclins. For these reasons much attention has been focused on chromatin
regulation in transcriptional control by pRB and this function has been reviewed
extensively (Burkhart and Sage, 2008; Classon and Harlow, 2002b; Korenjak and Brehm,
2005). Cell cycle exit during terminal differentiation of neurons and skeletal muscle
requires pRB function (Chen et al., 2004a; de Bruin et al., 2003b; Ferguson et al., 2002;
Huh et al., 2004a; MacPherson et al., 2004; Zhang et al., 2004). In addition, deposition
of heterochromatin at E2F responsive cell cycle promoters is reported to be pRB
dependent during differentiation of these same cell types (Blais et al., 2007; Panteleeva et
al., 2007). Unfortunately, efforts to uncouple cell cycle exit from differentiation through
loss of pRB have been complicated because this often leads to cell death, particularly in
muscle development (Camarda et al., 2004; Huh et al., 2004a; Zacksenhaus et al., 1996).
This raises the question of whether chromatin regulation by pRB is the cause of cell cycle
exit, or a consequence of differentiation.
Cell cycle exit in senescence also involves the coordinated action of CDK inhibitors
and RB family proteins (Peeper et al., 2001a; Serrano et al., 1997b). However, the
frequent participation of p53 in the induction of senescence distinguishes it from cell
cycle exit in differentiation (Campisi and d'Adda di Fagagna, 2007b; Collado et al.,
2007). In this cell cycle arrest paradigm, pRB has a central role in the generation of
senescence associated heterochromatic foci (SAHF) (Narita et al., 2003b). SAHFs are
single chromosomes compacted into microscopically visible heterochromatin bodies
(Funayama et al., 2006b; Zhang et al., 2007a). This compressed genomic structure
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ensures efficient silencing of E2F regulated cell cycle genes. Thus, pRB function is
critical to establishing one of the features of senescence that best defines its permanence.
However, not all senescent human fibroblasts form SAHFs (Funayama et al., 2006b).
Fibroblasts from knock out mice have been used extensively to genetically dissect the
pathway that induces senescence and this analysis has demonstrated that it requires RB
family proteins (Dannenberg et al., 2000a; Peeper et al., 2001a; Sage et al., 2000a).
Interestingly, the presence of SAHFs in senescent mouse cells remains in question
because pericentromeric heterochromatin bodies are present under all growth conditions.
Because not all senescent cells contain SAHFs, it is unclear whether pRB regulates
chromatin structure in senescence in their absence.
Despite these gaps in our knowledge, regulation of chromatin structure by pRB is
frequently linked with its function in cell cycle control (Burkhart and Sage, 2008;
Classon and Harlow, 2002b). Many reports have shown that chromatin regulating
enzymes such as Brg1 (Dunaief et al., 1994), Brm (Singh et al., 1995a), HDAC1
(Magnaghi et al., 1998), DNMT1 (Robertson et al., 2000b), and Suv39h1 (Nielsen et al.,
2001) among others, use a peptide motif called LXCXE to interact with the pocket
domain of pRB (Classon and Harlow, 2002b; McClellan and Slack, 2007). Through the
simultaneous interaction with E2F transcription factors, this complex is recruited to E2F
target genes to block transcription and arrest the cell cycle in G1 (Burkhart and Sage,
2008). In this way, a one-size-fits-all model of pRB has emerged in which this E2FpRB-chromatin regulating repressor module is activated under all G1 cell cycle arrest
circumstances to remodel chromatin and block proliferation. However, it is noteworthy
that reports investigating the myriad of chromatin regulators that interact with pRB have
largely been carried out using cell culture assays and this has prevented us from truly
understanding the biological significance of chromatin remodeling by pRB. At present it
is unclear if induction of senescence or terminal differentiation invokes the same pRB
functions, even though they both can lead to a permanent G1 arrest that is frequently
characterized by changes in chromatin structure.
To investigate how the recruitment of chromatin regulating activities by pRB
influences mammalian development and disease, we have generated a gene-targeted
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mouse strain in which mutations in pRB disrupt only LXCXE dependent interactions
(Isaac et al., 2006b). We have validated that this mutation (called Rb1∆L) disrupts
numerous interactions between chromatin regulators and pRB, but leaves interactions
with E2Fs intact (Isaac et al., 2006b). Importantly, the Rb1∆L allele expresses pRB at
levels equivalent to wild type and the expression of the related RB-family proteins p107
and p130 are unchanged (Isaac et al., 2006b). This suggests that defects in Rb1∆L/∆L are
not suppressed by over expression of other family members as is the case for Rb1-/- mice
(Hurford et al., 1997; Mulligan et al., 1998). Despite the interactions that are disrupted,
Rb1∆L/∆L knock in mice are viable (Isaac et al., 2006b), raising the question of what
physiological circumstances require pRB to use chromatin regulation in cell cycle
control?
In this report we compare the cell cycle exit properties of skeletal muscle and
retinal neurons, two long-lived cell types, with senescent cells derived from Rb1∆L/∆L
mice. Our work shows that there is defective inhibition of DNA replication in senescent
Rb1∆L/∆L cells, but not in permanent cell cycle exit during development. This indicates
that one of the primary functions of chromatin regulation by pRB is an arrest checkpoint
that is used during senescence. The defect in senescence is a failure to create a repressive
chromatin structure at E2F responsive genes and is characterized by a deficiency in
H3K9me3. Conversely, ChIP analysis of the same promoters in Rb1∆L/∆L muscle reveals
a different transcriptional silencing pathway characterized by a combination of
H3K27me3 and H3K9me3 modifications that are present in normal abundance in
Rb1∆L/∆L mutants. Unexpectedly, this reveals that pRB possesses a stress-responsive
growth control mechanism that is distinct from cell cycle exit in terminal differentiation
during development.

2.3
2.3.1

Results
The Rb1∆L mutation causes defects in a senescent cell cycle
arrest

Based on pRB’s well known role in controlling G1 to S-phase progression, we
surveyed the ability of fibroblast cells from Rb1∆L/∆L mutant mice to respond to DNA
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damaging agents, activated oncogenes, and other stimuli that are known to impinge upon
proliferative control by pRB. Consistent with the discrete nature of the knock in
mutation some growth arrest mechanisms worked normally, such as serum deprivation
for 3 to 5 days (Fig. 2.1A). However, a number of senescence inducing stimuli like γirradiation and oncogenic ras were unable to generate a complete cell cycle exit in
Rb1∆L/∆L fibroblast cells despite the fact that the cells ceased to divide and assumed a
senescent morphology characterized by SA-β-Gal staining (Fig. 2.1B). Rb1∆L/∆L MEFs
showed a normal response to DNA damage during the first 48 hours following γirradiation and largely ceased to incorporate BrdU (Fig. 2.1C). However, even at this
early time point, reduced accumulation of cells in G1 became apparent (Fig. 2.1C). A
similar analysis of DNA content five days post treatment revealed a striking failure of
mutant cells to collect in G1 with many cells exhibiting abnormally high DNA content at
8N and beyond, indicative of endoreduplication (Fig. 2.1D). This occurred regardless of
whether the arrest was induced by γ-irradiation or activated ras. Furthermore, 10 days
following the induction of senescence by HrasV12, mutant MEFs still had elevated levels
of BrdU incorporation relative to wild type controls (Fig. 2.1E). This suggests that
persistent, but low levels, of DNA synthesis leads to the elevated DNA content found in
Rb1∆L/∆L MEFs following the induction of senescence. We interpret this phenotype to
mean that Rb1∆L/∆L cells are capable of entering a senescent state based on morphology,
the presence of SA-β-Gal staining, and the inability to undergo mitosis. However, the
mutation in pRB prevents an irreversible withdrawal from the cell cycle that allows
endoreduplication. For these reasons, we will refer to the state of these cells as defective,
or incomplete, senescence throughout this report.

2.3.2

Permanent cell cycle exit during development is normal in
Rb1∆L/∆L mice
Because cellular senescence is thought to be an irreversible arrest, we decided to

examine cell cycle exit and differentiation in long-lived cell types that remain growth
arrested throughout life. A number of tissues possessing permanently arrested cells that
fit this description are also known to require pRB for cell cycle exit during terminal
differentiation. In particular, pRB has a well recognized role in cell cycle control of
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Figure 2.1 Defective arrest of DNA synthesis in Rb1 mutant cells during senescence
(A) MEFs were serum deprived for 72 hours and DNA synthesis was measured by BrdU incorporation.
(B) Ten days following retroviral transduction of MEFs with HrasV12, senescent cell morphology and SAβ-Gal activity were examined by light microscopy and the % SA-β-Gal positive cells is displayed in the
graph to the right. (C) MEFs were irradiated with 15 Gys of radiation. 48 hrs later, cells were pulse labeled
with BrdU and processed for PI/BrdU flow cytometry analysis. Quantification of the ratio of %G1 cells and
%S phase cells from PI/BrdU analysis reveals that the G1 checkpoint in Rb1∆L/∆L mutant cells is defective.
(D) DNA content of wild type and mutant MEFs was examined by PI staining and flow cytometry 5 days
following irradiation or viral infection to express HrasV12. Numbers above the peaks indicate % nuclei
with respective DNA content (E) DNA synthesis in senescent MEFs was measured by BrdU incorporation
over eight hours, 10 days following viral infection. Error bars in all graphs indicate one standard deviation
from the mean of at least three replicates. P value for t-test comparing mean measurements in E is 0.04.
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muscle (de Bruin et al., 2003b; Zacksenhaus et al., 1996), as well as the retina (Chen et
al., 2004a; MacPherson et al., 2004; Zhang et al., 2004), and we have examined the
effects of the Rb1∆L mutation in these contexts.
When the placental defects of Rb1-/- mice are complemented, knock out animals
die at birth with defects in myogenesis and are characterized by gross histological
abnormalities and numerous apoptotic cells (de Bruin et al., 2003b). The fact that
Rb1∆L/∆L mice are viable and appear normal suggests that pRB’s role in muscle
differentiation is complemented by the Rb1∆L allele (Fig. 2.2A). Indeed, histological
analysis of skeletal muscle stained with Haematoxylin and Eosin (H & E) from Rb1∆L/∆L
mutant mice reveals that they are indistinguishable from wild type controls (Fig. 2.2B).
Beyond the ability of the Rb1∆L mutant to function in the differentiation of muscle, we
also investigated the permanence of cell cycle exit in this tissue. Anti-BrdU staining
demonstrates infrequent proliferation in cross sections of wild type and Rb1∆L/∆L muscle
fibers, less than one per microscopic field of view (Fig. 2.2C). The quantity of rare,
positively stained nuclei is consistent with proliferation of myosatellite cells that repair
post-mitotic muscle fibers. From this analysis, ectopic DNA replication in myotubes
appears to be absent. As a control for our ability to sensitively detect DNA replication,
we also stained highly proliferative cells from intestinal crypts in the same mice to
confirm that our labeling and staining robustly detect DNA replication (Fig. 2.2C). This
analysis of cell proliferation in the muscle of Rb1∆L/∆L mice indicates that cells exit the
cell cycle and remain post-mitotic in a manner comparable to wild type. In order to test if
the transcriptional silencing function of pRB is intact in differentiated muscle of Rb1∆L/∆L
mice, we studied the expression of E2F target genes like Pcna, Ccne1 (cyclin E), Rbl1
(p107), Ccna2 (cyclin A), and Tyms (thymidylate synthase) (Fig. 2.2D). We found equal
expression of these genes between wild type and mutant muscle. Western blots also
showed similar levels of protein expression among E2F targets across the two genotypes,
further suggesting that control of gene expression is properly maintained in Rb1∆L/∆L
muscle (Fig. 2.2D). Importantly, this also reveals that expression of the related pRB
family protein, p107, remains normal under these conditions. This indicates that
myogenesis in Rb1∆L/∆L mutants is likely not the result of compensation by other pRB
family members.
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Figure 2.2 Normal cell cycle exit and differentiation of muscle in Rb1∆L/∆L mice
(A) Rb1∆L/∆L mutant animals are viable and appear indistinguishable from wild type littermates. (B)
Anterior tibialis muscle tissue from 8 to 10-week old animals was stained with H & E to examine gross
morphology of wild type and Rb1∆L/∆L mutants. Transverse and sagittal sections are shown. (C) Cell
proliferation in muscle was examined by BrdU staining and the number of BrdU positive cells per
microscopic field was quantified and the average displayed in the graph. As a control for detection of
BrdU in mature muscle fibers we also stained cryosections of intestinal epithelia prepared from the same
mice. (D) mRNA and protein was extracted from the muscle of 6 week old wild type and Rb1∆L/∆L mutant
mice. Western blots show expression of known E2F target genes and the graph to the right displays the
relative abundance of the specified transcripts. Message levels of acidic ribosomal phospho protein P0
(Rplp0) and protein levels of Actin were used as controls. (E) MEFs were infected with MyoD expressing
retroviruses and induced to differentiate into myocytes under low serum conditions. Cells were then restimulated with 15% FBS and pulse labeled with BrdU (24 hours) to detect DNA synthesis. Myocytes
were identified by MHC staining (red), DNA synthesis was detected by BrdU staining (green), and DNA
was counterstained with DAPI (blue). The percentage of myocytes (MHC positive) and surrounding
fibroblasts (MHC negative) that incorporated BrdU in response to serum is shown in the graph to the right.
Error bars in all graphs indicate one standard deviation from the mean of at least three replicates.
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To complement the in situ analysis of muscle proliferation above, we also
analyzed the permanence of cell cycle exit in a cell culture based assay of muscle
differentiation. This allows us to directly compare the Rb1∆L/∆L, Rb1-/-, and Rb1+/+
genotypes, since Rb1-/- myoblasts don’t form muscle fibers (Huh et al., 2004a). We
infected MEFs with a MyoD expressing retrovirus to induce the formation of myocytes
and stimulated differentiation in low serum as described previously (Novitch et al.,
1996). Prior reports have revealed that Rb1-/- myocytes generated by this methodology
are susceptible to cell cycle re-entry upon serum stimulation (Novitch et al., 1996). The
Rb1∆L allele readily supports a growth factor resistant cell cycle exit that is
indistinguishable from the wild type control (Fig. 2.2E). These data suggest that the
Rb1∆L mutant is capable of supporting a permanent cell cycle exit in terminal
differentiation that is just as robust as wild type. This result stands in stark contrast to the
incomplete senescent arrest described in Figure 2.1 because these cell cycle arrest assays
start with the same fibroblast cells.
Similarly, it is known that conditional deletion of Rb1 in the retina causes cell
death of ganglions, as well as bipolar and rod cells (Chen et al., 2004a). In addition, Rb1
deficiency causes differentiation defects in starburst amacrine cells (SACs). Our analysis
of Rb1∆L/∆L mutants reveals that all of these cell types are specified normally, and at the
same developmental time as wild type (Fig. 2.3A). Cell types that are unaffected by
conditional deletion of pRB are also normal in the Rb1∆L/∆L mutant (Fig. 2.4), indicating
that retinal cells are correctly specified in Rb1∆L/∆L mice. We also investigated the
proliferative status of Rb1∆L/∆L mutant retinas at both P8 and P18. As shown in Figure
2.3B, proliferation has ceased in Rb1∆L/∆L retinas at P8 and remains absent at P18. In
contrast, proliferation persists in conditional Rb1 knockouts at both time points as
indicated by Ki67 staining (Fig. 2.3B). This reveals that the Rb1∆L mutant is capable of
mediating normal cell cycle exit during retinal development, further emphasizing that the
cell cycle exit and terminal differentiation of long-lived cell types is essentially normal in
Rb1∆L/∆L mice.
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Figure 2.3 Developmental cell cycle arrest is normal in Rb1∆L/∆L mutant retinas
(A) Cross sections of retinas were used to examine morphology and cellular composition in eight day-old
newborn mice. Ganglion, bipolar, rod, and starburst amacrine cells (SACs) were stained for the protein
marker indicated to the left of each panel (red or green) and nuclei were counterstained with DAPI (blue).
α-crystalin-Cre deletion of Rb1f/f in the retina and its effects on development in these cells is included as a
control. (B) Cell proliferation in differentiated retinal cells was examined by Ki67 staining (green) and
counterstained with DAPI (blue) in eight day old and 18 day old mice. α-crystalin-Cre deletion of Rb1f/f in
the retina and its deregulation of proliferation is included as a control. The number of Ki67 positive cells
per tissue section was counted for each genotype and is shown to the right. Error bars in all graphs indicate
one standard deviation from the mean of at least three replicates.
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Figure 2.4 Normal specification of cells in the developing Rb1∆L/∆L retina.
P8 retinas were fixed and cryosectioned followed by staining with cell specific retinal markers. Cone cells
were stained with cone arrestin, horizontal cells with calbindin, amacrine cells with calretinin, and Muller
cells were visualized with CRALBP. Tissues were counterstained with DAPI (blue).
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2.3.3

Defective senescence in Rb1∆L/∆L fibroblasts contributes to
immortalization
In contrast to the cell cycle exit that occurs normally during development in

Rb1∆L/∆L mice, we investigated whether the defective senescent arrest allows cells to
escape and resume proliferating. Using a 3T3 culture protocol we passaged wild type
and mutant fibroblasts to determine if they have similar proliferative potential by
measuring the passage at which they enter senescence. Figure 2.5A shows that they enter
senescence at an equivalent passage. DNA replication was measured in successive
passages of senescent cultures by BrdU incorporation and levels were found to be
elevated in Rb1∆L/∆L mutants (Fig. 2.5B, C). This indicates that Rb1∆L/∆L MEFs respond
similarly to a 3T3 culture protocol as they do to other senescence inducing stimuli (Fig.
2.1) that produce an incomplete arrest. To detect early escape from this defective
senescence, we continued to culture these fibroblasts and counted the first passage at
which they resumed doubling as escape (Fig. 2.5A). Based on this criteria, Rb1∆L/∆L
cultures become immortal significantly earlier than wild type controls (P<0.05). This
suggests that cells from Rb1∆L/∆L mutant mice not only enter into an incomplete senescent
state, but this allows them to escape and resume proliferating more readily.
We also sought a developmental comparison for the rapid escape from senescence
that we observed in Rb1∆L/∆L 3T3 cells. Unfortunately, none of the experiments
characterizing the cell cycle arrest of whole tissues in mutant Rb1∆L/∆L mice in Figures 2.2
or 2.3 are capable of detecting rare cells that undergo sporadic DNA replication. Thus, to
search for rare DNA replication events, we analyzed the DNA content of hepatocyte
nuclei. While hepatocytes retain proliferative potential for regeneration that separates
them from muscle and retinal cells, they become extensively growth arrested in adult
mice (Steer, 1996). As mice age, ectopic DNA replication occurs in hepatocytes at a low
level, however, many of these cells fail to undergo a subsequent cell division resulting in
endoreduplication (Mayhew et al., 2005). Thus, rare replication events that accumulate
over time are identifiable by increased nuclear DNA content. Importantly, conditional
deletion of pRB in hepatocytes is known to exacerbate this age dependent,
endoreduplication effect (Mayhew et al., 2005). Our analysis of Rb1∆L/∆L livers showed
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Figure 2.5 Defective senescence of Rb1∆L/∆L mutants contributes to immortalization
(A) MEFs were subjected to a 3T3 culture protocol to induce entry into senescence. We measured the
number of passages that it took the cells to senesce and the number of passages it took them to become
immortalized. Senescence was defined as the first passage without a population doubling and
immortalization was the next passage where cells resumed doubling and continued to double each passage
thereafter. Scatter plots showing the passage where each wild type or Rb1∆L/∆L culture ceased to proliferate
is shown at left. Plots that reveal when cultures resumed proliferating are shown at right. Horizontal bars
represent the mean for each measurement. P values are 0.66 (for entry) and 0.04 (escape). (B) Cells were
counted at each passage to calculate the cumulative population increase and it is plotted against the passage
number. (C) At key passages in this experiment, some cells were grown on cover slips, BrdU labeled, and
the percentage of positive cells was determined.
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Figure 2.6 Normal long term arrest of hepatocytes in Rb1∆L/∆L mutant
(A) H&E and Immuno-histochemical staining of liver sections from wild type and Rb1∆L/∆L mutants stained
with Ki67 antibody (or IgG control). Each field of view is centered on a portal duct to ensure equivalent
orientation of the tissue. (B) DNA content of nuclei extracted from livers was analyzed by PI staining and
flow cytometry. Each ploidy content category is expressed as a percentage of the total number of nuclei
analyzed. Error bars indicate one standard deviation from the mean for at least three replicates. (C) Protein
expression of known E2F target genes as well as other pRB family proteins are shown for nuclear extracts
prepared from hepatocytes.

58

that they appear histologically normal by H&E staining of tissue sections (Fig. 2.6A). We
also didn’t detect any proliferating cells as measured by Ki67 staining in either wild type
or mutant liver sections (Fig. 2.6A) suggesting that the growth arrest is normal in
Rb1∆L/∆L livers. We also found that DNA content increases uniformly with age in wild
type and Rb1∆L/∆L animals, indicative of normal control of DNA replication (Fig. 2.6B).
In addition, expression levels of E2F targets and other RB family proteins remain normal
under these circumstances further suggesting that compensation by related proteins does
not underlie the maintenance of cell cycle arrest in Rb1∆L/∆L hepatocytes (Fig. 2.6C).
Because hepatocytes undergo sporadic DNA replication as part of a normal aging
process, this analysis shows that even the most sensitive measures of DNA replication
support the conclusion that cell cycle exit in development is as robust in Rb1∆L/∆L mice as
wild type controls.

2.3.4

Incomplete senescence in Rb1∆L/∆L cells is characterized by
defective transcriptional repression.
Our initial experiments have revealed that cells from Rb1∆L/∆L mice are defective

in their senescent cell cycle arrest. To explore the cause of this defect further, we
investigated the effects of the Rb1∆L mutation on transcriptional silencing of E2F target
genes. In order to generate an opportunity to manipulate E2F dependent gene
transcription in a senescent environment, we induced senescence using oncogenic ras and
ectopically expressed human E2F1 by subsequent adenoviral infection. In this way we
were able to probe the accessibility and potential for transcriptional activation of E2F
responsive promoters. As shown in Figure 2.7A, E2F1 was expressed equally in wild
type and mutant cells. In addition, expression levels of three E2F responsive targets,
p107, MCM7, and PCNA were increased in the incompletely senescent Rb1∆L/∆L MEFs
and are further elevated by E2F1 expression. More importantly, E2F1 induced higher
levels of BrdU incorporation in Rb1∆L/∆L mutant cells compared to wild type (Fig. 2.7B).
Because basal levels of BrdU incorporation in Rb1∆L/∆L cells are slightly higher than wild
type under these conditions (see Fig. 2.1 E), we also calculated the fold induction of
BrdU incorporation in response to E2F1 (Fig. 2.7B) and this was also significantly higher
in mutant cells (P<0.05). Thus, by using ectopic E2F1 expression we have demonstrated
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Figure 2.7 Defective repression of E2F target genes in senescent Rb1∆L/∆L MEFs
(A) Ten days following retroviral transduction with oncogenic ras, senescent MEFs were infected with
recombinant adenoviruses expressing either GFP or human E2F1 at a multiplicity of infection (MOI) of
100 PFU/cell. The expression level of ectopic E2F1 was measured by western blotting with a human
specific α-E2F1 antibody (KH95) after 48hrs. The protein expression level of three known E2F target
genes is also shown. Western blotting for Actin serves as a loading control. (B) Synthesis of DNA in
response to E2F1 expression was measured by BrdU incorporation. Two days following Ad-E2F1
infection, cells were pulse labeled with BrdU for 16hrs and positive cells were identified by
immunofluoresence microscopy. The fold increase in BrdU incorporation between control and E2F1
infected cells was calculated and is shown in the graph on the right. The mean fold increase was compared
by a t-test (P <0.05). (C) The relative abundance of mRNA corresponding to five E2F target genes is
shown. To facilitate comparisons, the expression level in uninfected wild type cells is designated as a
relative abundance of one. Expression of acidic ribosomal phospho protein P0 (Rplp0) is used as internal
control. (D) The fold increase in mRNA abundance in E2F1 expressing Rb1∆L/∆L cells relative to wild-type
control is shown for each E2F target gene (P value is <0.05 for each gene). Error bars indicate one
standard deviation from the mean for at least three replicates.
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that the incomplete senescent cell cycle arrest in Rb1∆L/∆L cells is more susceptible to
being overridden by proliferative signals that activate E2F dependent transcription.
To examine the transcriptional effects of E2F1 expression more closely we
compared mRNA levels from five well-characterized E2F responsive genes, Pcna,
Ccne1, Ccna2, Rbl1, and Tyms (thymidylate synthase). In each case the expression level
was higher in senescent Rb1∆L/∆L cells than in the wild type controls (Fig. 2.7C). Upon
E2F1 expression, these target genes were also more readily transcribed as they
accumulated to higher levels in the Rb1∆L/∆L mutants. Furthermore, by measuring the fold
induction of each E2F target gene, the ability of E2F1 to activate transcription in Rb1∆L/∆L
cells was again significantly higher than in wild type (Fig. 2.7D). This demonstrates that
cell cycle regulated, E2F-responsive promoters are more readily activated in defectively
senescent Rb1∆L/∆L mutants. This suggests that the transcriptional silencing is probably
altered in senescent Rb1∆L/∆L cells. Importantly, this difference allows E2F1 expression to
stimulate senescent Rb1∆L/∆L cells to synthesize DNA more readily.

2.3.5

Rb1∆L/∆L cells fail to heterochromatinize E2F target gene
promoters in senescence.
Given recent studies that have demonstrated the role of chromatin regulation in

re-organizing the genome during senescence (Narita et al., 2003b), we wondered if the
Rb1∆L mutation affects this process. We sought to investigate repressive histone tail
modifications to determine if they are also altered or absent. In particular, we were
interested in H3K9me3 status because one of the histone methyltransferases responsible
for adding this modification, Suv39h1, is required for oncogene induced senescence
(Braig et al., 2005b) and is reported to interact with pRB through its LXCXE binding
cleft (Nielsen et al., 2001).
Chromatin from proliferating and ras induced senescent cells was
immunoprecipitated to determine the relative abundance of H3K9me3 at E2F responsive
promoters. As a control for our immunoprecipitation experiments we amplified
sequences from the imprinted Airn promoter. Because of its allele specific expression,
we are able to detect H3K9me3 that originates from the silenced allele under all growth
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conditions (Regha et al., 2007). In cells that have been induced to senesce with
oncogenic ras, H3K9me3 becomes enriched at E2F responsive promoters (Fig. 2.8A).
Importantly, H3K9me3 is not enriched at E2F promoters in Rb1∆L/∆L cells. This analysis
reveals that LXCXE interactions by pRB are crucial for assembling heterochromatin in
senescence. In addition to the increase in H3K9me3, it has also been proposed that
repressive marks like H3K27me3 play an important role in silencing cell cycle genes
such as Ink4a in an RB family dependent manner (Bracken et al., 2007; Kotake et al.,
2007). For these reasons we also investigated H3K27me3 histone tail modifications at
the same E2F responsive promoters in senescence (Fig. 2.8B). We also amplified
sequences from HoxD10 homeobox gene promoter that has been shown previously to be
enriched for this mark, as an additional control for our immunoprecipitations. This
analysis demonstrates that some E2F target genes also increase their abundance of
H3K27me3 in senescence when compared with asynchronously growing cells.
Interestingly, deposition of this histone tail modification is not dependent on pRBLXCXE interactions. Given the ability of ectopic E2F1 to activate genes like Ccne1 in
incompletely senescent Rb1∆L/∆L cells and the fact that only H3K9me3 is added at this
promoter in a pRB-LXCXE dependent manner, we suggest that H3K9me3 is a key
repressive modification that silences gene expression.
Assembly of repressive heterochromatin has also been implicated in the
establishment of a stable cell cycle exit in terminal differentiation (Ait-Si-Ali et al., 2004;
Blais et al., 2007; Panteleeva et al., 2007). We next wanted to determine if the epigenetic
landscape of the same E2F responsive genes was similar in differentiated muscle and
whether it differs between wild type and mutant mice. In agreement with previous work,
we found that the H3K9me3 mark can be detected at the promoters of E2F responsive
cell cycle genes in muscle (Fig. 2.9 left). We observed that some promoters like Ccne1
and Mcm3 are enriched for both H3K9me3 and H3K27me3 and in the case of genes like
Mcm5 there is a significant enrichment of H3K27me3 whereas we were unable to detect
H3K9me3 levels above background suggesting it has a prominent role in repression of
this gene (Fig. 2.9). Surprisingly, neither the deposition of H3K27me3 or H3K9me3 is
different between wild type and mutant muscle tissue. This strongly suggests that a
different mechanism governs the silencing of E2F responsive genes in terminal
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Figure 2.8 Disrupted heterochromatin structure in senescent Rb1∆L/∆L cells
(A and B) Chromatin immunoprecipitations (ChIP) were performed on extracts from asynchronous or ras
induced senescent MEFs. Sheared chromatin was precipitated with either rabbit IgG control, antiH3K9me3, or anti-H3K27me3 antibodies. Input control PCR was performed on 0.5% of chromatin used
for each ChIP. Precipitated DNA fragments were amplified by PCR using primers specific for the
promoter regions of Airn, Hoxd10, Pcna, Ccne1, Ccna2, Mcm3 and Mcm5. Band intensities are quantified
using image quantification software from Bio-Rad and presented as graphs. Error bars indicate standard
deviation from mean value generated from multiple trials of chromatin immunoprecipitations.
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Figure 2.9 Heterochromatin regulation during terminal differentiation is distinct
from senescence
Muscle tissue from 6 week old, wild type and mutant mice were used for ChIP with either rabbit IgG
control, anti-H3K9me3 (left) or anti-H3K27me3 (right) antibodies as in figure 2.6. Band intensities are
quantified same as in fig 2.8.
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differentiation. Previous reports demonstrate that H3K9me3 and H3K27me3 deposition
at E2F target genes occurs in response to pRB dependent myogenesis (Blais et al., 2007).
For these reasons we interpret our results to mean that pRB has multiple growth arrest
mechanisms at its disposal, and that the pathways used in cell cycle arrest during
senescence and terminal differentiation are fundamentally distinct.

2.4

Discussion

Our work reveals the surprising finding that pRB possesses the ability to block
DNA replication in senescence using a fundamentally different mechanism from a
permanent cell cycle arrest in development. In particular pRB requires LXCXE type
interactions to regulate chromatin structure and silence E2F responsive genes in
senescence. This is an important distinction because it demonstrates that pRB uses more
than just a single growth suppressive mechanism to block proliferation. It reveals that
specific growth arrest signals like DNA damage elicit different functions from pRB than
the development programs that govern myogenesis and neurogenesis. It also suggests that
different external signals (for example expression of MyoD versus rasV12) could activate
different functions of pRB. Although seemingly growth restrictive there lies an important
qualitative distinction between these two types of stimuli that activate distinct functions
of pRB. Whereas the expression of MyoD in growth restrictive conditions, signal the
cells to exit the cell cycle and differentiate, expression of oncogenic ras under normal
growth conditions activates conflicting signals by driving rapid proliferation on one hand
and activating growth arrest signals by inducing DNA damage on the other. We think it is
in such a context of persistent conflicting signals that specific functions of pRB are
activated, further highlighting its role as a tumor suppressor.
This study emphasizes that cell cycle arrest in senescence requires a repressor
module containing E2F-pRB and a chromatin regulatory component (Fig. 2.10).
Rowland et al. have previously shown that expression of a pRB binding deficient mutant
of E2F3 can disrupt pRB-E2F function in senescence, demonstrating the need for E2F to
recruit this complex to promoters (Rowland et al., 2002). The response of Rb1∆L/∆L cells
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Figure 2.10 Model of cell cycle exit regulation in senescence and terminal
differentiation
During the induction of a senescent arrest, pRB-E2F interactions regulate proliferation sufficiently to
induce a reversible arrest state. Incomplete senescence of Rb1∆L/∆L cells appears to reach this state where
they remain susceptible to re-replication of their DNA. Establishment of a heterochromatin barrier that can
block inappropriate cell cycle re-entry is dependent on pRB-LXCXE interactions and H3K9me3 histone
tail modifications. Cell cycle exit associated with terminal differentiation requires pRB regulation of E2Fs.
Through unknown mechanisms the initial withdrawal from the cell cycle becomes permanent. E2F target
promoters become heterochromatinized with H3K27me3 and H3K9me3 modifications in a manner that is
independent of pRB-LXCXE interactions.
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to DNA damage indicates that the initial steps in cell cycle arrest take place normally
allowing these cells to reach a reversible arrest. This suggests that pRB-E2F interactions
are sufficient to mediate this initial step (Fig. 2.10). The low level of DNA synthesis that
persists over time in Rb1∆L/∆L mutants suggests that the true role for chromatin regulation
by pRB in senescence is to function as a failsafe mechanism in cell cycle arrest that
establishes permanence. Because complete cell cycle exit in senescence is dependent on
chromatin remodeling, we describe pRB’s role at this step as a checkpoint.
The discovery that pRB-LXCXE interactions are dispensable for a terminal
differentiation related cell cycle arrest is very surprising. As stated earlier, an E2F-pRBchromatin regulatory complex such as that shown for a permanent arrest in Figure 2.10
(left) is highlighted in many reviews of pRB function as controlling cell cycle exit in a
ubiquitous arrest scenario that includes terminal differentiation (Brehm and Kouzarides,
1999; Burkhart and Sage, 2008; Classon and Harlow, 2002b; Harbour and Dean, 2000;
Korenjak and Brehm, 2005). We offer the following explanations as well as our own
data in support of the model of terminal differentiation shown in Figure 2.10 (right)
where LXCXE dependent chromatin regulation is dispensable. We think that pRB’s role
in a developmentally induced cell cycle exit may be accomplished largely through
negative regulation of activator E2F activity. This interpretation is supported by the fact
that a number of differentiation defects caused by complete loss of pRB can be rescued
by crossing to null alleles of activator E2Fs. In the murine retina, it is known that
conditional deletion of Rb1 triggers ectopic division and death of ganglions, bipolar, and
rod cells (Chen et al., 2004a). These defects in terminal differentiation are reversed by
E2f1 deficiency. Furthermore, ablation of Rb1 in the telencephalon has been reported to
dissociate proliferative control from the initiation of neuronal differentiation (Ferguson et
al., 2002). Ectopic cell division in the intermediate zone and cortical plate regions of
Rb1-/- brain tissue in these mice can be suppressed by E2f1 or E2f3 deficiency (McClellan
et al., 2007). Beyond E2F regulation, a number of reports have also shown pRB
dependent effects on chromatin in terminal differentiation of muscle that may, on the
surface, seem to contradict our model. Ablation of Rb1 in skeletal muscle progenitors
has been demonstrated to lead to complete failure of myogenesis (Huh et al., 2004a), and
recent experiments using RNAi to deplete pRB expression in myotubes indicates that cell
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cycle re-entry is triggered in its absence (Blais et al., 2007). For these reasons formation
of myotubes and resulting chromatin changes are clearly pRB dependent. However, pRB
is also able to influence the activity of differentiation inducing factors like ID2 and
MyoD and through molecules like these it may regulate chromatin in differentiation
indirectly (Burkhart and Sage, 2008). For these reasons we suggest that chromatin
regulation in terminal differentiation of muscle that is pRB-dependent is either an indirect
consequence of cell cycle exit, is independent of LXCXE interactions with pRB, or is
induced indirectly through pro-differentiation factors (Fig. 2.10, right).
In addition to senescence, we have also determined that pRB-LXCXE interactions
are critical to TGF-β regulation of continuously proliferating mammary epithelial cells
(Francis et al., 2009a). While this is a different growth regulatory paradigm, the ability
of TGF-β to induce senescence through chronic stimulation further suggests that pRBLXCXE interactions can be implicated in a broad, stress responsive growth control
program (Lin et al., 2004). It is tempting to speculate that the pRB-LXCXE dependent
arrest pathway plays a key role in pRB’s tumor suppressor function. We have not
detected spontaneous tumors in our Rb1∆L/∆L mutants (Coschi et al., 2010). However, it is
noteworthy that the Rb1∆L mutation doesn’t abrogate senescence completely, but
uncouples its permanence from the initial arrest. Other genetically modified strains of
mice whose lesions completely abrogate this senescence arrest pathway, such as Ink4a-/mice, already have surprisingly low rates of spontaneous tumorigenesis themselves
(Krimpenfort et al., 2001; Sharpless et al., 2001). Future work to determine the
importance of heterochromatin at E2F responsive targets in senescence will require
crosses to transgenic mice with defined oncogenic lesions. In this way we will be able to
directly relate the chromatin assembly step in senescence to cancer progression.
Intriguingly, our data reveal an unexpected parallel between pRB and p53 in
mammalian physiology. Like our Rb1∆L/∆L mice, Trp53-/- mice are relatively normal
developmentally (Donehower et al., 1992). While, p53’s role in responding to cancer
causing insults like DNA damage is well known, only recently has it been demonstrated
that p53’s role in stellate cell senescence is essential for the liver to respond appropriately
to chemical toxicity and avoid fibrosis (Krizhanovsky et al., 2008). The unique role for
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pRB-LXCXE regulation of chromatin in senescence that we describe offers a similar
glimpse at a fundamental stress response mechanism. Indeed, other reports have
suggested a role for pRB in stress responses (MacLeod, 2008; Mason-Richie et al., 2008).
In particular, lung epithelium appears to use pRB in a very specific role in controlling
proliferation following injury, but not in development (Mason-Richie et al., 2008). Thus,
it seems that pRB plays a unique role in this growth control paradigm that developed to
respond to stressful exogenous stimuli, including DNA damage, the release of TGF-β in
response to tissue trauma, or as a protective response to chemical toxicity. Such
responses, which are largely independent of cell cycle control during development, imply
that a stress-responsive growth control program is a pervasive and important aspect of
mammalian physiology. It is difficult to know to what degree evolution has selected for
anti-cancer functions in the genes that code for p53 and pRB, however, the involvement
of these master regulators in a stress specific growth arrest reveals an important
biological feature of proliferative control. Genes involved in a checkpoint that is stress
responsive, as opposed to ones that are largely regulated by developmental cues, may
offer a starting point for growth control mechanisms that in present day offer antioncogenic properties as genetic damage accumulates in response to environmental
pressures.

2.5
2.5.1

Materials and Methods
Mice

The generation of Rb1∆L/∆L mutant mice has been described previously (Isaac et
al., 2006b). Rb1-/- mice were obtained from MMHCC. Mice bearing Rb1f/f alleles and
the α-crystalin-Cre transgene were generated as before (Chen et al., 2004a). All animals
were housed and handled according to Canadian Council on Animal Care regulations.

2.5.2

Cell culture
Mouse embryonic fibroblasts (MEFs) were generated from d13.5 embryos using

standard procedures and cultured as previously described (Isaac et al., 2006b). Retroviral
transduction with pBABE-HrasV12 was as reported by Serrano et al. (Serrano et al.,
1997b) and viruses were packaged in Bosc-23 cells. Cells infected with viruses encoding
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ras were selected in 4 µg/ml puromycin for at least 3 days before processing for further
experiments using flow cytometry, microscopy, or extract preparation. Senescent cells
prepared by this method were allowed to senescence for at least 10 days following
retroviral infection. Cells induced to senesce with γ-irradiation were exposed to 15 Gys.
Senescence associated β-galactosidase (SA-β-Gal) staining was performed as described
(Serrano et al., 1997b). Infections with Ad-E2F1 were according to standard methods
and cells were cultured for an additional 48 hours before labeling with BrdU for 16 hours,
or preparing extracts. Myogenic differentiation was carried out by infecting MEFs with a
pBABE-MyoD based retrovirus and following the differentiation protocol of Novitch
(Novitch et al., 1996). Cells were re-stimulated with 15% serum and labeled with BrdU
for 24 hours. 3T3 culture assays were carried out following previously reported methods
(Todaro and Green, 1963), as modified by Classon et al. (Classon et al., 2000).

2.5.3

Histology and Fluorescence Microscopy
Haematoxylin and Eosin (H & E) stained tissues were fixed in formalin,

embedded and stained with H&E using standard procedures. All other tissues were fixed
in optimum cutting temperature (OCT) compound and embedded for cryosectioning.
Staining of retinal sections was carried out as described by Chen (Chen et al., 2004a), and
anti-BrdU staining was as recommended by the manufacturer (Becton-Dickinson, San
Jose, California). Cell cultures were fixed and permeabilized in alcohol, blocked, and
stained for BrdU or protein markers as previously described (Isaac et al., 2006b).
Antibodies against MHC were obtained from the Developmental Studies Hybridoma
Bank, University of Iowa.

2.5.4

Quantitation of DNA, protein, and mRNA
DNA content and BrdU incorporation were measured by flow cytometry in Fig.

2.1A and C as described in Isaac et al. (Isaac et al., 2006b). All other measurements of
BrdU incorporation were generated from in situ staining and microscopic evaluation
described above. Flow cytometry measurements of hepatocyte nuclear DNA content
were as described by Mayhew et al. (Mayhew et al., 2005). Protein expression levels
were detected by western blotting using antibodies against E2F1 (KH95), p107 (C-18),
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PCNA (pc10), p130 (C-20) and MCM7 (141.2) from Santa Cruz. Actin (Sigma, A2066)
or Lamin A/C (Chemicon, MAB3211) levels were detected as loading controls. Message
levels for Pcna, Ccne1, Ccna2, Tyms, and Rbl1 were detected using the Quantigene Plex
2.0 reagent system from Panomics (Fremont, CA) and quantified by comparison with the
message for acidic ribosomal phosphoprotein P0 (Rplp0) using a BioPlex200 multiplex
analysis system according to Panomics instructions. Chromatin immunoprecipitation
assays were performed as described previously using anti-H3K9me3 and H3K27me3
antibodies (Upstate) and 2 x 107 cells per immunoprecipitation (Aparicio et al., 2005).
DNA released from precipitated complexes was amplified by PCR using primers specific
to the promoter regions of Airn (AGG GTG AAA AGC TGC ACA AG and CCC TGA
TCA CAG AAC CCT TC) (Regha et al., 2007), Pcna (CTG CGC GAG GTC ATG ACG
CCA and CTT CCG TGG CGC GGA AAC TTC C), Ccne1 (TGA GGG GCT CGC AGC
CCT CG and CCC GGC TTC GAG CGG GAC AT), Mcm3 (GAA TGC AGT GCT TCC
TAG CC and CGG AAG TTT ATG GTG GAG GA) (Blais et al., 2007), Mcm5 (AAC
CAA TAG GAG CGC AGA GA and AAG CCC GAC ATG ACT GTA CC) (Blais et al.,
2007). HoxD10 (GCT GAA AAC CTC CCC ATC TT and CCT ACT TGG CGC ATT
TTC TC), and Ccna2 (ATC CAC TGA GCA GCA GAG AT and TTG TAG TTC AAG
TAG CCC GCG). All primer sequences are oriented in 5`-3` direction.
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Chapter 3

3

The Retinoblastoma protein and PML collaborate to
organize heterochromatin and silence E2F responsive
genes during senescence
3.1

Abstract

Cellular senescence is characterized by silencing of genes involved in DNA
replication and cell cycle progression. Stable repression is crucial for preventing
inappropriate DNA synthesis and maintaining a prolonged senescent state. Many of these
genes are targets for E2F transcription factors. The pRB pathway plays a major role in
senescence by directly repressing E2Fs and also by regulating chromatin at the promoters
of E2F target genes using its LXCXE cleft dependent interactions. In this study, we
sought to investigate the mechanisms by which pRB stably silences E2F target gene
transcription during cellular senescence. We report that in mouse embryonic fibroblasts,
endogenous Promyelocytic leukemia protein (PML) associates with E2F target genes in a
pRB LXCXE dependent manner during HrasV12 induced senescence. Furthermore,
using a PML-IV induced senescence model, we show that the pRB LXCXE binding cleft
is essential for PML association with gene promoters, heterochromatinization and
silencing of E2F target genes. GST pull down assays show that pRB can interact with
PML specifically during senescence, implicating an actively regulated assembly step that
brings PML and pRB together to establish heterochromatin and create a permanent cell
cycle arrest.

3.2

Introduction

Cellular senescence is a stable cell cycle exit that protects cells from
transformation and prevents malignancy (Campisi, 2001). Cellular senescence is
characterized by cell cycle arrest, repression of proliferative genes, and activation of
growth suppressing genes (Chicas et al., 2010). Senescence inducing stimuli such as
telomere shortening, expression of activated oncogenes, and DNA damaging agents cause
DNA damage and subsequent activation of the DNA damage response (Bartkova et al.,
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2006; Di Micco et al., 2006; Mallette and Ferbeyre, 2007). This engages key tumor
suppressor pathways regulated by p53 and pRB proteins that act as the effectors of
senescence by inducing cell cycle arrest (Campisi, 2001).
One of the defining characteristics of senescence is its permanence and senescent
cells are highly refractory to growth promoting signals (Campisi, 2005). Maintaining this
stable cell cycle arrest is also considered to be critical to the tumor suppressive role of
senescence in vivo (Braig et al., 2005). Key to the maintenance of a permanent cell cycle
arrest is stable repression of proliferative genes involved in DNA replication and cell
cycle progression (Chicas et al., 2010). Senescence is often associated with
heterochromatin assembly and this is thought to contribute to stable gene silencing
(Narita et al., 2003). In general, there is enrichment of transcriptionally repressive histone
modifications such as H3K9me3 and H3K27me3 and a decrease in activating marks such
as H3K4me3 on proliferative gene promoters (Chandra et al., 2012; Chicas et al., 2012;
Talluri et al., 2010). Furthermore, in some cell types such as IMR90 fibroblasts these
chromatin changes are accompanied by pronounced compaction of whole chromosomes
into structures that are called SAHFs (senescence associated heterochromatic foci)
(Funayama et al., 2006; Narita et al., 2003; Zhang et al., 2007). Although the precise
contribution of each of these chromatin changes to the senescent state is not fully
understood, they are proposed to contribute to the permanence of senescent arrest by
stably silencing proliferative genes and preventing cell cycle entry (Beausejour et al.,
2003). There is some in vivo evidence supporting this, as mice lacking the enzymes
responsible for these repressive histone modifications show defective chromatin
assembly and increased susceptibility to cancer, suggesting that chromatin changes
contribute to the tumor suppressive role of senescence (Braig et al., 2005).
The pRB-E2F pathway is a key tumor suppressor pathway that regulates the
expression of a number of genes involved in DNA synthesis and cell cycle advancement
in response to growth factor stimuli (Dimova and Dyson, 2005). Many of these
proliferative genes are direct targets of E2F transcription factors, which in turn are
negatively regulated by pRB family proteins. This places the pRB-E2F pathway at the
core of the cellular senescence response. Genetic models have confirmed this hypothesis
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where in MEFs lacking all the RB family proteins (TKO MEFs) fail to senesce, and
immortalize spontaneously in culture (Dannenberg et al., 2000; Sage et al., 2000).
Amongst the pocket protein family, pRB has a unique role in senescence. pRB is required
for repression of key cell cycle genes and prevents DNA synthesis in response to
oncogene expression (Chicas et al., 2010). Furthermore, acute knock down of pRB alone
is sufficient to induce DNA synthesis and cell cycle re-entry in senescent MEFs,
suggesting a crucial role for pRB in the maintenance of a stable senescent state (Sage et
al., 2003). This unique role for pRB can be attributed, at least in part, to its ability to
regulate the heterochromatinization of cell cycle gene promoters and stable silencing of
these genes (Talluri et al., 2010). However, the mechanistic role of pRB in establishing
stable senescence is not understood. Taken together, heterochromatin changes
accompany senescence induced cell cycle arrest, however, it is unclear if these are a
direct effect of pRB, or an indirect consequence of its other functions.
The Pro-myelocytic leukemia protein (PML) is essential for senescence (Bischof
et al., 2002; Ferbeyre et al., 2000; Pearson et al., 2000). PML is the primary component
of PML nuclear bodies, the sub nuclear structures that increase in abundance in response
to a variety of cellular stresses. Expression of oncogenic HrasV12 in fibroblasts results
in a dramatic increase in the number and size of PML nuclear bodies (Ferbeyre et al.,
2000). The essential role for PML in senescence comes from the observation that
fibroblasts from Pml-/- embryos fail to senesce and continue proliferating in response to
HrasV12 (Bischof et al., 2002). Furthermore, forced expression of PML is sufficient to
induce senescence in primary fibroblasts. The Pml gene is subject to extensive alternate
splicing resulting in at least 7 major isoforms PML I-VII that differ mainly in their Cterminal region (Jensen et al., 2001). PML-IV, among the major isoforms, is the only one
able to induce senescence when overexpressed, suggesting an important role for this
isoform (Bischof et al., 2002). However, PML-IV fails to induce senescence when
expressed in Pml -/- MEFs suggesting that other isoforms are also required for efficient
induction of senescence (Bischof et al., 2002).
The precise role of PML and its constituent nuclear bodies during senescence is
an area of intense research. A functional co-operation between PML and pRB-E2F

79

pathways during senescence was recently reported (Vernier et al., 2011). pRB and E2Fs
were shown to localize to the PML nuclear bodies during senescence and disruption of
pRB-E2F interactions, or degradation of RB family proteins by expression of human
papilloma virus E7, was sufficient to compromise PML-IV induced senescence. This
association between PML and pRB-E2F is proposed to be responsible for repression of
E2Fs and their target gene expression. However, since HPV-E7 inhibits RB family
proteins and PML alike, the precise aspects of pRB or PML function that are required for
senescence remain unknown.
We previously showed that MEFs from a gene-targeted mouse carrying a mutant
pRB that is specifically defective for LXCXE type interactions (called Rb1∆L) are
defective for stable repression of E2F target genes during oncogene-induced senescence
(Talluri et al., 2010). This mutation also compromises the stability of senescence arrest
and enables escape. In the current study, we explored the mechanism of pRB mediated
silencing and heterochromatinization of E2F responsive genes using two different
senescence contexts, oncogene induced senescence (HrasV12) and PML induced
senescence (PML-IV). Here we show that endogenous PML is enriched at the promoters
of E2F target genes in a pRB-LXCXE dependent manner during both forms of
senescence. The same E2F target genes fail to be repressed in Rb1∆L/∆L MEFs
overexpressing either HrasV12 or PML-IV. Interestingly, Rb1∆L/∆L MEFs overexpressing
PML-IV fail to enrich the repressive histone mark H3K9me3 at Ccne1 and Mcm3 gene
promoters. This suggests a requirement for PML recruitment by pRB-LXCXE type
interactions to induce heterochromatinization and gene silencing. Furthermore, using
GST pull down experiments we show that PML is only capable of binding pRB under
senescent growth conditions and these interactions are disrupted by mutations in the
pRB-LXCXE binding cleft. Our experiments support a model in which pRB interacts
with PML in a LXCXE cleft dependent manner and this complex mediates
heterochromatinization and silencing of the E2F genes during senescence. Taken
together with previous reports in the literature, our data demonstrates that the interaction
between pRB and PML is critical to switching from a transient arrest state to a permanent
one.
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3.3
3.3.1

Results
Defective enrichment of PML on E2F target gene promoters
in Rb1∆L/∆L cells during senescence

In a previous study we investigated the role of pRB-LXCXE interactions in
cellular senescence using MEFs derived from Rb1∆L/∆L mice (Talluri et al., 2010). We
reported that Rb1∆L/∆L MEFs enter a state of partial senescence in response to oncogenic
HrasV12 expression in which they take on many of the morphological features of
senescent cells, but fail to stably repress E2F target genes, and these genes remain
susceptible to activation by ectopic stimuli. Importantly, the Rb1∆L mutation allows
partially senescent Rb1∆L/∆L MEFs to initiate DNA synthesis, re-enter the cell cycle and
resume proliferation. We found defective enrichment of the repressive histone
modification H3K9me3 on E2F target gene promoters in Rb1∆L/∆L MEFs during
senescence ((Talluri et al., 2010) and Fig. 3.1A). Our goal in this study was to use
Rb1∆L/∆L cells to identify components of the switch mechanism that converts reversible
growth arrest into permanent withdrawal from the cell cycle through heterochromatin
formation at E2F promoters.
We searched for proteins whose association with E2F responsive promoters in
chromatin immunoprecipitation assays (ChIP) is sensitive to the Rb1∆L mutation. We
examined the Ccne1 and Mcm3 gene promoters as these genes are key targets of pRB in
proliferative control during senescence (Chicas et al., 2010). As shown in Fig. 3.1B
endogenous PML is enriched at both these promoters during senescence in Rb1+/+ cells.
Strikingly, this enrichment is eliminated in Rb1∆L/∆L cells suggesting that PML requires
pRB-LXCXE binding cleft mediated interactions for recruitment. Furthermore, pRB is
equally enriched at these promoters in both Rb1+/+ & Rb1∆L/∆L cells (Fig. 3.1C). This
shows that while pRB∆L is capable of binding to E2F target genes during senescence this
mutation specifically disrupts PML association with these promoters, suggesting that it
might participate in the switch from short term to long term growth arrest.
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Figure 3.1 Defective enrichment of the PML (Pro-myelocytic leukemia) protein on
E2F responsive cell cycle gene promoters in senescent Rb1∆L/∆L cells
Asynchronously growing wild type and Rb1∆L/∆L MEFs were induced to senesce by retroviral-mediated
expression of oncogenic HrasV12. Chromatin from proliferating and senescent cells was used for
chromatin immunoprecipitation. Real time PCR was used to amplify the immunoprecipitated DNA using
primers specific to Cyclin E1 (left) and Mcm3 (right). The quantity of precipitated DNA is represented as
percent of input chromatin. (A) ChIP of proliferating and senescent cells of the indicated genotypes using a
α-H3K9me3 antibody or an IgG control. (B) ChIP of chromatin from proliferating and senescent wild type
and Rb1∆L/∆L cells using a α-PML antibody and an IgG control. (C) ChIP on senescent wild type and
Rb1∆L/∆L cells using a α-pRB antibody and an IgG control. Error bars indicate one standard deviation from
the mean, n = 3. An asterisk indicates a statistically significant difference (t-test, P<0.05).
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3.3.2

Early events during senescence induction occur normally in
Rb1∆L/∆L MEFs
Expression of oncogenic ras in primary fibroblasts induces hyper proliferation

resulting in replicative stress and DNA damage (Bartkova et al., 2006; Di Micco et al.,
2006; Mallette et al., 2007). This leads to the activation of DNA damage signaling and
activation of p53 and pRB pathways. Oncogenic ras expression also leads to induction of
PML and PML nuclear body formation in a p53 dependent manner (Ferbeyre et al.,
2000). Persistent activation of the DNA damage response has also been shown to be
important for the maintenance of senescence arrest (Di Micco et al., 2006). We wanted to
investigate whether these signaling events that are required for senescence induction are
intact in Rb1∆L/∆L MEFs and could explain failure to recruit PML to E2F regulated
promoters in senescent Rb1∆L/∆L cells.
First we tested if DNA damage signaling is intact in Rb1∆L/∆L MEFs and if it is
activated in response to ras similar to wild type controls. Rb1+/+ & Rb1∆L/∆L MEFs
induced to senesce by expression of oncogenic HrasV12 were stained with antibodies
against γH2AX a marker of DNA double strand breaks. As a control, we also assessed
DNA damage in low passage, proliferating MEFs. As shown in (Fig. 3.2A and B)
HrasV12 expression induces a significant increase in the number of γH2AX foci both in
wild type and Rb1∆L/∆L MEFs. The damage foci can be seen very early after the
expression of HrasV12 and this damage also persists during senescence in both
genotypes.
We next determined if PML bodies are formed normally in our mutant
background. We used immunofluorescence staining with a α-PML antibody in Rb1+/+
and Rb1∆L/∆L MEFs expressing oncogenic HrasV12. We observed a clear increase in the
number of PML nuclear bodies in senescent cells compared to asynchronously
proliferating MEFs (Fig. 3.2C). Importantly, Rb1∆L/∆L MEFs showed accumulation of
PML bodies similar to wild type cells (Fig. 3.2C and 3.2D). We observed a significant
shift towards more PML bodies per nucleus (>10) in MEFs induced to senesce by
HrasV12 expression (Fig. 3.2D).
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Figure 3.2 Oncogenic ras induces DNA damage and accumulation of PML nuclear
bodies in both wild type and Rb1∆L/∆L cells
Asynchronously growing wild type and Rb1∆L/∆L MEFs were induced to senesce by retroviral-mediated
expression of oncogenic HrasV12. After 3 days of selection, cells were re-plated and cultured for the
indicated amount of time. (A) Immunofluorescent (IF) staining of wild type and Rb1∆L/∆L cells with γH2AX
antibody (Red) to detect double strand breaks at different times after induction of senescence. Nuclei were
counter stained with DAPI (Blue). (B) Quantification of DNA damage foci in A. The percent of nuclei
with >3 γH2AX foci was compared between genotypes. (C) IF staining for PML nuclear bodies using a αPML antibody (Green) and DNA counter staining with DAPI (Blue). Inset images show detailed PML
staining of individual nuclei. (D) Quantification of the number of PML bodies per nucleus in C. The
proportion of cells with fewer than 10, 10 to 25, or more than 25 PML bodies per nucleus are displayed in
graphical format. Error bars represent one standard deviation from the mean, n =3. Scale bars are 50µm.
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Taken together the above experiments suggest that the early events in senescence
leading up to PML body assembly occur normally in Rb1∆L/∆L cells compared to wild
type. This suggests that the defective enrichment of PML on E2F target gene promoters
we observed is not due to decreased PML accumulation in Rb1∆L/∆L MEFs or diminished
signals that induce senescence.

3.3.3

Defective senescence arrest in Rb1∆L/∆L MEFs expressing
PML-IV
We next sought to determine if ectopic PML expression could rescue defective

association with E2F regulated promoters in Rb1∆L/∆L fibroblasts undergoing senescence.
We took advantage of the ability of PML-IV to induce senescence when overexpressed in
MEFs (Bischof et al., 2002; Ferbeyre et al., 2000). We induced senescence in Rb1+/+ and
Rb1∆L/∆L MEFs by expressing FLAG tagged PML-IV by retroviral transduction and
followed the cells over a 10 day time course as above. Following selection in puromycin,
cells were re-plated at low density and cultured for 10 more days to investigate the
induction of senescence. Since PML induced senescence earlier than HrasV12 (Fig. 3.3A
and C) we have focused on day 8 as an equivalent endpoint for these experiments. We
analyzed PML-IV expressing cells for DNA synthesis, senescence associated βgalactosidase expression, and E2F target gene expression. As shown in Fig. 3.3B, FLAGPML-IV is expressed in most cells in both the genotypes tested. 8 days post re-plating
most cells had stopped proliferating as determined by BrdU and senescence associated βgalactosidase (SA-β-gal) staining (Fig. 3.3C, D and E). However, we noticed that the
Rb1∆L/∆L cultures are more densely packed compared to Rb1+/+ MEFs at the same time
points suggesting more cell growth during this time course. To determine if Rb1∆L/∆L cells
continue to proliferate following PML-IV expression before eventually exiting the cell
cycle, we performed BrdU labeling at different time points after initial selection and replating. In response to PML-IV expression, wild type MEFs arrest as early as day 1 after
re-plating and remain arrested throughout the experiment (Fig. 3.3C). In contrast,
Rb1∆L/∆L cells showed elevated DNA synthesis at earlier time points as indicated by
higher BrdU incorporation relative to wild type (Fig. 3.3C). However, 8 days post re-
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Figure 3.3 Defective senescent arrest in Rb1∆L/∆L MEFs expressing PML-IV
Asynchronously growing wild type and Rb1∆L/∆L MEFs were transduced with retroviruses expressing
pBabe-HrasV12 or pBabe-FLAG-PML-IV. After 3 days of drug selection, cells were re-plated in selection
medium and cultured for the indicated amount of time. (A) Cells of the indicated genotypes were pulsed
with BrdU for 4 hours, followed by fixation and staining with α-BrdU antibodies. The % BrdU positive
nuclei at the indicated time points following HrasV12 expression are plotted. (B) Immunofluorescent (IF)
staining was performed with a α-FLAG antibody (Green) to detect FLAG-PML-IV or nuclei with DAPI
(Blue). (C) The percentage of BrdU positive nuclei at the indicated time points following FLAG-PML-IV
expression in the indicated genotypes. (D) PML-IV expressing cells were stained for senescence associated
β galactosidase (SA-β-gal) expression 8 days after the expression of PML-IV. The number of SA-β-gal
positive cells in each genotype were quantified and plotted in the right. (E) Quantification of E2F target
gene mRNA from wild type and Rb1∆L/∆L MEFs either from proliferating (left), or PML-IV expressing cells
(right). Samples are normalized to expression of the ribosomal protein gene Rplp0. (F) Western blots to
determine the expression of protein products of E2F target genes (p107 and cyclin E) following empty
vector (V) or FLAG-PML-IV expression (PML) are shown. Error bars indicate one standard deviation from
the mean, n = 3. An asterisk indicates a statistically significant difference (P<0.05). Scale bars are 50 µm.
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plating Rb1∆L/∆L cells reduce DNA synthesis to control levels (Fig. 3.3C). Furthermore,
both genotypes displayed features of senescent cells at this time point as they were flat
and ubiquitously positive for SA-β-gal expression (Fig. 3.3D & E). This suggests that
pRB-LXCXE interactions are essential for efficient arrest of DNA synthesis and proper
cell cycle exit in response to PML-IV expression, however, mutant cells still possess
features of senescence in response to PML-IV.
One of the major roles of pRB in senescence is repression of E2F target genes
involved in DNA replication and cell cycle advancement (Chicas et al., 2010). We next
investigated if the E2F target genes are silenced in Rb1∆L/∆L MEFs in response to PML-IV
expression and senescence induction. We used 8 days post re-plating as our time point for
assaying E2F target gene message levels as both Rb1+/+ and Rb1∆L/∆L MEFs showed
similar inhibition of DNA synthesis and SA-β-gal expression at this time point (Fig.
3.3C, D & E). We quantified the mRNA levels of six known E2F target genes Ccne1
(cyclin E1), Ccna2 (Cyclin A2), Rbl1 (p107), Tyms (thymidylate synthase), Pcna
(proliferating cell nuclear antigen) and Mcm3 (minichromosome maintenance complex
component 3) along with Rplp0 (60S acidic ribosomal protein P0), as a control (Fig.
3.3F). In proliferating cultures, the expression levels of E2F target genes is similar in
Rb1∆L/∆L MEFs compared to wild type (Fig. 3.3F left). However, in senescent cultures
expressing PML-IV, 8 days post re-plating, we observed elevated expression of the E2F
target genes tested in Rb1∆L/∆L MEFs relative to wild type controls (Fig. 3.3F right).
Moreover, western blotting further confirmed the failure of Rb1∆L/∆L MEFs to properly
repress E2F target gene expression in response to PML-IV as p107 and Cyclin E protein
levels are elevated compared to controls (Fig. 3.3G).
Taken together, BrdU incorporation and E2F target gene expression analysis in
response to PML-IV expression suggest that pRB-LXCXE interactions are required for
proper repression of proliferative genes and efficient exit from the cell cycle. Robust
induction of SA-β-gal suggests that Rb1∆L/∆L MEFs respond normally to other aspects of
PML-IV induced senescence. These data suggest that PML-IV induces an incomplete
state of senescence similar to HrasV12 as we have reported previously. This suggests
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that PML function is critical to the switch that creates a permanent barrier to proliferation
in senescence.

3.3.4

Induction of senescence signals the assembly of PML-pRB
complexes that are essential for heterochromatin formation
in senescence
Senescence is associated with a number of chromatin changes, and

heterochromatin assembly has been suggested to play an important role (Funayama et al.,
2006; Narita et al., 2006; Narita et al., 2003; Ye et al., 2007; Zhang et al., 2007; Zhang et
al., 2005). Both pRB and PML have been shown to be involved in heterochromatin
formation during senescence (Narita et al., 2003; Zhang et al., 2007). Consequently, we
hypothesized that the defective repression of E2F target genes observed in Rb1∆L/∆L
MEFs might be due to the inability of PML to assemble with pRB and regulate
heterochromatin at these promoters.
Our analysis of PML bodies in proliferating and senescent cells in Figure 3.2C &
3.D indicates that PML bodies exist under both growth conditions. Previously, pRB was
shown to bind to PML in interaction assays when over expressed in cancer cell lines
(Alcalay et al., 1998). To distinguish if PML-pRB interactions are simply driven by
abundance, or whether there is an active assembly process, we tested PML binding to the
large pocket fragment of pRB (amino acids 379-928) fused to GST. We performed pull
down experiments with GST-RB or GST-RB∆L using nuclear extracts prepared either
from proliferating MEFs or those made senescent by expressing oncogenic HrasV12. As
shown in Figure 3.4A GST-RB is able to pull down PML protein from senescent nuclear
extracts, but not from proliferating nuclear extracts, even with relatively equal input of
PML proteins. In contrast GST-RB∆L is unable to pull down PML from the same extract
(Fig. 3.4A). Furthermore, GST-p107 is incapable of pulling down PML from the same
extracts (Fig. 3.4B). As a control to show that the GST-RB∆L and GST-p107 proteins are
functional and that equivalent amounts of extract were used in each, we stripped and reprobed the membranes with either E2F3 or E2F4 antibodies respectively. As shown in
Fig. 3.4A, GST-RB∆L is able to pull down E2F3 as efficiently as wild type and
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Figure 3.4 The pRB∆L mutation disrupts PML-pRB interactions during senescence
GST pull down experiments were performed using nuclear extracts from proliferating or senescent MEFs
induced to senesce by expression of oncogenic HrasV12. (A) GST pull down using GST tagged pRB large
pocket or pRB large pocket with ∆LXCXE mutations (∆L). GST alone is used as a negative control. Pull
down fractions were probed with antibodies specific to murine PML and E2F3. (B) GST pull down as in A
using GST tagged p107 large pocket. Pull down fractions are probed with antibodies specific to either
murine PML or E2F4. (C) Nuclear extracts from proliferating and senescent cells were analyzed by SDSPAGE and western blotting with a pan PML antibody that recognizes numerous isoforms. The arrow
indicates a differentially expressed band. (D) GST pull downs were carried out as in A except the blot was
probed with a pan PML antibody that recognizes many PML isoforms. Arrows indicate PML species that
are sensitive to ∆L mutations in pRB. Stars indicate cross reactivity with the GST-RB protein. (E) U2OS
cells were transfected with expression constructs for each of the indicated PML isoforms. Following SDSPAGE and western blotting, membranes were probed with the same pan PML antibody as in C to identify
the migration pattern of PML isoforms.
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GST-p107 is capable of pulling down E2F4 from the nuclear extracts. This indicates that
GST-RB is specifically capable of interacting with PML from senescent nuclear extracts,
it is dependent on LXCXE cleft interactions, and this ability is unique to pRB. These
data suggest that senescence inducing stimuli such as HrasV12 signal the generation of a
unique PML body that can assemble with pRB through its LXCXE binding cleft.
To expand this analysis and better understand the signal that initiates pRB-PML
interactions in senescence, we used a polyclonal antibody that recognizes most isoforms
of PML. First we examined PML protein expression in nuclear extracts from
proliferating and HrasV12 senescent fibroblasts (Fig. 3.4C). This demonstrates the
senescent dependent appearance of bands that react with PML antibodies, most notably at
150 kD molecular weight (Fig. 3.4C, marked by an arrow). In GST-RB pulldown assays
we observed binding of multiple isoforms of PML with pRB in a LXCXE dependent
manner (Fig.3. 4D, marked by arrows). To clarify the identity of PML proteins in this
pulldown assay, we expressed FLAG tagged versions of PML I-VI individually by
transfection and resolved nuclear extracts by SDS-PAGE and identified PML by western
blotting (Fig. 3.4E). In agreement with previous publications, PML isoforms range from
approximately 50 kD to 100 kD. Our pulldown assays reveal that some PML bands
correspond to individual isoforms (eg. at 60 kD). However, it is notable that others at 150
kD and higher do not. PML is extensively modified post translationally by Sumo, among
others in response to stress, which could alter their electrophoretic mobility (Jensen et al.,
2001). We hypothesize that pRB-PML interactions in senescence rely on posttranslational modification of known PML isoforms, to stimulate their interaction.
In order to determine the functional relevance of pRB-PML interactions in
senescence we performed ChIP using α-FLAG antibodies on chromatin from cells that
were induced to senesce by expressing FLAG-PML-IV. While we were able to detect
FLAG-PML-IV on both Ccne1 and Mcm3 promoters in wild type MEFs, we could not
detect a signal above background in Rb1∆L/∆L MEFs (Fig. 3.5A). This further suggested
that PML-pRB interactions are LXCXE dependent at E2F responsive gene promoters.
We next tested if PML-IV interaction with these gene promoters in Rb1+/+ MEFs is
coincident with heterochromatinization by ChIP assay. As shown in Fig. 3.5B, in Rb1+/+
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Figure 3.5 Defective enrichment of FLAG-PML-IV and heterochromatin formation
at E2F target gene promoters in Rb1∆L/∆L MEFs
Asynchronously growing wild type and Rb1∆L/∆L MEFs were transduced with pBabe-FLAG-PML-IV
retrovirus. After 3 days of drug selection cells were re-plated and cultured for 8 more days before
processing for chromatin immunoprecipitation. (A) ChIP on wild type and Rb1∆L/∆L MEFs expressing FlagPML-IV using a α-FLAG antibody or an IgG control. Real time PCR was used to amplify the
immunoprecipitated DNA using primers specific to the promoter regions of Ccne1 (left) and Mcm3 (right).
(B) ChIP on wild type and Rb1∆L/∆L MEFs expressing PML-IV using a α-H3K9me3 antibody or an IgG
control. Real time PCR was used to amplify the immunoprecipitated DNA using primers specific to the
promoter regions of Ccne1 and Mcm3. Error bars indicate one standard deviation from the mean, n = 3.
An asterisk indicates a statistically significant difference (t-test, P<0.05).
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MEFs expressing FLAG-PML-IV, H3K9me3 is enriched at Ccne1 and Mcm3 gene
promoters. In contrast, in Rb1∆L/∆L MEFs the enrichment of this repressive histone
modification following the expression of PML-IV is drastically reduced.
The above experiments show that pRB and PML functionally interact to regulate
the assembly of repressive heterochromatin at E2F target genes involved in replication
and cell cycle progression. Furthermore, this interaction is mediated by the LXCXE
binding cleft of pRB and pRB-PML interactions are actively stimulated by senescence.

3.3.5

Defective chromatin compaction in Rb1∆L/∆L MEFs
undergoing senescence
Expression of oncogenic ras in human IMR90 fibroblasts induces widespread

chromatin compaction. Individual chromosomes condense into distinct structures called
senescence associated heterochromatin foci (SAHF) (Narita et al., 2003). These foci are
also enriched for repressive histone modifications such as tri-methylation of histone H3 at
lysine 9 (H3K9me3) a marker of heterochromatin ((Narita et al., 2003) and Figure 3.6B).
However, in MEFs such global changes in heterochromatin assembly are difficult to
analyze. This is because MEFs under all growth conditions show constitutive
heterochromatin bodies in their nucleus that are stained by DAPI. They are comprised of
the pericentromeric repeat DNA and are called chromocentres.
Interestingly, our analysis of the cells undergoing senescence suggests that the
centromeric chromatin is bundled into fewer but larger chromatin bodies when compared
to asynchronously growing cells (Figure 3.6A, left). Importantly, quantification of the
number of the DAPI rich foci showed that senescent Rb1∆L/∆L MEFs are not as efficient in
compacting their chromatin during senescence compared to the wild type cells (Figure
3.6A, right). Senescent Rb1∆L/∆L MEFs show smaller but more foci per nucleus that is
very similar to what is seen in asynchronously growing cells. Moreover, the foci in the
senescent Rb1∆L/∆L MEFs do not stain positive for the H3K9me3 mark, the same
repressive histone modification that we found to be less enriched at the E2F target gene
promoters in these cells (Figure 3.6B). This suggests that pRB plays a role in both
heterochromatinization of the E2F target gene promoters and broader chromatin
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Figure 3.6 Defective chromatin compaction in Rb1∆L/∆L MEFs
Asynchronously growing wild type, Rb1∆L/∆L MEFs and IMR90 human fibroblasts were induced to senesce
by retroviral mediated expression of oncogenic HrasV12. After three days of initial selection, cells were replated at low density and cultured for additional ten days when they become senescent. A) DAPI stained
confocal images of asynchronously growing and senescent wild type and Rb1∆L/∆L MEFs showing
chromocenters. Quantification of the number of nuclei with indicated number of chromocentres (N=2). B)
Immunofluorescent (IF) staining of senescent wild type, Rb1∆L/∆L MEFs and IMR90cells with H3K9me3
antibody (Green). Nuclei were counter stained with DAPI (Blue). Scale bars are 10 µm.

93

compaction in a LXCXE dependent manner during senescence. In the future, it would be
interesting to determine if these two phenomenon are related or if they are two
independent functions of pRB during senescence.

3.4

Discussion

Our study demonstrates the cooperative action of PML and pRB during
senescence in silencing of E2F target genes involved in DNA synthesis and cell cycle
advancement. This interaction is important for heterochromatinization of these promoters
as H3K9me3 deposition is severely reduced when PML and pRB are unable to assemble
together at these promoters. Using a mutant version of pRB that is defective for LXCXE
type interactions we demonstrated that senescence actively stimulates interactions
between PML and pRB through this conserved interaction domain on pRB. The
complexity of PML protein isoforms that exist in senescent cells likely contributes to
their interaction with pRB. This assembly step is key to understanding the events that
commit senescent cells to a permanent cell cycle arrest, and our study adds important
new knowledge to ongoing work on this question.
Previous work using Rb1∆L/∆L MEFs and mice have allowed us to probe the
circumstances where pRB uses LXCXE type interactions in cell cycle arrest.
Surprisingly, pRB-LXCXE interactions are critical for stress responsive growth arrest,
but not in reversible growth arrest or cell cycle arrest in development, even though each
paradigm of proliferative control is pRB dependent (Andrusiak et al., 2013; Isaac et al.,
2006a; Talluri et al., 2010). Notably, senescent Rb1∆L/∆L MEFs can re-initiate DNA
synthesis in response to ectopic E2F1 expression whereas wild type cells are resistant
(Talluri et al., 2010). Furthermore, serially cultured Rb1∆L/∆L MEFs escape senescence
more readily than their wild type counterparts, suggesting that defective silencing of
proliferative genes can compromise the long-term stability of senescence arrest (Talluri et
al., 2010). For these reasons we have described Rb1∆L/∆L cells as entering into a state of
partial senescence, whereby morphological features of senescence and SA-β-gal activity
are typical of senescent cells, but their arrest remains reversible. A role for PML in gene
silencing in growth control has been suggested, but has been less clear. First, ectopic
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expression of PML inhibits growth of a number of cancer cell lines (Fagioli et al., 1998;
Le et al., 1998). In addition, PML is also able to suppress the transformation of
fibroblasts by activated oncogenes (Liu et al., 1995; Mu et al., 1994). Indeed, Pml-/- mice
show increased susceptibility to cancer promoting agents (Salomoni and Pandolfi, 2002;
Wang et al., 1998). Interestingly, in a recent study by Vernier et al. the authors showed
that expression of PML in U2OS osteosarcoma cells results in the association of PML
with E2F target genes and repression of their expression (Vernier et al., 2011). However,
other studies have suggested that the formation of PML nuclear bodies is dispensable for
induction of senescence and that the constituent proteins are key (Bischof et al., 2002).
Our work reconciles these conflicting observations from two perspectives. Demonstration
that endogenous PML proteins associate with E2F target promoters during the induction
of senescence places PML in the right genomic location at the appropriate time to play an
active role in repression of these genes by directing heterochromatin assembly.
Furthermore, studies that suggest PML body formation is dispensable for senescence predate our description of incomplete senescence. Thereby, cells that are incapable of
assembling PML bodies, but that still become SA-β-gal positive, may not have silenced
E2F target genes and remain capable of cell cycle re-entry.
In our studies we demonstrate that HrasV12 expression in Rb1∆L/∆L fibroblasts
triggers a similar DNA damage response as in control Rb1+/+ cells. In addition, the
quantity of PML bodies that are induced by HrasV12 in Rb1∆L/∆L and Rb1+/+ cells is
similar. Differences only appear when PML fails to associate with E2F target genes in
senescing Rb1∆L/∆L fibroblasts. We interpret this defect to result from the failure of an
active PML-pRB assembly step. We describe this event as active assembly because
similar quantities of PML protein from proliferating cells fail to bind to GST-RB-LP in
our assays. This interaction assay is highly relevant to PML-pRB interactions in vivo
because it is disrupted by the same LXCXE binding cleft mutation as is present in
Rb1∆L/∆L fibroblasts. Understanding how PML engages this binding site on pRB is
complex. Since PML is not reported to contain an LXCXE motif it may be that the
interaction is indirect and could be mediated by one or more proteins that bind to pRB
through its LXCXE binding cleft. HDACs are one such potential candidate as they have
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been shown to interact with both pRB and PML (Dick, 2007; Wang et al., 1998). We
don’t favor this interpretation because our previous studies have indicated that HDAC
containing complexes interact with pRB in this type of pull down assay in a passive
fashion (Isaac 2006). Based on this line of reasoning we expect that PML-pRB
interactions are likely quite direct.
There are at least 6 isoforms of PML (I-VI) capable of forming nuclear bodies,
and pRB has been shown to bind some isoforms preferentially (Alcalay et al., 1998).
Oncogene induced senescence results in the up regulation of PML at the transcriptional
and translational levels (de Stanchina et al., 2004; Ferbeyre et al., 2000). Thus,
expression of PML increases in senescence, but our data indicates that relatively equal
quantities of PML obtained from proliferating cells still fail to bind to GST-RB. We
hypothesize that the signal to actively form pRB-PML interactions may be coincident
with PML body assembly. Examination of the forms of PML present in nuclear extracts
of senescent cells compared to proliferating indicates that senescence generates species of
PML that are far larger than the predicted molecular weights of the largest PML
isoforms. This implies that post translational modifications, such as Sumoylation, may
trigger PML body assembly as well as direct the interaction with pRB.
The precise mechanism of how PML-pRB complexes inhibit the expression of
E2F target genes is still unclear. Defective enrichment of repressive histone modification
H3K9me3 in Rb1∆L/∆L MEFs provides a clue. PML might recruit and/or facilitate the
incorporation of this mark to render the genes transcriptionally inert. Indeed both pRB
and PML are reported to interact with Suv39h1, the enzyme capable of trimethylating
histone H3K9 (Carbone et al., 2006; Nielsen et al., 2001). In addition, Suv39h1 knock out
mice are defective for chromatin condensation in senescence (Braig et al., 2005).
Unfortunately, we were unable to reliably detect an interaction between pRB and
Suv39h1 either by co-immunoprecipitation or by ChIP in extracts from senescent MEFs.
It is possible that this interaction is very transient and the conditions we used in our
experiments were not conducive to detecting this interaction. Alternatively, a different
enzyme may be responsible for incorporating this modification at E2F target gene
promoters during senescence in a PML-pRB dependent manner. Nevertheless, ectopic
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expression of PML-IV in Rb1∆L/∆L MEFs demonstrates that H3K9me3 addition to
promoters might be dependent on PML-pRB interactions and the active processes
described above. Previously, Nielsen et al. have demonstrated that Suv39h enzymes
passively interact with GST-RB in an LXCXE cleft dependent manner. For this reason,
we expect that the actual enzymatic methylation of H3K9 is downstream of a cell’s
commitment to enter a permanently arrested state. Our data suggests that PML-pRB
interactions are likely closer to the switch that converts reversible arrest to permanent
through E2F target gene heterochromatinization. Future work in this area will need to
focus on the signals that assembly PML-pRB complexes as they hold the key to
understanding how senescent cells become committed to permanent cell cycle arrest.
Furthermore, more work is needed to better define the relationship between promoter
level chromatin modifications and global chromatin reorganization during senescence.

3.5
3.5.1

Material and Methods
Cell culture

Mouse embryonic fibroblasts (MEFs) were generated from E13.5 embryos using
standard procedures and cultured as previously described (Isaac et al., 2006b). The Rb1∆L
allele encodes I746A, N750A, and M754A substitutions, and is detected by PCR
genotyping as reported before (Isaac et al., 2006a). All cells were cultured in Dulbecco
modified Eagle medium (DMEM) supplemented with L-glutamine, streptomycin,
penicillin, and 10% fetal bovine serum in a 37°C incubator with 5% CO2. Retroviral
transduction with pBABE-HrasV12 was done as reported by Serrano et al. (Serrano et al.,
1997) and viruses were packaged in Bosc-23 cells. Cells infected with viruses encoding
ras were pre-selected in 4µg/ml puromycin for at least 3 days before re-plating and
further culturing in selection medium for 1, 5, 8 or 10 days depending on the experiment.
Senescence associated ß-galactosidase (SA-β-gal) staining was performed as described
(Serrano et al., 1997).

3.5.2

Immunofluorescence
Cells on coverslips were fixed in 4% PFA for 10 min at room temperature (RT),

permeablized with 0.5% triton- X-100 for 5min at RT, blocked with 3% BSA/PBS for 15
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min, followed by incubation with primary antibodies diluted in blocking buffer for 1hr at
RT or overnight at 4oC in a humidified chamber. Cells were washed in the blocking
buffer 5min each for 3 times. Cells were incubated with secondary antibody diluted in
blocking buffer for 1hr at RT. Cells were washed again 3 times in PBS followed by
mounting on slides with mounting medium containing DAPI before analyzing by
Confocal microscopy.

3.5.3

mRNA expression analysis
mRNA expression analysis of the E2F target genes was done using Quantigene

Plex 2.0 reagent system from Affymetrix (Santa clara, CA) using a BioPlex200 multiplex
analysis system according to Affymetrix instructions.

3.5.4

GST pull downs and Immunoprecipitations
For GST pull down assays, nuclear extracts were prepared as described before

(Cecchini and Dick, 2011). GST tagged proteins were expressed in E. coli and purified
using glutathione sepharose beads. Nuclear extracts were diluted in low-salt GSE buffer
(20 mM Tris [pH 7.5], 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT and
0.1% NP-40) and incubated with either GST, GST-RB (large pocket, amino acids 379928), GST- RB∆L (large pocket, with I753A, N757A, and M761A substitutions) or GSTp107 (large pocket, amino acids 385-1069) for 1 hr. Protein complexes were collected
with 25 µl of Glutathione sepharose bead slurry for 1 hr. and eluted in 1X SDS PAGE
sample buffer before using for western blots.

3.5.5

Chromatin Immunoprecipitations
Senescent MEFs were fixed in 1% formaldehyde in PBS for 10 min at room

temperature. The reaction was stopped with Glycine at a final concentration of 0.125M.
Chromatin was extracted as described before (Cortazar et al., 2011) with the following
changes. Cells were sonicated for 30  min (30  s on, 30  s off, power high) using a Bioruptor
sonicator (Diagenode). Diluted chromatin was pre-cleared at 4  °C for 1  h with 40  µl of a
50% slurry of magnetic Protein G Dyna beads (Invitrogen) pre bound with respective
IgG. Pre-cleared chromatin was incubated with 5  µg of the antibody overnight at 4  °C
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with gentle rotation. DNA was purified by using PCR purification kit from Invitrogen.
Real-time PCR amplification was performed using iQSYBRGreen master mix on a
BioRad CFX Connect Real Time System.

3.5.6

Antibodies
Anti-H3K9me3 (07-442), anti-γH2AX (05-636) and mouse anti-PML

(MAB3738) antibodies are from Millipore. Anti-FLAG antibody (F-1804) is from Sigma.
Anti-pRB (M-153), anti-PML (polyclonal) antibody H-238 (SC-5621) and anti-p107
(SC-318) antibodies are from Santa Cruz biotechnology. The anti-Cyclin-E antibody was
purchased from Abcam (ab7959).
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Chapter 4

4

Mutation of the LXCXE binding cleft of pRB allows
escape from oncogenic ras induced senescence and
transformation in vitro but does not promote
tumorigenesis in vivo
4.1

Abstract

The Retinoblastoma protein (pRB) is a key tumor suppressor that is functionally
inactivated in most cancers. pRB regulates the cell division cycle and cell cycle exit
through protein-protein interactions mediated by its multiple binding interfaces. The
LXCXE binding cleft of pRB mediates its interactions with cellular proteins that have
chromatin regulatory functions. Chromatin regulation mediated by pRB is vital for stress
responsive cell cycle arrest such as oncogene induces senescence (OIS). The in vivo role
of chromatin regulation during oncogene induced senescence and its relevance to tumor
suppression is an area of active investigation. Using gene-targeted mice uniquely
defective for pRB mediated chromatin regulation we investigated its role during
transformation and tumor progression in response to activation of oncogenic ras. We
report that the Rb1∆L mutation confers susceptibility to escape from HrasV12 induced
senescence and allows transformation in vitro although these cells possess high levels of
DNA damage. In contrast, the same mutation does not promote tumorigenesis in tumor
models with activated ras mutations. Intriguingly, KrasG12D, Rb1∆L/∆L mice show
delayed lung tumor formation compared to controls. This is likely due to the increased
apoptosis seen in the atypical hyperplastic lesions shortly following ras activation in
KrasG12D, Rb1∆L/∆L mice. Furthermore, DMBA treatment to induce ras mutations in
other tissues also failed to reveal greater susceptibility to cancer in Rb1∆L/∆L mice. Our
data suggests that chromatin regulation by pRB can function to limit proliferation, but its
loss fails to contribute to cancer susceptibility in ras driven tumor models because of
elevated levels of apoptosis.
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4.2

Introduction

Oncogene induced senescence (OIS) has emerged as a putative tumor suppressor
mechanism acting as a barrier for transformation in vivo (Campisi, 2001). Pre-malignant
lesions such as melanocytic nevi and prostatic intraepithelial neoplasias (PIN lesions) in
humans are rich in cells expressing markers of senescence, while senescent cells are
rarely found in the corresponding malignant stages (Chen et al., 2005; Collado and
Serrano, 2010; Michaloglou et al., 2005). In recent years several mouse models of human
cancer have been generated that show activation of senescence in response to the
expression of oncogenes (Collado and Serrano, 2010). Similar to human lesions,
senescence in these mouse models is predominantly associated with pre-malignant stages
of tumorigenesis suggesting a role for senescence in inhibiting or delaying tumor
progression in response to oncogene activation in vivo.
Senescence is associated with activation of key tumor suppressor pathways
regulated by p53 and pRB proteins (Campisi, 2005; Campisi and d'Adda di Fagagna,
2007). These two pathways coordinately inhibit the growth of pre-cancerous cells and
prevent them from becoming tumors. Accordingly, disruption of these tumor suppressor
pathways results in increased susceptibility to tumorigenesis in response to oncogenes
(Braig et al., 2005; Chen et al., 2005; Dankort et al., 2007; Goel et al., 2009; Sarkisian et
al., 2007). In mouse models, simultaneous activation of oncogenes such as HrasG12V or
BRAFV600E combined with loss of p53 or p16 that act upstream of pRB resulted in
escape from OIS and malignant transformation (Dankort et al., 2007; Goel et al., 2009;
Sarkisian et al., 2007). Notably, enhanced tumor progression in these models strongly
correlates with loss of oncogene induced senescence markers, further supporting the
notion that escape from OIS is a prerequisite for malignant progression.
Senescence is a permanent cell cycle exit in which senescent cells can remain in a
state of arrest throughout the life span of the organism (Campisi, 2005). The permanence
of senescent arrest is partly attributed to the chromatin changes that are transcriptionally
repressive and non permissible to DNA synthesis and cell division (Narita, 2007).
Senescent cells form heterochromatin bodies called SAHFs (senescence associated
heterochromatic foci) that are proposed to encompass and silence proliferative genes
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(Narita et al., 2003). SAHFs are enriched in repressive chromatin modifications such as
H3K9me3 and H3K27me3 and several chromatin associated proteins that aid in
chromatin compaction and transcriptional repression (Chandra et al., 2012; Narita et al.,
2003). Defects in this heterochromatin assembly pathway compromises the stability of
the senescence arrest in vitro and are predicted to promote tumorigenesis in vivo (Braig et
al., 2005). Intriguingly, mice lacking Suv39h1, the enzyme capable of tri-methylating
histone H3K9, show defective senescence in response to oncogenic stress and increased
susceptibility to tumorigenesis in the Eµ-Nras model that expresses oncogenic NrasG12D
in the hematopoietic compartment (Braig et al., 2005). However, whether or not the
chromatin changes during senescence have a broader tumor suppressive role in vivo, in
response to oncogene activation in different tissues is still an open question and needs
further investigation.
Lung cancer is the leading cause of cancer related deaths in humans and the most
common type of lung cancer is pulmonary adenocarcinoma (Herbst et al., 2008; Jemal et
al., 2008). Activated Kras mutations are the most frequently genetic alteration associated
with approximately 30% of human lung adenocarcinomas (Herbst et al., 2008; Rodenhuis
and Slebos, 1990). Over the last two decades a number of mouse models have been
generated to model human lung adenocarcinomas in mice and they have greatly aided our
understanding of the progression of the disease and the oncogene and tumor suppressor
pathways involved in the process (Meuwissen and Berns, 2005). Conditional mutant
models were generated harboring a latent mutant allele of Kras (LSL-KrasG12D) at its
endogenous locus that can be activated sporadically in the lung cells by administering a
cre expressing adenovirus (DuPage et al., 2009; Jackson et al., 2001; Meuwissen et al.,
2001). This model closely mimics the human disease and has been helpful in
understanding different stages of lung cancer progression.
The pRB tumor suppressor pathway is disabled in most human cancers (Sherr and
McCormick, 2002). Although mutations of RB1 are rare in lung adenocarcinomas,
CDKN2A, the gene encoding p16INK4a the upstream activator of pRB pathway is
frequently targeted for mutations in these tumors (Wistuba et al., 2001). p16Ink4a is a
cyclin dependent kinase inhibitor (CKI) that inhibits D type cyclins in the G1 phase of
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the cell cycle resulting in hypo-phosphorylation and activation of pRB in response to
oncogenic insults. The pRB tumor suppressor protein acts by repressing E2F dependent
transcription of genes involved in cell cycle progression both by direct binding and also
through recruitment of chromatin regulatory complexes to these promoters (Dick, 2007).
pRB is one of the major effectors of senescence and both E2F inhibition and chromatin
regulatory functions are crucial for proper senescence arrest in cultured cells in response
to activated oncogenes (Narita, 2007; Narita et al., 2003; Talluri et al., 2010). In the LSLKrasG12D lung cancer model, lack of pRB promotes malignant transformation and
enhance tumorigenesis (Ho et al., 2009). However, the contribution of different functions
of pRB to its tumor suppressive role in this model is still not completely clear as
complete deletion of the Rb1 gene has many effects.
In order to investigate the role of chromatin regulation by pRB during oncogene
induced senescence and tumorigenesis in vivo, we used a gene targeted mouse model in
which the endogenous Rb1 allele is replaced by a mutant allele Rb1∆L that is defective in
binding to chromatin regulators (Isaac et al., 2006). This allowed us to study the role of
chromatin regulation by pRB in isolation, as the pRB∆L is able to interact with and
regulate E2F transcription factors similar to wild type. In order to investigate what affect
the Rb1∆L mutation might have on tumor susceptibility in vivo in response to activated
oncogenes, we crossed Rb1∆L/∆L mice with LSL-KrasG12D mice. We show that the
Rb1∆L mutation allows escape for OIS and transformation in vitro. However, these cells
sustain extensive DNA damage. Surprisingly, the Rb1∆L mutation delays lung tumors in
the LSL-KrasG12D mice. Rb1∆L/∆L; LSL-KrasG12D compound mutant mice show fewer
lung adenomas compared to LSL-KrasG12D mice alone following adenovirus-cre
mediated activation of oncogenic KrasG12D in the lung. Increased apoptosis in the
atypical hyperplastic lesions early during tumorigenesis correlates with reduced
adenomas later during tumor development. However, this defect did not affect the tumor
free survival of these mice. We further show that chromatin regulation by pRB does not
affect tumor free survival in a DMBA chemical carcinogen induced tumorigenesis model.
Taken together our results suggest that loss of chromatin regulation by pRB facilitates
escape from cell cycle arrest, but elevated levels of apoptosis prevent it from synergizing
with oncogenic ras.
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4.3
4.3.1

Results
The Rb1∆L mutation promotes escape from OIS and
transformation in vitro

Using mouse embryonic fibroblasts (MEFs) we previously reported that the pRB LXCXE
binding cleft mediated interactions are required for heterochromatin assembly and stable
repression of E2F target genes during senescence (Talluri et al., 2010). In response to
oncogenic HrasV12 expression, Rb1∆L/∆L MEFs undergo a defective senescence arrest
that is characterized by elevated DNA synthesis and sensitivity to cell cycle re-entry in
response to stimuli such as ectopic E2F1 expression. We wondered if the Rb1∆L mutation
allows senescent Rb1∆L/∆L MEFs to escape permanently from oncogenic HrasV12 induced
senescent arrest and immortalize. In order to test this, we induced senescence in
asynchronously growing wild type and Rb1∆L/∆L MEFs by expressing oncogenic HrasV12
by retroviral transduction. HrasV12 expressing cells were selected for 3 days in
puromycin containing medium following which they were re-plated at low density and
cultured further in selection medium until they become senescent. 10 days after replating, most cells in both genotypes were senescent as determined by senescence
associated β-galactosidase (SA-β-gal) staining and BrdU incorporation (Fig 4.1A). We
then continued to culture the cells in puromycin containing medium to monitor
spontaneous escape from senescence arrest. We quantified the number of spontaneous
escape events by counting the distinct foci that appear in the senescent cultures. We
counted a significantly higher number of foci in Rb1∆L/∆L cultures compared to the wild
type cultures 3 weeks following HrasV12 expression (Fig. 4.1B). The cells in these foci
have lost the characteristic features of senescence such as flattened morphology,
vacuolated cytoplasm and enlarged nucleus. Interestingly, the foci in Rb1∆L/∆L cultures are
bigger and often formed multilayered aggregates suggestive of loss of contact inhibition,
characteristic of immortalized cell clones (Fig. 4.1C). This suggests that the Rb1∆L
mutation confers increased susceptibility to escape from oncogene induced senescence
(OIS) and this might lead to spontaneous immortalization in culture.
In order to determine if these foci are composed of immortalized cells that have
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Figure 4.1 Escape from oncogenic HrasV12 induced senescence arrest and
transformation in Rb1∆L/∆L MEFs
Asynchronously growing wild type and Rb1∆L/∆L MEFs are induced to senesce by retroviral mediated
expression of oncogenic HrasV12. After 3 days of pre-selection cells were plated in selection medium and
cultured for at least 10 days. All the cells were pulsed with BrdU for 4 hrs. A) % BrdU and SA-β-gal
positive cells in senescent Rb1+/+ and Rb1∆L/∆L cultures. B) Quantification of senescence escaped foci from
Rb1+/+ and Rb1∆L/∆L cultures. Average number of foci formed 3 weeks post pre-selection were compared
between genotypes (student t-test). C) Phase contrast images of wild type and Rb1∆L/∆L cells either
senescent (10 days post pre-selection) or escaped (3 weeks post pre-selection). D) % BrdU and SA-β-gal
positive cells in escaped Rb1+/+ and Rb1∆L/∆L clones. Escaped Rb1∆L/∆L clones were grouped into slow
growing (slow) or fast growing (fast) based on their proliferative capacity as determined by BrdU
incorporation and SA-β-gal staining. E) Escaped Rb1∆L/∆L clones show increased anchorage independent
growth in soft agar. 293-T cells were used as a positive control. Arrowheads point toward dead cells
Quantification of the number of colonies after 2 weeks of culturing in soft agar is shown on the right.
Average number of colonies/field (5x) from 10 random fields. (* p<0.05).
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permanently escaped from senescence and to study their growth characteristics we
isolated cells from the foci from both Rb1+/+ and Rb1∆L/∆L cultures expressing HrasV12.
We sub-cultured the cells extracted from the foci in puromycin containing medium and
analyzed them for proliferation and senescence using BrdU labeling and SA-β-gal
staining respectively. Interestingly, most of the clones recovered from Rb1+/+ cultures
failed to survive the sub-culturing process and all of them eventually arrested with
features of senescence (Fig.4.1D). In contrast, we were able to successfully sub-culture
about half the clones generated from Rb1∆L/∆L cultures. However, these clones showed
varied growth properties prompting us to categorize them into slow growing and fast
growing groups (Fig. 4.1D). The slow growing clones (Rb1∆L/∆L slow) still showed
significantly higher BrdU incorporation compared to the cells from Rb1+/+ clone which
showed growth properties very similar to senescent cultures (Fig. 4.1A and 4.1D).
Strikingly, the fast growing clones (Rb1∆L/∆L fast) had a very high proportion of BrdU
positive cells and very few cells stained positive for SA-β-gal. These cells showed highly
refractive spindle shaped appearance and had an increased metabolic rate as suggested by
rapid acidification of culture medium. This suggests that the Rb1∆L/∆L MEFs that escape
from oncogenic HrasV12 induced senescent arrest have increased proliferative capability
and some of them show characteristic properties of immortalized cell clones.
We next performed soft agar colony formation assays to determine if any of the
escaped clones are capable of anchorage independent growth, indicative of
transformation in vitro (Fig.4.1E). We used 293-T transformed cell line as a positive
control for our assay. After two weeks of culturing, most cells from the Rb1+/+ clone
failed to grow in soft agar and many of the cells died. In contrast, cells from the fast
growing Rb1∆L/∆L clones formed multicellular aggregates suggesting that they are capable
of anchorage independent growth. Interestingly, although some of the cells from the slow
growing Rb1∆L/∆L clones managed to form small aggregates in soft agar, we noticed cell
death in these aggregates that seem to limit further growth. This suggested that in contrast
to the Rb1+/+ clones, senescence escaped Rb1∆L/∆L clones are capable of anchorage
independent growth. However, cell death limits the in vitro transformation potential of
these clones.
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Taken together, the experiments above suggest that the Rb1∆L mutation promotes
escape from oncogenic HrasV12 induced senescence and immortalization in vitro. Some
of these clones attain anchorage independent growth potential in soft agar, suggestive of
transformation.

4.3.2

The p53-p21 pathway limits the growth potential of escaped
Rb1∆L/∆L cell clones expressing HrasG12V
We wanted to further investigate the molecular basis of differential growth

properties and in vitro transformation abilities of the senescence escaped clones and to
determine which other pathways might be limiting the transforming ability of these
clones. Oncogenic ras induces hyper proliferation and replication stress resulting in
increased DNA damage (Bartkova et al., 2006; Di Micco et al., 2006; Mallette and
Ferbeyre, 2007). Elevated DNA damage signaling (DDR) results in the phosphorylation
and activation of the p53 tumor suppressor protein. Loss of pRB function has previously
been shown to result in aberrant p53 activation mediated by E2F-p19 (ARF) pathway
leading to increased apoptosis limiting the transformation ability of oncogenic ras (Lara
and Paramio, 2007). Interestingly, the Rb1∆L mutation leads to deregulated E2F target
gene expression during senescence in response to HrasV12 (Talluri et al., 2010). So, we
wondered if the p53 pathway could act as a checkpoint in the absence of pRB function in
limiting the transforming ability of the escaped Rb1∆L/∆L clones.
We first analyzed if DNA damage signaling is intact in the Rb1+/+ and Rb1∆L/∆L
clones (Fig. 4.2A and B). Escaped clones from both the Rb1+/+ and Rb1∆L/∆L senescent
cultures showed high level of DNA damage as shown by increased γH2AX foci/nucleus
(Fig. 4.2A). Strikingly, the fast growing clones have significantly higher number of
foci/cell (>10) compared to both the slow growing Rb1∆L/∆L and the Rb1+/+ clones.
Moreover, we often found cells in the Rb1∆L/∆L clones where γH2AX stained the entire
nucleus suggestive of drastic DNA damage. We speculate that this might be due to the
high rate of proliferation in these clones causing replicative stress. We then did western
blotting for γH2AX. As shown in Fig. 4.2B (right), we were able to detect γH2AX in all
the clones. However, similar to IF, the fast growing Rb1∆L/∆L clones showed relatively
higher levels of γH2AX compared to the slow growing clones suggesting elevated DNA
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Figure 4.2 Increased DNA damage in senescence escaped Rb1∆L/∆L clones
Escaped Rb1+/+ and Rb1∆L/∆L clones from Fig. 4.1 are stained with antibodies against γH2AX and PML. A)
Immuno fluorescent staining of escaped Rb1+/+ and Rb1∆L/∆L clones with γH2AX antibody to determine the
extent of DNA damage. Quantification is shown on the right. B) Western blots for DDR proteins in
senescent Rb1+/+ and Rb1∆L/∆L MEFs (left) and slow and fast growing Rb1∆L/∆L clones (right) C) Immuno
fluorescent staining of escaped Rb1+/+ and Rb1∆L/∆L clones stained with PML antibody. Quantification is
shown on the right. (* Student t-test p<0.05). Scale bars are 10µm.
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damage. All the clones however, showed similar expression of ras by western blotting
(Fig. 4.2B right). We wondered if the increased DNA damage results in the activation of
the p53-p21 pathway in these clones. As shown in figure 4.2B, we could detect
phosphorylation of p53 at ser15 in response to the DNA damage and we interpret p53 to
be active in these cells because we also detect p21 expression. Interestingly, in the fast
growing Rb1∆L/∆L clones p53 is incapable of inducing the expression of p21 despite being
phosphorylated at ser-15 suggesting that it is functionally inactive. Interestingly,
senescent Rb1∆L/∆L MEFs also showed higher γH2AX levels and p21 induction compared
to wild type cells suggesting that the Rb1∆L mutation confers susceptibility to DNA
damage and this results in increased activation of the p53-p21 pathway.
Oncogenic ras expression induces the expression of PML and assembly of PML
nuclear bodies in a p53 dependent manner (de Stanchina et al., 2004; Ferbeyre et al.,
2000). PML has an essential role during apoptosis and cooperates with p53 to induce
apoptosis in response to DNA damage (Bernardi and Pandolfi, 2003; Lara and Paramio,
2007). Consequently, we investigated the PML nuclear body formation in the escaped
clones. All of the clones tested displayed an abundance of PML bodies in the nucleus that
was similar to senescent cells. This suggests that the pathway upstream of PML body
formation is still intact and the escape from senescence is due to defects down stream of
PML body formation (Fig 4.2C).
These experiments show that the initial signaling events in response to the
expression of oncogenic ras are still active in the clones that escape from senescence. The
escaped clones accumulate DNA damage resulting in the activation of the p53-p21
pathway. p53 dependent apoptosis limits the growth of a subset of senescence escaped
clones. In vitro transformation and anchorage independent growth in soft agar correlates
with disruption of the p53-p21 pathway. Taken together, this indicates that defective
senescence in Rb1∆L/∆L cells allows resumption of proliferation, but this is opposed by p53
potentially limiting transformation.
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4.3.3

The Rb1∆L mutation does not enhance oncogenic KrasG12D
driven cancer
We wondered if the ability of the Rb1∆L mutation to allow escape from oncogene

induced senescence and immortalization in culture is sufficient to promote tumorigenesis
in vivo. In order to test this we used a well characterized oncogenic Kras induced lung
cancer model, Lox-STOP-Lox-KrasG12D (LSL-KrasG12D) (DuPage et al., 2009;
Jackson et al., 2001). We crossed +/LSL-KrasG12D mice with Rb1∆L/∆L mice that are
defective for LXCXE binding cleft mediated interactions to generate compound mutant
mice (LSL-Kras; Rb1∆L/∆L). We then induced the expression of the latent KrasG12D
allele in both the control mice (LSL-Kras; Rb1+/+) and our compound mutant mice (LSLKras; Rb1∆L/∆L) using adenovirus encoding the Cre recombinase (Ad-Cre) by intranasal
infection and monitored the mice following Ad-Cre infection for lung tumor free survival
as well as analysis at various time points.
Deletion of pRB has been previously shown to co-operate with oncogenic KrasG12D to
promote tumorigenesis in this background (Ho et al., 2009). The compound mutant mice
develop more aggressive tumors and succumb to their tumors earlier than KrasG12D
mice alone. We hypothesized that the Rb1∆L mutation would permit escape from
senescence in lung tumor lesions, thus accelerating tumorigenesis. However, as shown in
Fig. 4.3A the Rb1∆L mutation did not significantly alter the tumor free survival of the
oncogenic KrasG12D expressing mice. The median survival was 163.5 days following
activation of oncogenic KrasG12D by Ad-Cre for the LSL-Kras; Rb1+/+ mice compared
to183 days for the compound mutant LSL-Kras; Rb1∆L/∆L mice (p>0.05) (Fig. 4.3A). In
addition, the percentage of lung weight relative to body weight at the time of
euthanization was also similar between both the groups (Fig. 4.3B). This suggested that,
in contrast to our in vitro results where Rb1∆L promotes escape from oncogene induced
senescence and transformation, the Rb1∆L mutation does not promote tumorigenesis or
affect the tumor free survival of mice expressing oncogenic KrasG12D in vivo.
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Figure 4.3 The Rb1∆L mutation does not affect tumor free survival in the KrasG12D
lung tumor model
6-8 week old LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to
activate the oncogenic KrasG12D. The mice were monitored over time for tumor free survival. A) KaplanMeier survival curves LSL-Kras; Rb1+/+ (N=14) and LSL-Kras; Rb1∆L/∆L (N=14) mice. The median
survival age is 163.5 and 183 days respectively (p=0.636, log rank test). B) Mean lung weight represented
as % total body weight at the time of death.
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4.3.4

Fewer lung tumor lesions in Rb1∆L/∆L mice expressing
oncogenic KrasG12D
Oncogene induced senescence is widely believed to act as a barrier to

transformation and cancerous growth in vivo and expression of oncogenic ras has been
shown to activate senescence thereby limiting tumorigenesis in mouse models (Collado
and Serrano, 2010). Our in vitro results suggested that cells from Rb1∆L/∆L mice have
defective senescence allowing them to escape from this arrest and transform. However,
this did not lead to enhanced tumor susceptibility in vivo. As a result, we wanted to
further investigate tumorigenesis in the LSL-Kras; Rb1∆L/∆L mice more closely by
quantifying the number of lesions that develop in response to KrasG12D activation.
We measured the number of lung tumor lesions from both the LSL-Kras; Rb1+/+
and LSL-Kras; Rb1∆L/∆L mice post activation of oncogenic KrasG12D by Ad-Cre
recombinase. At 12 weeks post Ad-cre infection, we were able to detect different types
of lesions as reported in the literature such as atypical adenomatous hyperplasia (AAH),
adenoma, adenocarcinoma and epithelial hyperplasia of the bronchioles (EHB) in both
the experimental groups (Fig 4.4A) (Jackson et al., 2001). AAH and adenoma are benign
lesions and are considered precursors for adenocarcinoma, which is a malignant state.
Strikingly, as shown in Fig. 4.4B, lungs from LSL-Kras; Rb1∆L/∆L mice showed
significantly fewer adenomas compared to LSL-Kras; Rb1+/+ controls. We wondered if
the reduced number of adenomas we see in LSL-Kras; Rb1∆L/∆L mice is due to their
hastened progression to adenocarcinoma. However, we did not notice any concomitant
increase in the number of adenocarcinoma in LSL-Kras; Rb1∆L/∆L mice compared to
controls. We also did not notice any difference in the number of AAH, the precursor
lesions of adenoma between the two groups at this time point. Interestingly, at the time of
harvesting the lungs for histology we also observed that the lungs from LSL-Kras;
Rb1∆L/∆L mice are often smaller in size compared to the control LSL-Kras; Rb1+/+ mice
(Fig. 4.4 A). This suggested to us that, contrary to our original prediction, the Rb1∆L
mutation might be negatively affecting the growth of KrasG12D induced tumors. We
then performed the same analysis at an earlier time point at 6 weeks post Ad-Cre
infection, to rule out the possibility that the decreased adenoma incidence in
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Figure 4.4 Fewer lung tumor lesions in Rb1∆L/∆L mice expressing KrasG12D
6-8 week old LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to
activate the oncogenic KrasG12D. The mice were analyzed for lung tumors at 6 and 12 weeks post Ad-Cre
infection. A) Haematoxylin and Eosin stained lung sections from 12 week old mice of mentioned
genotypes showing different lung tumor lesions. Arrow heads points towards the smaller lesions. Scale bars
are 50µm unless otherwise specified. B) Quantification of the different lung tumor lesions 12 weeks post
Ad-Cre infection. (* Student t-test). Box and whisker plots show 25th percentile, median and 75th
percentiles. Whiskers show highest and lowest values in the group C) Same as B at 6 weeks post Ad-Cre
infection. D) Quantification of Ki67 positive cells in the adenomas from LSL-Kras; Rb1+/+ and LSL-Kras;
Rb1∆L/∆L lungs at indicated time points. E) Senescence associated β-galactosidase staining of cryo-sections
from LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L lungs at indicated time points. Sections were counter
stained with Haematoxylin. Scale bars are 50 µm unless stated otherwise.
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LSL-Kras; Rb1∆L/∆L mice was due to fewer early lesions in response to oncogenic
KrasG12D activation following Ad-Cre infection. The majority of the lesions seen at the
6-week time point are atypical adenomatous hyperplasia (AAH) and we noticed only a
few adenomas at this stage (Fig. 4.4C). Quantification of the number of lesions showed a
similar number of hyperplastic lesions between control and the LSL-Kras; Rb1∆L/∆L
groups at this time point. This suggests that the activated oncogenic KrasG12D is able to
initiate early lung lesions similarly between both the genotypes.
In order to investigate the possible cause for the decreased number of adenomas
in LSL-Kras; Rb1∆L/∆L mice we first tested the proliferation rate of the tumor cells
between the two genotypes at both 6 weeks and 12 weeks following the activation of
KrasG12D. We used Ki67 as a marker for proliferation and SA-β-gal staining as a
marker for senescence in the tumors. At both time points tested the number of Ki67
positive cells in the adenomas is very similar between the two experimental groups
suggesting that the tumor cells are proliferating at a similar rate in both groups (Fig.
4.4D). Furthermore, we also detected similar senescence staining in the adenomas from
LSL-Kras; Rb1+/+ and the LSL-Kras; Rb1∆L/∆L mice. This suggested that there is no
defect in the proliferation of tumor cells in the LSL-Kras; Rb1∆L/∆L mice and activation of
oncogenic KrasG12D induces senescence in these lesions similar to those in LSL-Kras;
Rb1+/+ controls.

4.3.5

Increased apoptosis in atypical adenomatous hyperplasia
(AAH) lesions from Rb1∆L/∆L lungs expressing KrasG12D
Oncogenic ras expression induces apoptosis through p53 or pRB-E2F1 pathways

(Fikaris et al., 2006). Our in vitro results suggested that the clones that escaped
senescence have high levels of DNA damage as shown by increased γH2AX staining and
activation of the p53-p21 pathway. We wondered if escape from senescence because of
the Rb1∆L mutation results in increased cell death by apoptosis in vivo, which could
potentially explain the reduced number of adenomas that we observe in LSL-Kras;
Rb1∆L/∆L mice.
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Figure 4.5 Elevated apoptosis in atypical adenomatous hyperplasia (AAH) lesions
from lungs of Rb1∆L/∆L mice expressing KrasG12D
6-8 week old LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L mice were infected intra-nasally with Ad-Cre to
activate the oncogenic KrasG12D. Paraffin embedded lung sections at 6 or 12 weeks post Ad-Cre infection
were processed for TUNEL staining using in situ cell death detection kit from Roche. Arrowheads point to
TUNEL positive cells. A) Representative TUNEL stained lung sections from LSL-Kras; Rb1+/+ and LSLKras; Rb1∆L/∆L mice 12 weeks following Ad-Cre infection. DAPI is used to stain the nuclei. B)
Representative TUNEL stained lung sections 6 weeks following Ad-Cre infection. DAPI is used to stain
the nuclei. C) Quantification of % TUNEL positive cells in B that are associated with atypical adenomatous
hyperplasia (AAH) lesions in the LSL-Kras; Rb1+/+ and LSL-Kras; Rb1∆L/∆L lungs (* t-test). Scale bars are
50 µm.
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We searched for evidence of apoptosis in the adenoma lesions in both Rb1
genotypes. We performed TUNEL staining on lung sections from LSL-Kras; Rb1+/+ and
LSL-Kras; Rb1∆L/∆L mice at different time points following KrasG12D activation. We
noticed very few TUNEL positive cells in the adenomas from the LSL-Kras; Rb1+/+ mice
(Fig. 4.5A) at 12 weeks post activation of KrasG12D, suggesting absence of cell death in
these lesions. However, some of the adenomas from LSL-Kras; Rb1∆L/∆L mice showed
TUNEL positive cells at this time point suggesting cell death. We hypothesized that
apoptosis might be activated early during tumor development in response to activated ras
and this limits the progression of these lesions. Therefore, we searched for apoptosis in
lung sections of mice 6 weeks post activation of KrasG12D by TUNEL staining. We
counted the TUNEL positive cells from at least 10 random fields from each lung section
and quantified how many of these are associated with early hyperplastic lesions i.e. AAH
(Fig. 4.5B). We saw a significantly higher number of TUNEL positive cells that are
associated with AAH lesions in the LSL-Kras; Rb1∆L/∆L mice compared to the controls.
This suggested that cell death by apoptosis may play a role in inhibiting tumor
progression in this model and that the pRB∆L mutation is exacerbating this cell death.
This would result in fewer AAH lesions progressing to the adenoma stage. This could in
part explain why we see lower numbers of adenomas in the LSL-Kras; Rb1∆L/∆L mice
compared to controls at 12 weeks post activation of KrasG12D.

4.3.6

Rb1∆L mutation does not exacerbate tumorigenesis in a
DMBA induced chemical carcinogenesis model
To complement the KrasG12D mice study and to investigate whether tissue

specificity plays a role on the affect of Rb1∆L mutation on the tumor susceptibility, we
used 7,12-dimethyl benz[a]anthracine (DMBA) induced chemical carcinogenesis to
induce tumors. Administration of DMBA has been shown to cause ras mutations and
promote tumorigenesis in several tissues in mouse models (Pazzaglia et al., 2001;
Quintanilla et al., 1986). We wanted to investigate if the Rb1∆L mutation promotes
tumorigenesis in response to DMBA treatment. We treated 6 week old Rb1+/+ and
Rb1∆L/∆L mice with DMBA once a week for four weeks by oral gavage and monitored the
mice for tumors (Fig. 4.6A).
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Figure 4.6 The Rb1∆L mutation does not affect tumor free survival in DMBA
induced carcinogenesis model
6-8 week old Rb1+/+ and Rb1∆L/∆L mice were dosed with 1mg/ml of DMBA in canola oil as vehicle, weekly
for 4 weeks A) Kaplan-Meier survival curves of Rb1+/+ (N=20) and Rb1∆L/∆L (N=20) mice treated with
DMBA. The median survival age is 299 and 320.5 days respectively (p=0.0537, log rank test). B)
Quantification of the tumors in various tissues at the time of death in Rb1+/+ and Rb1∆L/∆L mice treated with
DMBA.
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As seen in Fig. 4.6A, the Rb1∆L mutation did not significantly alter the tumor free
survival of the mice in DMBA carcinogen induced tumor model. The over all tumor free
survival rate was similar between the genotypes with 95% of Rb1+/+ mice and 100%
Rb1∆L/∆L mice succumbing to tumors. The median tumor free survival is 320.5 days for
the Rb1∆L/∆L mice compared to 299 days for the Rb1+/+ mice (p=0.0537). Necropsy of the
mice from both the groups showed tumor incidence in a number of tissues (Fig. 4.6B). In
addition, we did not observe significant difference between the two groups in terms of
disease site as both genotypes developed a broad range of cancer types.
Given the preponderance of ras mutations that are known to be caused by DMBA,
when considered along with the KrasG12D lung cancer model, it suggests that the Rb1∆L
mutation does not promote tumorigenesis in a mutant ras background irrespective of the
tissue type or the mode of activation of the ras oncogene.

4.4

Discussion

Our study shows that mutation of the LXCXE binding cleft that disrupts
chromatin regulation by pRB is sufficient for escape from oncogene induced senescence
and transformation in vitro. Interestingly, the Rb1∆L mutation does not promote
tumorigenesis in vivo but instead, reduces tumorigenesis in the KrasG12D lung cancer
model by negatively affecting early tumor progression.
We think there are a number of explanations for the discrepancy we observe
between our in vitro findings and in vivo results. One potential explanation could lie in
the obvious differences in cell types between our experiments. Unlike the lung alveolar
pneumocytes, mouse embryonic fibroblasts (MEFs) are not terminally differentiated
cells. It is thus possible that MEFs in culture are more readily immortalized whereas
additional checkpoints that prevent transformation of the differentiated cells exist in vivo.
The increased apoptosis we observe in the primary AAH lesions that are precursors of
adenomas and adenocarcinomas suggests this might be the case. It is also interesting to
note that MEFs do not undergo apoptosis as robustly and rather activate senescence in
response to stress. Defective heterochromatinization and deregulation of cell cycle genes
during senescence, as a result of the Rb1∆L mutation, seems to be sufficient for random
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cells to escape from this arrest and immortalize in vitro. However, the relative
contribution of apoptosis and senescence during tumor suppression in vivo is not fully
understood. Even though both phenomenon are known to be tumor suppressive and are
regulated by the same tumor suppressor networks, how and at what stage during tumor
progression they coordinate to suppress tumorigenesis is still not completely understood.
We show that senescence is activated in the lungs in response to the activation of
oncogenic KrasG12D at a very early stage, and benign lesions stain positive for SA-β-gal
suggesting that senescence does play a role in suppressing tumor progression in this
model. From this perspective it appears that oncogenic KrasG12D expression activates
both apoptosis and the senescence pathway. Based on our data, cell death by apoptosis
prevents early lesions from progressing to the later stages. Senescence further acts by
suppressing the growth of the benign lesions thereby preventing or delaying tumor
progression.
The cause of the increased apoptosis we observe in the LSL-Kras; Rb1∆L/∆L mice
is not clear. A recent report has suggested a complex interplay between heterochromatin
assembly during senescence and suppression of DNA damage response (DDR) signaling
(Di Micco et al., 2011). The authors show that disruption of heterochromatin in oncogene
expressing cells increases DDR signaling leading to apoptosis. So, it is possible that
defective heterochromatinization during senescence as a result of the Rb1∆L mutation
might be exacerbating DDR signaling and induce apoptosis in these lesions early during
tumorigenesis in our model. However this could be context specific as defective
heterochromatinization in mice lacking Suv39h1, the enzyme capable of tri-methylating
histone H3K9, show increased susceptibility to lymphoma development in the Eµ-N-ras
model (Braig et al., 2005). In short, loss of heterochromatin assembly can’t universally
antagonize cancer progression as we’ve shown here.
Our studies using the KrasG12D model and the DMBA chemical carcinogenesis
model show that Rb1∆L mutation does not promote tumorigenesis or affect overall
survival of the mice. Previous studies done using the Rb1∆L/∆L mice also suggested a
context specific role for the LXCXE binding cleft during tumorigenesis (Coschi et al.,
2010; Francis et al., 2011). The Rb1∆L mutation co-operates with p53 loss to hasten
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tumor formation in mice (Coschi et al., 2010). The tumors in the compound mutant mice
are more genomically unstable and are also more aggressive. Also, in a mammary
tumorigenesis model the Rb1∆L mutation exacerbates the tumor phenotype in the Wapp53 (R172H) transgenic background. However, in the same study they found that the
Rb1∆L mutation does not affect Neu oncogene induced mammary tumors. This suggests
that tumor suppression by the LXCXE binding cleft of pRB is highly context specific.
While the Rb1∆L mutation enhances tumorigenesis when combined with p53 loss the
same mutation does not cooperate with oncogene activation in the receptor tyrosine
kinase (RTK)-ras pathway to promote tumor formation. This might suggest that even
though the Rb1∆L mutation results in deregulated cell cycle gene expression and defective
cycle arrest, in vivo, the p53 pathway might act as an additional barrier to suppress
tumorigenesis. Increased apoptosis seen in our LSL-Kras; Rb1∆L/∆L tumors also seems to
supports this hypothesis. Tumor progression in these models might require additional
disruption of the p53 tumor suppressor pathway. Future experiments using gene targeted
mouse models with subtle mutations like ours will help our understanding of the complex
relationship between different tumor suppressor and oncogene networks that exist in vivo.

4.4.1

Material and Methods

4.4.2

Mice
The generation of Rb1∆L/∆L mutant mice has been described before (Isaac et al.,

2006). LSL-KrasG12D mice (Jackson et al., 2001) were obtained from NCI mouse
repository in a B6.129 background and maintained as heterozygotes and were bred to the
Rb1∆L mice also in B6.129 background. Genotyping methods and PCR primers were
provided by the suppliers, or are as outlined by Isaac, et al. All animals were housed and
handled as approved by the UWO animal use subcommittee (protocol 2007-058) and
Canadian Council on Animal Care (CCAC) guidelines.

4.4.3

Ad-Cre infection

Ad-Cre was administered by intranasal instillation as described before (DuPage et al.,
2009; Jackson et al., 2001). We infected mice with 5x106 infectious particles of Ad-Cre
in 75 µl volume per mouse.
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4.4.4

Histology

Lungs were fixed in formalin for 48hrs before embedding in paraffin for staining with
Haematoxylin and Eosin. For immunohistochemistry, formalin fixed, paraffin embedded
tissues were deparrafinized in xylenes followed by rehydration by serial washes in 100%,
95%, 70% ethanol and water. Antigen retrieval was done by boiling the sections in a
pressure cooker for 15 min in 10 mM sodium citrate buffer pH6.0. TUNEL staining was
performed using in situ cell death detection kit from Roche as per the manufacturers
instructions (Cat. No. 11 684 795 910). Tissues for SA β-gal staining were fixed in
optimum cutting temperature (OCT) compound and embedded for cryo-sectioning.

4.4.5

Senescence β-galactosidase staining on tissues

Tissue sections were processed immediately after cryo-sectioning by fixing them in 0.5%
glutaraldehyde/PBS for 15 minutes followed by O/N incubation in SA-β-gal staining
buffer (40 mM citric acid/sodium phosphate buffer at pH 6.0 containing 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2 and 1mg/ml X-gal) at 37oC in
a humidified chamber. Sections were washed with PBS before sealing with cover slips
using Vectamount mounting medium.

4.4.6

Microscopy

Haematoxylin and Eosin and antibody stained sections are scanned using Aperio Scan
Scope CS2 system. Scanned sections were analyzed using Aperio Image Scope viewer
software. Lesions were manually counted and graded based on the recommendations of
the Nikitin et al. and mouse models of human cancer consortium (Nikitin et al., 2004).

4.4.7

Cell culture

Mouse embryonic fibroblasts (MEFs) were generated from d13.5 embryos using standard
procedures and cultured in DMEM with 10% FBS and antibiotics(Hurford et al., 1997).
Retroviral transduction with pBABE-HrasV12 was as reported by Serrano et al. (Serrano
et al., 1997) and viruses were packaged in Bosc-23 cells. Cells infected with viruses
encoding HrasV12 were pre-selected in 4µg/ml puromycin for at least 3 days before
processing for further experiments. Senescent cells prepared by this method were
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allowed to senescence for at least 10 days following retroviral infection. Senescence
associated β-galactosidase (SA-β-Gal) staining was performed as described before
(Serrano et al., 1997). Escaped clones were continuously sub-cultured in standard
medium with 4µg/ml puromycin and passaged every 3 days.

4.4.8

Soft agar colony formation assay

6 well dishes were coated with a bottom layer of 1.5 ml 0.7% low melting agarose in
DMEM with 10% FBS and antibiotics. 3x104 cells were resuspended in 1.5 ml of 0.35%
low melting agarose in DMEM with 10%FBS and antibiotics and added as the top layer
to the 6 well plates. All genotypes were tested in triplicate. Cells were allowed to grow in
soft agar for 2 weeks before counting the number of colonies formed.

4.4.9

Antibodies

Anti-γH2AX (05-636) and anti-PML (MAB3738) antibodies are from Millipore. Anti
actin (A2066) antibody is from Sigma. Anti-phospho-p53-ser15 (9284) antibody is from
cell signaling. Anti pan-ras antibody (FL-189) is from Santa cruz. Anti-p21 (AB-4)(OP76) antibody was purchased from Calbiochem.

4.4.10

Immunofluorescence

Cells were fixed in 3% PFA for 10 min at room temperature (RT) and permeablized with
0.5% triton- X-100 for 5min at RT. Cells were blocked with 3% BSA/PBS for 15 min at
RT followed by incubation with primary antibodies diluted in blocking buffer (1:300
PML, 1:200 γH2AX) overnight at 40C in a humidified chamber. Cells were washed in the
blocking buffer 3 times for 5min each. Cells were incubated with Alexa-fluor conjugated
secondary antibodies diluted in blocking buffer (1:4000) for 1hr at RT. Cells were
washed again 3 times in PBS followed by mounting on slides with mounting medium
containing DAPI before analyzing by Confocal microscopy.
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Chapter 5

5

Discussion
5.1

Summary and significance of current work

The primary goal of this study was to investigate how the recruitment of
chromatin regulating proteins by pRB influences mammalian development and disease.
In order to investigate this, I used a gene targeted mouse strain in which mutations in the
Rb1 gene disrupt only LXCXE binding cleft mediated interactions.
In chapter 2 I investigated whether pRB-LXCXE interactions are required under
all G1 arrest circumstances to regulate chromatin and block cell cycle as has traditionally
been suggested in the field, or if they have a more specialized role during stress response.
I studied the role of pRB-LXCXE interactions in two permanent cell cycle exit paradigms
terminal differentiation and cellular senescence. I investigated cell cycle exit in skeletal
muscle and retinal neurons, two long lived cell types, and compared it with cell cycle exit
during senescence using cells derived from Rb1∆L/∆L mice. I showed that there is
defective inhibition of DNA synthesis specifically during senescence in Rb1∆L/∆L cells,
but not during terminal differentiation. Senescent Rb1∆L/∆L fibroblasts fail to
heterochromatinize E2F responsive genes as shown by a deficiency in enrichment of
H3K9me3. This causes de-repression of cell cycle genes and leaves the Rb1∆L/∆L cells
susceptible to proliferative stimuli. However, analysis of the same genes in terminally
differentiated muscle tissue from Rb1∆L/∆L mice showed normal abundance of
heterochromatin marks and proper silencing of these genes similar to wild type.
Unexpectedly, this study revealed that pRB uses LXCXE interactions specifically to
regulate a stress responsive growth control mechanism that is distinct from cell cycle exit
in terminal differentiation during development.
In chapter 3 I further explored the mechanism of pRB mediated stable silencing of
the E2F responsive cell cycle genes during senescence. My experiments show that during
oncogene induced senescence endogenous PML is recruited to E2F responsive cell cycle

134

gene promoters in a pRB-LXCXE dependent manner. Interestingly, during PML induced
senescence the E2F target genes fail to be repressed in Rb1∆L/∆L MEFs. Overexpressed
PML is also unable to bind to the cell cycle gene promoters in Rb1∆L/∆L cells. Importantly,
this is associated with a striking reduction in the enrichment of the repressive histone
mark H3K9me3 at these promoters. Taken together, the experiments in chapter 3 suggest
a model in which pRB interacts with PML in a LXCXE cleft dependent manner
specifically during senescence. This pRB-PML complex is important for
heterochromatinization and stable silencing of E2F target cell cycle genes during
senescence.
In chapter 4 I investigated if chromatin regulation by pRB is required for
preventing oncogenic ras induced transformation in vitro and tumorigenesis in vivo. I
showed that the LXCXE interactions of pRB are necessary to prevent escape from OIS
and transformation in vitro. However, in vivo, Rb1∆L/∆L mice expressing oncogenic
KrasG12D develop fewer lung tumors compared to the control mice. My results suggest
that increased apoptosis in hyperplastic lesions early during tumorigenesis might be one
of the reasons for reduction in lung tumor numbers in the +/LSL-KrasG12D; Rb1∆L/∆L
mice. However, this reduction in lung tumors did not effect long-term survival of these
mice. I further showed that DMBA, which can induce oncogenic ras mutations in mice,
do not alter the tumor spectrum or affect tumor free survival of mice carrying the Rb1∆L
mutation. These tumor studies show that loss of chromatin regulation by the LXCXE
binding cleft of pRB does not universally enhance tumorigenesis. My work also shows
that loss of chromatin regulation by pRB can inhibit tumorigenesis under some
circumstances.
Over all, this thesis enhances our current understanding of the unique role of pRB
among the pocket proteins in cell cycle regulation by showing how pRB utilizes LXCXE
binding cleft mediated interactions to stably block the cell cycle, specifically in response
to oncogenic stress signals. The pRB tumor suppressor pathway is inactivated in most
cancers. Among pocket proteins, pRB is uniquely targeted for inactivation by mutations
in a number of cancers. Investigating the molecular basis of this unique role for pRB in
tumor suppression further can lead us to uncover novel tumor suppressive mechanisms
that are important during cancer pathogenesis.
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5.2

pRB regulation of a stable senescence arrest

My work, along with recent literature in the field, have highlighted a critical role
for pRB in orchestrating a stable cell cycle arrest in response to the expression of
activated oncogenes. Based on these studies our current understanding of pRB function
during senescence can be summarized as follows (Fig. 5.1).
Expression of activated oncogenes such as HrasV12 induces replication stress
resulting in the activation of DNA damage response signaling (DDR) (Bartkova et al.,
2006; Di Micco et al., 2006; Mallette et al., 2007). This is characterized by the expression
of cyclin dependent kinase inhibitors (CKIs) such as p21 and p16 that inhibit
Cyclin/CDK complexes that are responsible for phosphorylation and inactivation of pRB.
The hypo-phosphorylated pRB directly binds to and inhibits the E2F transcription factors.
This is essential for the transcriptional repression of key genes involved in DNA
replication. pRB is indeed found to be enriched at these E2F target gene promoters during
senescence and acute knock down of pRB results in de-repression of these genes and
deregulated DNA synthesis during senescence (Chapter 2 and (Chicas et al., 2010) ).
Thus, in response to oncogenic stress pRB regulates cell cycle exit and entry into
senescence by direct repression of E2Fs and E2F dependent transcription. The Rb1∆L/∆L
fibroblasts in which the pRB-E2F interactions are intact exit the cell cycle and enter into
senescence normally in response to oncogene expression (Chapter 2). This further
emphasizes that acute cell cycle exit during senescence is primarily dependent on direct
pRB-E2F interactions (Fig 5.1 top).
However, the Rb1∆L/∆L mutant cells ultimately re-enter the cell cycle and can
resume proliferation indicating that later pRB dependent steps in establishing a senescent
arrest are critical for the stability of senescence (Chapter 2). Recent reports in the
literature alongside my work uncovered a critical role for chromatin regulation by pRB
that potentially contributes to this stable senescence arrest. pRB interacts with H3K4
demethylases Jarid1a and Jarid1b and mediates the removal of activating methylation
(H3K4me3) on E2F target gene promoters during senescence (Chicas et al., 2012). pRB
is also required for the enrichment of repressive histone methylation (H3K9me3) at these
promoters (Chicas et al., 2010; Narita et al., 2003). The addition of H3K9me3 is
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Figure 5.1 Proposed model of regulation of a stable senescence arrest by pRB
In response to activation by cyclin dependent kinase inhibitors (CKIs) such as p16 and p21 during
senescence, pRB induces an acute cell cycle arrest by inhibiting cell cycle gene transcription by directly
blocking trans-activation by E2Fs. Further, pRB cooperates with Promyelocytic leukemia protein (PML) to
recruit chromatin regulating proteins that can assemble and spread heterochromatin, resulting in permanent
silencing of proliferative genes.
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defective in Rb1∆L/∆L fibroblasts implicating it in long term stability of senescence. The
identity of histone methyl transferases responsible for the enrichment of this repressive
mark during senescence is yet to be uncovered. Regardless of the precise mechanism of
H3K9me3 deposition, these studies illustrated how pRB dependent chromatin regulation
by means of removal of activating histone marks (H3K4me3) and enrichment of
repressive modifications (H3K9me3) results in transcriptional repression across E2F
responsive promoters. Further more, pRB mediates global compaction of chromatin and
formation of senescence associated heterochromatic foci (SAHFs) thereby sustaining the
stable repression of key cell cycle genes during senescence (Narita et al., 2003).
The exact signal that triggers the chromatin regulatory function of pRB is only
beginning to be elucidated. Recent work including that presented in this thesis suggests
that Promyelocytic leukemia (PML) bodies and pRB mediated recruitment of PML to the
E2F target gene promoters might be at the core of the downstream chromatin changes
during senescence (Chapter 3 and (Vernier et al., 2011)). PML bodies might serve as sites
of nucleation of the proteins involved in chromatin assembly and aid in the
heterochromatinization of cell cycle genes (5.1 bottom).
Since loss of pRB results in deregulated gene expression, DNA synthesis, and
eventual escape from senescence, it is imperative that we further investigate the steps in
gene silencing and higher order chromatin assembly that are controlled by pRB. In this
way we will come to a thorough understanding of pRB function as a tumor suppressor
protein.

5.3
Advantages of the gene targeted approach to
study tumor suppressor protein function
Knockout mice have long been used to study tumor suppressor function of
proteins (Ghebranious and Donehower, 1998). It has greatly aided in our understanding
of the tumor suppressive ability of proteins like pRB and p53 both alone and in
combination with other tumor prone models (Donehower, 1996; Lin et al., 1996).
However, the knockout approach has some caveats while studying multifunctional
proteins because it eliminates all of their functions. Complete loss of the protein prevents
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the assignment of individual biochemical functions to the overall tumor suppressor ability
of the protein. In addition, germ line deletion can also lead to compensation by related
proteins thereby masking their normal physiological function. Gene targeted (Knock-in)
mouse models circumvent some of these caveats in studying protein function
(Kenzelmann Broz and Attardi, 2010; Taneja et al., 2011).
For example, pRB is a multifunctional protein capable of interacting with a
number of other proteins and protein complexes to regulate the mammalian cell division
cycle. Over a 100 cellular proteins have been reported that interact with pRB either
directly or indirectly and the list continues to grow, emphasizing its functional
complexity (Dick, 2007). Investigating the specific role of these different interactions in
isolation and their relevance to tumor suppression is important for understanding pRB as
a tumor suppressor protein. A structure-function approach, using point mutants of pRB,
has helped separate some seemingly related functions. For example, a pRB mutant
(∆663) that is defective for E2F binding and cell cycle arrest was shown to still be
capable of inducing markers of differentiation, suggesting they could be independent
from one another (Sellers et al., 1998). However, in vitro overexpression studies can be
misleading and the physiological relevance of these findings have to be validated using in
vivo models. For example, in vitro experiments suggested that mutating the LXCXE
binding cleft of pRB is sufficient to inhibit MyoD dependent terminal differentiation of
cells into myotubes (Puri et al., 2001). However, gene targeted mice harboring mutations
in the LXCXE binding cleft of pRB showed that these interactions are dispensable for
muscle differentiation in vivo highlighting the advantages of gene targeted mouse models
(Talluri et al., 2010).
Gene targeted models can serve as great tools to test and sometimes challenge
accepted dogma about tumor suppressive functions of proteins that are largely based on
knock out studies. This can lead to the discovery of novel functions that have been
overlooked. A recent example of this is the p533KR/3KR mice bearing lysine to arginine
mutations at three p53 acetylation sites (Li et al., 2012). p53’s role as a tumor suppressor
has largely been attributed to its ability to induce cell cycle arrest, apoptosis or
senescence in response to genotoxic stress. However, the p533KR/3KR mice, despite being
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defective for all the above functions still suppresses early onset spontaneous tumors in
mice (Li et al., 2012). This model helped uncover a novel tumor suppressive role for
unconventional activities of p53 in regulating energy metabolism and antioxidant
function.
However, it is important to note that the advantages of gene-targeted approaches
are limited by our understanding of the molecular determinants of individual proteinprotein interactions. Most often, proteins use the same binding site to interact with
multiple binding partners. For example, pRB has been show to interact with over 20
proteins through its LXCXE binding cleft (Dick, 2007). Consequently, attributing the in
vivo phenotypes to specific interactions is still a challenge. In the future, co-crystal
structures of proteins in functionally relevant complexes will be very useful in designing
mutations that selectively disrupt interactions for making better gene targeted models.

5.4

Chromatin regulation during terminal differentiation

The normal development and terminal differentiation in Rb1∆L/∆L mice suggest
that LXCXE interactions with pRB are dispensable for differentiation (Chapter 2).
Furthermore, E2F target genes in differentiated muscle from the Rb1∆L/∆L mice show
similar abundance of heterochromatin modifications as wild type controls and they are
properly silenced.
On the surface, our results might seem to contradict earlier reports suggesting that
pRB mediates heterochromatinization of E2F target genes during muscle differentiation
(Blais et al., 2007; De Falco et al., 2006). This raises the question of what regulates
heterochromatinization of cell cycle genes during terminal differentiation in Rb1∆L/∆L
mice. Since pRB∆L is capable of binding to E2Fs normally, it is possible that the
heterochromatinization of these genes during differentiation is an indirect consequence of
cell cycle exit. During muscle differentiation, pRB acts by negatively regulating the E2Fs
and also by positively affecting the MyoD dependent transcriptional program (De Falco
et al., 2006). This might enable the repressive chromatin complexes to be recruited to cell
cycle genes independently of pRB to modify chromatin and permanently silence them.
Consistent with this interpretation, Andrusiak et al. recently demonstrated that pRB-E2F
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regulation alone is sufficient to induce heterochromatin changes in terminally
differentiated neurons (Andrusiak et al., 2013).
Alternately, p107 and p130 could have a compensatory role for enriching
repressive chromatin marks during differentiation in the absence of the pRB-LXCXE
interactions. Both p107 and p130 have been shown to have overlapping roles during
development and differentiation (Classon and Dyson, 2001; Cobrinik et al., 1996). In
addition, both these proteins have a LXCXE binding cleft and interact with chromatin
regulatory proteins such as HDACs through this binding cleft. However, we did not
notice any increase in the expression of p107 in the Rb1∆L/∆L muscle suggesting this
possibility is less likely (Talluri et al., 2010). It will be interesting to test if chromatin
regulation by the pocket protein family plays a direct role in heterochromatinization of
the cell cycle genes during terminal differentiation. Generation of mice with multiple
pocket protein family members defective for LXCXE interactions could answer some of
these questions in a physiological setting.

5.5

pRB’s unique role during cellular stress response

Among the pocket protein family pRB is selectively targeted for disruption by
direct mutations in a number of cancers, most notably retinoblastoma and small cell lung
cancer, suggesting a unique role for pRB in tumor suppression within its family (Sherr
and McCormick, 2002). Disruption of pRB alone is also tumorigenic in mouse models
whereas disruption of p107 and p130 is not (Classon and Harlow, 2002; Harrison et al.,
1995). This raises the question of what the molecular basis of the unique tumor
suppressive ability of pRB is.
This study along with other recent literature in the field provides important clues
regarding the unique roles of pRB that are potentially tumor suppressive in vivo. Our
work suggests that cellular stress stimuli that are potentially tumor promoting, activate
the stress responsive pathways that uniquely engage pRB function. These stress stimuli
include activation of oncogenes, genotoxic agents that induce DNA damage such as γ
irradiation and reactive oxygen species (ROS).
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My work along with others show that oncogenic stress uniquely activates a
silencing program mediated by pRB to stably repress a group of cell cycle genes involved
in DNA replication and S-Phase progression (Chicas et al., 2010; Talluri et al., 2010). In
response to the expression of activated oncogenes pRB specifically binds to these gene
promoters to assemble heterochromatin and stably silence their expression. This function
seems to be unique to pRB and can’t be compensated by the other pocket proteins p107
and p130. Other stimuli activate this unique growth inhibitory function of pRB as well.
Rb1∆L/∆L fibroblasts are defective in arresting in response to DNA damage induced by γirradiation and expression of the CDK inhibitor p16INK4a (Francis et al., 2009). Both
activate the pRB pathway and induce senescence in MEFs (Harrington et al., 1998;
Takahashi et al., 2006). Apart from MEFs, mammary epithelial cells and keratinocytes
from the Rb1∆L/∆L mice are defective in arresting in response to TGF-β treatment, which
is a potent growth inhibitor of these cell types (Francis et al., 2009). Interestingly, TGF-β
is activated in response to irradiation and has been shown to play a role in response to
genotoxic stresses (Barcellos-Hoff et al., 1994; Kirshner et al., 2006). Furthermore,
oxidative stress and chronic TGF-β stimulation is known to induce senescence in certain
cell types (Ksiazek et al., 2007; Yu et al., 2009). Collectively, these growth arrest signals
that fail to arrest Rb1∆L/∆L cells indicate that the mutant cells have a unique deficit in
responding to stress induced growth arrest signals.

5.6
Studying senescence in mouse fibroblasts in
comparison with human
The cellular and molecular differences between senescence in mouse and human
cells were detailed in the introduction to this thesis. The Arf-p53 pathway is considered
to be the dominant pathway regulating senescence in mouse cells, compared to the
p16/pRB pathway. This argument mainly stems from the observation that MEFs from
p16Ink4a null or Rb1-/- embryos enter at least a partial state of senescence in culture and in
response to oncogenic stress (Krimpenfort et al., 2001; Sharpless et al., 2001; Sherr and
DePinho, 2000). On the other hand, MEFs from p19Arf null or Trp53-/- mice continue to
proliferate under the same circumstances (Harvey et al., 1993; Kamijo et al., 1997).
Consequently, most studies investigating the role of pRB during senescence use human
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fibroblasts. In addition, mouse fibroblasts do not form senescence associated
heterochromatin foci (SAHFs) similar to human diploid fibroblasts (HDFs) undergoing
senescence (Itahana et al., 2004). As a result there are many gaps in our knowledge of
chromatin changes in senescent mouse fibroblasts.
It is interesting to note that pRB acts downstream of the INK4/ARF locus that
encodes for both the p16Ink4a and p19Arf proteins (Sherr, 2012). Rb1-/-/p107-/- MEFs and
Rb1-/-/p107 -/-/p130-/- MEFs (TKO MEFs) fail to senescence in response to oncogenic ras
despite normal induction of the p53 and p21 proteins suggesting that the pathway
regulated by the pocket proteins is required for efficient senescence in MEFs (Peeper et
al., 2001). Furthermore, acute depletion of pRB in MEFs is shown to be sufficient for
escape from senescence and these escaped cells start synthesizing DNA and re-enter the
cell cycle indicating that pRB is essential for stable maintenance of the senescence state
in MEFs (Sage et al., 2003). Therefore, understanding the molecular mechanisms of the
senescence arrest in mouse cells and the basis of the differences between mouse and
human senescence is of great importance. This is particularly vital in order to interpret
data from cells derived from knockout mice and for studying senescence and its
contribution to tumor suppression in vivo using mouse models.
My study shows that the fundamental feature of senescence that is common
between MEFs and human cells is the stable repression of E2F target cell cycle genes
involved in DNA replication and S phase progression. I showed that LXCXE cleft
mediated interactions with pRB are critical for this stable repression of E2F target cell
cycle genes during senescence (Chapter 2). This function of pRB is crucial for the
permanence of the senescence arrest as disruption of LXCXE cleft mediated interactions
in our Rb1∆L/∆L MEFs allows escape from senescence and results in transformation.
Importantly, this function is unique to pRB and cannot be compensated by the other
pocket proteins p107 and p130. A recent study by Chicas et al. used IMR90 human
diploid fibroblasts and has come to a similar conclusion by showing that pRB is recruited
to these genes during oncogene induced senescence and is required for their stable
repression (Chicas et al., 2010). Furthermore, by using shRNA’s targeting pRB, p107 or
p130 they showed that this function is unique to pRB. Taken together, these studies show
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that RB’s unique ability to silence key cell cycle genes during senescence is a critical
component of the cellular response to oncogenic stress and is highly conserved across
species.
Some of the differences observed during premature senescence in mouse vs.
human cells are due to the oxygen sensitivity of MEFs in culture (Coppe et al., 2010).
MEFs are highly sensitive to oxygen levels (20%) used in standard cell culture
(Parrinello et al., 2003). The effect of oxidative stress is often one of the
underappreciated aspects while studying premature senescence in MEFs. Reactive
oxygen species (ROS) and oxidative DNA damage is one of the primary causes of
mutations contributing to ageing and age associated diseases such as cancer (Denver et
al., 2009; Kryston et al., 2011; Sedelnikova et al., 2010). Strikingly, MEFs grown under
standard cell culture conditions (20% O2) have about 3 fold higher mutation frequency
compared to the cells cultured at physiological oxygen levels (3%) with an additional 3
fold increase in mutation rate upon spontaneous immortalization (Busuttil et al., 2003).
Although oxidative stress induces premature senescence in MEFs, it might also
contribute to the spontaneous escape from this senescence arrest as a result of high
mutation rate. This makes it difficult to predict in vivo outcomes in cancer models based
on the in vitro experiments done under these conditions. It is possible that oxidative stress
might cooperate with or exacerbate some of the effects of Rb1∆L mutation thereby
contributing to the increased spontaneous escape from oncogene induced senescence and
transformation that we observe in Rb1∆L/∆L MEFs in culture. Less oxidative stress and
spontaneous mutation rate under physiological conditions would allow additional tumor
suppressor pathways such as p53 to delay and/or inhibit tumor progression in vivo.
Tumor progression would require eventual loss of these additional checkpoints. Whether
the Rb1∆L/∆L MEFs are more sensitive to oxidative stress in culture compared to the wild
type cells and if they have increased mutation frequency has yet to be determined. More
studies are needed to determine the effect of oxidative stress due to culture conditions and
how it contributes to the differences in senescence phenotypes between mouse and
human cells.
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5.7
Chromatin assembly during senescence and its
contribution to tumor suppression
Senescence is associated with a number of chromatin changes (Adams, 2007;
Funayama and Ishikawa, 2007; Narita, 2007). However, the importance of each of these
chromatin changes to the senescence phenotype is still not completely understood. Are
they simply a consequence of senescence or do they actively contribute to the senescent
state? Which of the chromatin changes associated with senescence are essential for
induction and/or maintenance of senescence arrest in vivo? Recent reports in the literature
have tried to address some of these issues.
The precise role of large scale chromatin compaction and its contribution to
senescent arrest is still not clear. In some human diploid fibroblasts (HDFs) like IMR90
senescence is associated with condensation of whole chromosomes into structures called
senescence associated heterochromatic foci (SAHFs) (Narita et al., 2003). However,
SAHF formation is not a universal feature of senescence. It is specific to some cell types
and certain senescence inducing signals suggesting that SAHFs are not a requirement for
senescence (Kosar et al., 2011). Our work in mouse embryonic fibroblasts (MEFs)
suggests that senescence in this cell type is associated with re-organization of
heterochromatin without the condensation of whole chromosomes. This is evident by
increased compaction of chromatin into fewer, but bigger heterochromatin bundles.
Interestingly, chromatin compaction is defective in Rb1∆L/∆L MEFs suggesting that it is
LXCXE dependent. Whether this is an indirect consequence of the inability of Rb1∆L/∆L
MEFs to heterochromatinize E2F target genes or if it is an independent function of pRB
has to be determined. A recent study showed that incorporation of repressive
heterochromatin marks and SAHF formation are separable, suggesting that they could be
independently regulated (Chandra et al., 2012). Nevertheless, large scale chromatin
compaction might play a role in the permanence of senescence arrest by stable silencing
of proliferative genes. Disruption of SAHFs in the cells that form them, have been shown
to result in de-repression of cell cycle genes such as cyclin A and MCM3 (Narita et al.,
2006).
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The best in vivo evidence available so far for the role of heterochromatin
modifications during senescence come from mice lacking Suv39h1, the histone methyl
transferase capable of tri-methylating H3K9 (Braig et al., 2005). In response to oncogenic
ras expression, splenocytes from the Suv39h1-/- mice fail to arrest and show defective
accumulation of oncogene induced senescence markers such as H3K9me3,
heterochromatin protein 1(HP1), and SA-β-gal. Furthermore, Suv39h1-/- mice expressing
oncogenic NrasG12D in their hematopoietic compartment develop aggressive cancers
and succumb to the disease significantly sooner than the control mice. This demonstrates
that Suv39h1 mediated H3K9-trimethylation is important for senescence and tumor
suppression in vivo (Braig et al., 2005). It is also possible that germ line deletion of
Suv39h1 could have pleotropic effects that might affect tumorigenesis in this model.
Conditional inactivation of Suv39h1 in the context of oncogene activation will be more
informative in addressing the role of chromatin assembly specifically during oncogene
induced senescence and tumorigenesis. More experiments are needed to determine if the
increased tumor susceptibility is tissue specific, and future crosses of the Suv39h1-/- mice
with other tumor prone models will tell us if loss of Suv39h1 has broader effects on
senescence and tumor suppression in vivo. The data from our Rb1∆L/∆L mice, that have
defects in the incorporation of the H3K9me3 repressive mark specifically during
senescence suggests that tissue and cell type specificity, and the type of mutations may
play a role in determining the course of cancer development in vivo.

5.8
The pRB LXCXE binding cleft in tumor
suppression
Rb1∆L/∆L mice do not develop spontaneous tumors. In an interesting parallel,
disruption of the CDKN2A gene which encodes for p16Ink4a protein that acts upstream of
pRB causes only a rare incidence of spontaneous tumors (Krimpenfort et al., 2001;
Sharpless et al., 2001). However, these mice have increased susceptibility to
tumorigenesis when crossed with a number of different cancer prone models. This
suggests that the p16Ink4a /pRB pathway might have context specific roles in tumor
suppression in mouse models of cancer, or is activated in response to specific stress
signals.
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Interestingly, Rb1∆L/∆L mice show increased susceptibility to cancer in a Trp53-/background (Coschi et al., 2010). Compound mutant mice have an altered tumor
spectrum with an increased number of sarcomas and more aggressive tumors. Strikingly,
these tumors show high levels of genomic instability compared to TP53-/- tumors.
Furthermore, the Rb1∆L mutation promotes loss of heterozygosity and hastens tumor
formation in TP53+/- mice (Coschi et al., 2010). This suggests that one of the key tumor
suppressive roles of the pRB-LXCXE binding cleft is to maintain genome stability. In
Rb1∆L/∆L mice the p53 pathway might be acting as a secondary barrier to eliminate
genomically unstable cells thus preventing spontaneous tumor formation. In the absence
of this secondary checkpoint in the TP53-/- background the genomically unstable cells in
the Rb1∆L/∆L mice progress towards tumorigenesis unhindered (Manning et al., 2013).
Rb1∆L/∆L mice also cooperate with p53 loss during Wap-p53 (R172H) induced
mammary tumors (Francis et al., 2011). However, the Rb1∆L mutation does not promote
tumorigenesis in the Neu oncogene induced mammary tumor model or DMBA chemical
carcinogen model (Francis et al., 2011)(Chapter 4 of this thesis). Interestingly, the same
Rb1∆L mutation reduces lung tumors in response to the activation of oncogenic
KrasG12D (Chapter 4). These results point to the need for more studies in order to
understand the context specific role of the LXCXE binding cleft and how the Rb1∆L
mutation affects tumorigenesis in vivo. Recent reports in the literature and unpublished
work from our lab provide some clues in this regard.
The Rb1∆L/∆L MEFs show evidence of increased replication stress pointing to a
role for pRB and the LXCXE cleft in maintaining genome integrity (C. Coschi,
unpublished). The oncogenic ras-MAPK pathway induces replication stress causing DNA
damage (Di Micco et al., 2006). Replication stress can promote tumorigenesis if the DNA
damage is allowed to accumulate as a result of inactivation or loss of cellular DNA
damage response pathways that limit the damage by inducing apoptosis and
senescence(Halazonetis et al., 2008). However, the threshold of replication stress was
shown to impact tumor progression in vivo with very high replication stress resulting in
death of precancerous cells that are defective for stress response (Bartek et al., 2012;
Murga et al., 2011). Therefore, it is tempting to speculate that activation of the
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oncogenic ras pathway in combination with the Rb1∆L mutation might result in elevated
replication stress that is too high to the cell to handle. This could potentially lead to the
activation of the apoptosis pathway depending on the cell and tissue type, thus
eliminating these precancerous cells. However, disruption of the DDR pathway by loss of
proteins such as p53 allows these cells to survive and progress towards cancer.
Overall, these studies suggest that the tumor suppressor function of the pRBLXCXE binding cleft could be highly context specific and crossing the Rb1∆L/∆L mice
with different tumor prone models will help us better understand the signals that impinge
on this function of pRB to suppress tumorigenesis.

5.9

Future perspectives

The role of PML during senescence is well documented (Bischof et al., 2002;
Salomoni and Pandolfi, 2002). Our work in Rb1∆L/∆L MEFs suggests that pRB-PML
interaction could act as a molecular switch that triggers heterochromatin assembly during
senescence and determines the stability of senescence arrest. However, the signaling
events that trigger this interaction are still not known. One of the potential signals is the
posttranslational modification of the PML protein. There are multiple isoforms of the
PML protein and PML is a target for extensive posttranslational modifications in
response to diverse stress signals (Cheng and Kao, 2012; Jensen et al., 2001). However,
the specific role of individual isoforms of PML and their posttranslational modifications
during senescence is yet to be determined. Sumoylation is important for nuclear body
formation and the function of PML (Seeler and Dejean, 2001). Interestingly, expression
of SUMO-2/3 induces senescence in a p53 and pRB dependent manner (Li et al., 2006).
This study suggests that Sumoylation could potentially act as a trigger that induces the
interaction between PML and pRB during senescence. The presence of higher molecular
weight bands of PML in our interaction assays also suggests this possibility. Future
experiments aimed at identifying the senescence specific modifications of PML isoforms
and pRB will enhance our mechanistic understanding of the signaling events that regulate
pRB-PML interactions during senescence and their role in chromatin assembly.
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The role of large scale chromatin compaction during senescence and its impact on
the stability of the arrest is another key question. The Rb1∆L/∆L MEFs show defective
chromatin compaction during senescence suggesting a role for pRB and the LXCXE
binding cleft in this process. Knockdown of pRB in IMR90 human fibroblasts also
disrupts the formation of SAHFs in these cells suggesting that pRB plays an important
role in genome wide chromatin compaction (Chandra et al., 2012; Narita et al., 2003). It
is still not clear if pRB has a direct role in this process or if it acts upstream to promote
chromatin compaction. Disruption of already formed SAHFs by acute depletion of pRB
in IMR90 cells suggests a direct role (Chandra et al., 2012; Narita et al., 2003). However
more precisely timed experiments are needed to confirm this. Experiments done in
Rb1∆L/∆L fibroblasts hint at a potential pRB interaction that could mediate such global
compaction of chromatin during senescence. pRB interacts with the Condensin-II
complex through its LXCXE binding cleft and this interaction is necessary for proper
condensation of mitotic chromosomes (Coschi et al., 2010; Longworth et al., 2008).
Interestingly, unlike Condensin-I complex, which needs nuclear envelope breakdown
during prophase to bind to chromatin, the Condensin-II complex is present in the nucleus
during interphase and can associate with chromatin throughout the cell cycle (Hirano,
2005). So, one intriguing possibility is that the pRB-Condensin-II complex co-operates to
induce chromatin compaction and SAHF formation during senescence. Knocking down
Condensin-II subunits in fibroblasts undergoing senescence will tell us if this is the case.
Much has been learned about senescence and the role of pRB in senescence over
the last decade. But, there remain many unanswered questions. This thesis provides the
groundwork for further exploring the role of the LXCXE cleft mediated chromatin
regulation by pRB during senescence.

5.10
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Appendix C: List of Plasmids

Name

Genes encoded

Obtained/
Constructed

Resistance
marker

Stock
Number

pBABE

Puromycin

Dr. R. Hurford

Ampicillin
Puromycin

28

pBABE-HrasV12

ras

Dr. M. Classon

Ampicillin
Puromycin

450

pMOV-Psi

Ecotropic envelope
glycoprotein

Dr. M. Classon

pBABE-MyoD

MyoD

Srikanth Talluri

Ampicillin
Puromycin

667

pscodon-GST-RB-LP

GST-RB-LP

Dr. Fred Dick

Ampicillin

526

pscodon-GST-RB-∆L-LP

GST-RB-∆L-LP

Srikanth Talluri

Ampicillin

668

pCIneo-FLAG-PML I

PML isoforms I

Dr. Lawrence
Banks

Ampicillin

669

pCIneo-FLAG-PML II

PML isoforms II

Dr. Lawrence
Banks

Ampicillin

670

pCIneo-FLAG-PML III

PML isoforms III

Dr. Lawrence
Banks

Ampicillin

671

pCIneo-FLAG-PML IV

PML isoforms IV

Dr. Lawrence
Banks

Ampicillin

672

pCIneo-FLAG-PML V

PML isoforms V

Dr. Lawrence
Banks

Ampicillin

673

pCIneo-FLAG-PML VI

PML isoforms VI

Dr. Lawrence
Banks

Ampicillin

674

pBABE-FLAG-PML-I

pBABE-FLAG-PML-II

PML isoforms I

PML isoforms II

Srikanth Talluri

Srikanth Talluri

Ampicillin

Ampicillin
Puromycin
Ampicillin
Puromycin

530

675

676

160

pBABE-FLAG-PML-III

pBABE-FLAG-PML-IV

pBABE-FLAG-PML-V

pBABE-FLAG-PML-VI

PML isoforms III

PML isoforms IV

PML isoforms V

PML isoforms VI

Srikanth Talluri

Srikanth Talluri

Srikanth Talluri

Srikanth Talluri

Ampicillin
Puromycin
Ampicillin
Puromycin
Ampicillin
Puromycin
Ampicillin
Puromycin

677

678

679

680
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Appendix D: List of Adenoviruses

Name

Genes encoded

Obtained/ Constructed

Ad-E2F1

E2F1

Dr. Erik Knudsen

Ad-GFP

GFP

Dr. Trevor Shepherd

Ad-Cre

Cre recombinase

Dr. Trevor Shepherd
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Appendix E: List of Antibodies

Antibody name

Protein
recognized

Species

Supplier

Santa Cruz

CAT. #

Application

SC-251

WB (1:500)

SC-318

WB (1:500)

SC-56

WB (1:500)

SC-317

WB (1:500)

SC-9966

WB (1:500)

E2F1 (KH95)

E2F1

Mouse IgG

p107 (C-18)

p107

Rabbit IgG

PCNA (PC10)

PCNA

Mouse IgG

p130 (C-20)

p130

Rabbit IgG

MCM7 (141.2)

MCM7

Mouse IgG

β-Actin

Actin

Rabbit IgG

Sigma

A2066

WB (1:500)

Lamin A/C

Lamin

Rabbit IgG

Chemicon

MAB3211

WB (1:1000)

BrdU (B44)

BrdU

Mouse IgG

Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology
Santa Cruz
Biotechnology

BD
biosciences

347580

IF (1:500), FC
(1:200)

Developmental
MHC (MF20)

Myosin heavy
chain

studies
Mouse IgG

Hybridoma
bank, Univ. of
Iowa

MF-20

IF (1:200)
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H3K9me3

H3K9me3

Rabbit IgG

Millipore

07-442

H3K27me3

H3K27me3

Rabbit IgG

Millipore

07-449

Anti-PML clone
36.1-104

Mouse PML

(monoclonal)
Anti-PML H-238

Multiple PML

(polyclonal)

isoforms

Mouse
ascites

Rabbit

IF (1:1000),
ChIP (4µg)
IF (1:1000),
ChIP (4µg)
IF (1:300),

Millipore

MAB3738

WB (1:500),
ChIP (4µg)

Santa Cruz
Biotechnology

(SC-5621)

WB (1:500)

Anti-phosphoHistone H2A.X

Phospho-

(ser139) clone

histone H2A.X

Mouse IgG

Millipore

05-636

IF (1:300),
WB (1:500)

JBW301

Anti-FLAG M2
antibody

Anti Cyclin E
Anti-pRB
(M153)

Anti-p53-ser15

IF (1:500),
FLAG peptide

Mouse IgG

Sigma

F-1804

WB (1:1000),
ChIP (4µg)

Cyclin E

Rabbit

pRB

Rabbit

Phopho-p53
(ser15)

Abcam
Santa Cruz
Biotechnology

Ab7969

SC-7905

WB (1:500)
WB (1:500),
ChIP (5µg)

Rabbit

Cell signaling

#9284

WB (1:1000)

Calbiochem

OP76

WB (1:500)

FL-189

WB (1:250)

Ant-p21 (Ab-4)

p21

Mouse

Anti-Pan-ras

ras

Rabbit

Santa Cruz
Biotechnology
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Appendix F: PCR conditions for genotyping
PCR Conditions: Rb1-ΔLXCXE
Master Mix per reaction:
0.5 µL MgCl2 (50mM stock)
2 µL dNTPs (2mM stock)
2 µL PCR Buffer (10X stock)
0.25 µL of FD-134 primer (20 µM stock)
0.25 µL of FD-135 primer (20 µM stock)
12.5 µL water
0.5 µL Taq
2 µL DNA

Reaction Conditions: Program SL01
o

94 C for 2:30
o

94 C for 0:20
o

60 C for 0:20
o

70 C for 2:00
Go to step #2, 29 times
o

72 C for 10:00
o

12 C until stopped

Expected Results:
Wild type band 136 bp
Mutant band 274 bp

Primers:
FD134: 5’ AGC TTC ATA CAG ATA GTT GGG 3’
FD135: 5’ CAC AAA TCC CCA TAC CTA TG 3’
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PCR Conditions: KrasG12D
Master Mix per reaction:
0.6 µL MgCl2 (50mM stock)
2 µL dNTPs (2mM stock)
2 µL PCR Buffer (10X stock)
0.5 µL of K1 primer (20 µM stock)
0.5 µL of K2 primer (20 µM stock)
0.5 µL of K3 primer (20 µM stock)
11.4 µL water
0.5 µL Taq
2 µL DNA

Reaction Conditions: Program RasG12D
o

95 C for 2:00
o

95 C for 0:30
o

61 C for 0:30
o

72 C for 0:45
Go to step #2, 34 times
o

72 C for 10:00
o

4 C until stopped

Expected Results:
Wild type band =~622 bp
LSL cassette=500 bp
1Lox (Recombined after Cre)=~650bp

Primer K1: 5’ GTC TTT CCC CAG CAC AGT GC 3’
Primer K2: 5’ CTC TTG CCT ACG CCA CCA GCT C 3’
Primer K3: 5’ AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC A 3’
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Appendix G: Primers and real time PCR conditions for ChIP
Mcm3 Forward Primer: 5’ GAATGCAGTGCTTCCTAGCC 3’
Mcm3 Reverse Primer: 5’ CGGAAGTTTATGGTGGAGGA 3’
Expected band size: 205bp
Ccne1 Forward primer: 5’ GAGAACTTGGTAGACCAACTCTAAA 3’
Ccne1 Reverse primer: 5’ GCAGCTGTTCTTAACTCTGTCTAGT 3’
Expected band size: 71bp

Master Mix per reaction:
5 µL iQSYBRGreen master mix (2X stock)
1.0 µL of Forward primer (10 µM stock)
1.0 µL of Reverse primer (10 µM stock)
1.0 µL RNAase /DNAase free water
2 µL ChIP DNA

Real time PCR conditions:
o

95 C for 3:00
o

95 C for 0:10
o

58 C for 0:30
Go to step #2, 39 more times
o

95 C for 0:10
o

o

o

Melt curve 65 C to 95 C increment 0.5 C for 0:05
o

4 C
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